Don't miss our daily updates! Follow @Citeline on @LinkedIn : www.linkedin.com/company/citeline/
Datamonitor
Datamonitor is an international company providing market intelligence, data analysis, and opinion via a worldwide network of in-house analysts. The company tracks Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology, Sourcing and Telecommunications markets. Its website claims to have over 6,000 clients, which it helps make strategic and operational decisions. Datamonitor was acquired in 2007 by Informa for £513 million in cash. More on Wikipedia
-
Citeline
@Citeline
-
Citeline
@Citeline
Citeline's APAC team is poised to link the dots that matter to you in real-time: vist.ly/4zjpd
We proactively track trial trends and analyze policy shifts using data-led journalism, providing insights that will empower you in current industry discussions and decisions. -
Citeline
@Citeline
Everyone has an AI pilot.
Very few have AI embedded in trial execution.
This ebook focuses on where AI is delivering repeatable, real‑world impact across clinical trial workflows. Not just hype.
Downlaod the ebook today: vist.ly/4zimw -
Citeline
@Citeline
🎙 Season 2 of #smallbiotechsbigdecisions is now live! vist.ly/4zgzw
A high-level conversation on how the biotech playbook is changing and what leaders need to think differently about as the industry enters its next phase. Watch the series and tune in now! -
Citeline
@Citeline
On March 30, the US Food and Drug Administration (@FDA) reminded more than 2,200 medical product companies and researchers of the requirements to submit certain clinical trial results information to clinicaltrials.gov.
What you need to know: vist.ly/4zfe3
Citeline
@Citeline
Read the announcement: www.fda.gov/news-events/press-announcements/fda-reminds-m…
-
Citeline
@Citeline
The future of life sciences leadership is here: vist.ly/4ze2k
This release highlights 30 individuals who are not just advancing healthcare—but redefining it.
This list isn’t just about recognition—it’s a signal of where the industry is heading next. -
Citeline
@Citeline
"Investors are still willing to bet on the small innovators fueling Big Pharma’s R&D coffers," says @IanLloyd, author of Citeline's annual Pharma R&D Review, in a @PharmaVoice article on the drug pipeline.
Read now: vist.ly/4zd5r
Get the report: vist.ly/4zd5t -
Citeline
@Citeline
A @Bloomberg column on how generic Ozempic is a game changer for China and India cited data from Citeline: vist.ly/4z9ih
The world’s 2 most-populous countries are home to pharmaceutical companies capable of exploiting this to reshape the market for metabolic therapies. -
Citeline
@Citeline
What’s next in R&D, innovation, and clinical development?
We will host a panel exploring the evolving industry landscape and what it means for your development strategy.
Come join us at booth 34. Learn more and schedule a meeting: vist.ly/4z8h6 -
Citeline
@Citeline
🚨 Regulatory disclosure rules keep shifting in subtle ways that can derail trial visibility and publication readiness.
If you manage clinical trial disclosure, these changes matter.
🔗 March Roundup:
vist.ly/4z5rh
🔗 Disclosure Monthly Roundups:
vist.ly/4z5rk -
Citeline
@Citeline
🗓️ April 21 | 10am NYC | 3pm LDN
What you’ll learn:
-The key signals behind the latest pipeline data
-Where innovation is accelerating — and where it’s slowing
-Regional changes reshaping the landscape
-Live discussion + audience Q&A
Register now: vist.ly/4z3yx -
Citeline
@Citeline
Ready to see how AI is revolutionizing medtech? vist.ly/4yx25
Download the new Medtech Insight eBook for expert analysis on dealmaking trends, patient-focused innovations, and real-world perspectives from clinicians and patients. -
Citeline
@Citeline
According to an article in @biospace highlighting key findings from Citeline’s Pharma R&D Annual Review, despite 2025 posting the first decline in overall global drug development since the mid-1990s, there are signs this may not be an extended fall-off.
vist.ly/4yxz4 -
Citeline
@Citeline
Join us for Pharma R&D Review Live 2026 on April 21 | 10am NYC | 3pm LDN for a data-driven look at what’s taking root across the pipeline — and what’s set to bloom next.
Register here: vist.ly/4yvap -
Citeline
@Citeline
Let’s just say it’s all about unlocking smarter R&D decisions. Giving you a first glimpse of what’s coming to #swissbiotechday 2026.
🌿 Stop by booth 34 to find out more.
vist.ly/4yu4z
See you in Basel! @SwissBiotech -
Citeline
@Citeline
In an interview with @PharmExec, Matt Holms, Citeline’s VP of Commercial, Patient Engagement, and Recruitment, discusses ways clinical trial design and feasibility must adapt to address this evolving, multifaceted landscape.
vist.ly/4yqpn -
Citeline
@Citeline
The future of pharma doesn’t wait—and neither should you: vist.ly/4ynxm
Scrip Asks captures predictions from 300+ senior industry voices on the forces set to shape 2026, from dealmaking and data to AI and operational change. -
Citeline
@Citeline
Stay ahead of FDA shifts that could impact your strategy. vist.ly/4yi8m
The landscape of drug approvals is evolving under new leadership and changing regulations.
Save time and focus on what matters—accelerating life-saving therapies. Download our latest eBook now! -
Citeline
@Citeline
The long-range pipeline count shows a rare moment: 22,940 drugs in active R&D at the start of 2026 — down 3.92% vs. last year.
Harvest the full story behind the shift — download the report. vist.ly/4yfdk -
Citeline
@Citeline
Countdown to compliance has begun.
The UK’s updated clinical trial transparency requirements take effect 28 April, with significant implications for trial registration, results publication, and deferrals.
📌 Watch to understand: vist.ly/4yayz -
Citeline
@Citeline
How is AI shaping the future of medtech? vist.ly/4y7fi
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges. Get a first look at the trends driving smarter, more personalized healthcare! -
Citeline
@Citeline
When every patient is rare, the difference isn't just speed — it’s precision.
vist.ly/4xzuw
Discover how Citeline PatientMatch can propel qualified patients into your recruitment pipeline. -
Citeline
@Citeline
Citeline has been named a winner in @Global_H_Pharma Magazine's Biotechnology & Lifesciences Awards 2026. We are proud to be recognized as one of the Best AI-Powered Clinical Research Data Solutions.
vist.ly/4xz8v -
Citeline
@Citeline
What if you had real-time insights into biopharma's future? With The In Vivo Report, you do. vist.ly/4xwcj
Access crucial data, connect with industry decision-makers, and stay ahead of the competition. Elevate your strategy and make informed decisions that save lives. -
Citeline
@Citeline
The long-range pipeline count shows a rare moment: 22,940 drugs in active R&D at the start of 2026 — down 3.92% vs. last year.
Harvest the full story behind the shift — download the report. vist.ly/4xwcf -
Citeline
@Citeline
Looking for in-depth coverage of China’s biopharma industry? vist.ly/4xuxq
Our comprehensive eBook covers market-defining trends, top deals, and actionable strategies for financial professionals. -
Citeline
@Citeline
At #swissbiotechday 2026, Citeline will host a panel on what’s next in R&D, innovation, and clinical development, exploring how emerging trends are reshaping the industry.
Plan ahead and book a meeting with us:
vist.ly/4xrua -
Citeline
@Citeline
The number of drugs in development has fallen for the first time since the 1990s. Is this just a blip or the start of a trend?
An article in @FiercePharma and @FierceBiotech featured key findings from Citeline’s Pharma R&D Annual Review 2026.
vist.ly/4xq63 -
Citeline
@Citeline
It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4xgtg
-
Citeline
@Citeline
Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4xbi2
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
In rare disease trials, every match can change the outcome.
With AI‑powered prescreening, sponsors are finding qualified patients faster — and with more precision. In just one week, Citeline PatientMatch generated 398 actionable alerts, identifying 20% of all randomized U.S. patients for this study.
Discover how Citeline PatientMatch can propel qualified patients into your recruitment pipeline.
🔗 vist.ly/4xa2w
💬 What’s the biggest barrier you see today in connecting rare patients to the right trials?
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
AI is transforming patient care and product innovation in medtech - are you keeping up? vist.ly/4x8yn
Our latest eBook from Medtech Insight covers $9.2B in AI-enabled device deals, strategies for embracing AI-driven care, and insights from industry leaders. -
Citeline
@Citeline
A @Bloomberg column on how generic Ozempic is a game changer for China and India cited data from Citeline.
The column notes that the simultaneous patent expiry of Ozempic’s active ingredient in China and India is a watershed moment.. Now, the entry of affordable generic versions will be a leveling force in healthcare.
The world’s two most-populous countries are home to pharmaceutical companies capable of exploiting this to reshape the market for metabolic therapies. -
Citeline
@Citeline
The market for KRAS-targeting oncology drugs could be poised to boom in the next few years. | vist.ly/4x7kf
In a @PharmaVoice article on the KRAS space, Citeline analyst Neha Anand weighed in on the market performance of KRAS drugs like Amgen’s Lumakras and outlined how the next wave of KRAS therapies in the pipeline is taking shape.
What do you think will be the biggest opportunity in this emerging market? -
Citeline
@Citeline
Asia’s Biopharma Revolution: vist.ly/4x4td
China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs.
The Scrip Asia 100 report reveals the top 100 pharma companies in Asia by sales – plus the trends, data, and deals shaping the future of global pharma.
🔍 Want to know what’s driving the shift east?
Access the report: vist.ly/4x4td #scripasia100 #newsandinsights
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: vist.ly/4x4tf -
Citeline
@Citeline
The conversation continues with Series 2 of #smallbiotechsbigdecisions — Claire Riches, in conversation with four expert voices. Coming soon.
Explore more: vist.ly/4w22dThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Blooming, or withering on the vine? 🌱 In today’s R&D landscape, pipeline success is far from guaranteed and the cost of getting it wrong continues to rise.
Join Citeline at #swissbiotechday 2026 in Basel at booth 34 where we’ll connect with biotech and pharma leaders to explore the trends shaping R&D, clinical development, and innovation.
Plan ahead and book your meeting with us:
vist.ly/4wy3x
-----
Follow @Citeline and stay at the forefront of clinical trial innovation. We connect patients, caregivers, physicians, and partners with cutting-edge technology and data-driven solutions to simplify enrollment and accelerate life-changing treatments worldwide. -
Citeline
@Citeline
How sustainable can OTC really be? HBW Insight’s David Ridley interviews sustainability leader Steve Ramus in this season's latest episode of the Over the Counter podcast. They dig into what consumers will (and won’t) pay for, why being “unsustainable” is a business risk, and the tough realities of OTC packaging.
Listen: vist.ly/4wx3k
🤔 Which sustainability shift do you think will have the biggest industry impact — pricing, packaging innovation, or retailer demand? #overthecounter2026 -
Citeline
@Citeline
How do you reach patients when the condition is so rare most providers never see it in their careers? @SolGel teamed up with Citeline to launch a rapid, seven‑country HCP awareness campaign for Gorlin syndrome — an ultra‑rare disorder affecting just 1 in 31,000 people.
The result? Exceptional engagement, industry‑beating performance, and multiple qualified referrals. See how they did it:
vist.ly/4wtu6
With the right strategy, even the hardest‑to‑reach patients can be found.
#precisionrecruitment #clinicaltrials -
Citeline
@Citeline
We are excited to announce our partnership with @RecursionPharma, a leading tech-bio company decoding biology through advanced data science and automation.
Recursion’s end-to-end, AI-enabled platform is designed to connect discovery through development. The addition of Citeline’s real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions.
Read the full news release: vist.ly/4wrvd
-----
Follow @Citeline and stay at the forefront of clinical trial innovation. We connect patients, caregivers, physicians, and partners with cutting-edge technology and data-driven solutions to simplify enrollment and accelerate life-changing treatments worldwide. -
Citeline
@Citeline
March is Colorectal Cancer Awareness Month. In the wake of an uptick in cases of colorectal cancer among younger adults and actor James Van Der Beek's death from the disease, Citeline's Meredith Landry researched what the industry is doing to combat it.
She shares her findings in an article for PharmaLive on what the clinical pipeline signals in 2026. Her interviews with Citeline analysts Renu Bala, a Citeline Trialtrove analyst, and JT Toebbe, a Citeline Pharmaprojects analyst, reveal a shift toward precision-based treatments and advances in immune checkpoint inhibitors.
Read the full article: vist.ly/4wpai -
Citeline
@Citeline
🌍 February delivered meaningful regulatory momentum across global clinical trial landscapes—spanning data transparency, digital transformation, fee changes, and faster authorization pathways.
Three updates worth watching this month:
🇪🇺 EU: HMA–EMA RWD Catalogues introduced record completeness scores, boosting real‑world data transparency (with study‑level scores coming soon).
🇫🇷 France: ANSM confirmed a fast‑track CTA pathway launching 16 March 2026 for eligible early‑phase mono‑national trials.
🇪🇬 Egypt: The EDA rolled out a digital clinical trial application and protocol management platform, accelerating submission workflows.
❔👉 Which of these will have the biggest impact on your trial planning this year?
February updates: vist.ly/4wmz6
Last three monthly updates: vist.ly/4wmza -
Citeline
@Citeline
Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4wheg
-
Citeline
@Citeline
Struggling to find properly matched patients for your clinical study? Step up your game with Citeline's PatientMatch.
Our Phase II small cell lung cancer study saw boosted results: lesser site burden, quicker prescreening, and immediate impact on early randomization.
Click on the link to dive into our success story: vist.ly/4wgqa
#clinicaltrial #precisionrecruitment -
Citeline
@Citeline
Hot off the press! vist.ly/4wdgq
The data is in — and the Pharma R&D landscape is changing.
After a record-breaking year, Citeline’s 34th Pharma R&D Annual Review reveals a pipeline in transition: overall decline, stronger late stages, and shifting global leadership.
Unearth what’s growing, what’s retreating, and what it means for your 2026 strategy.
Download the full report: vist.ly/4wdgq -
Citeline
@Citeline
Our March edition of Citeline’s Patient Recruitment Pulse is now live! Finding patients for rare disease clinical trials can be an uphill battle. Fortunately, there are ways sponsors can ease the process.
In this month’s Pulse, we explore key findings from our latest white paper, highlighting the challenges and best practices for recruiting patients in rare disease clinical trials.
Explore the insights: vist.ly/4wb2v
What have your rare disease patient recruitment experiences been like? Let us know in the comments. -
Citeline
@Citeline
UK clinical trial transparency rules are changing—are you ready?
From 28 April, new UK requirements will impact how clinical trials are registered and how results are published, affecting global sponsors and CROs alike.
In this RAPS-sponsored, on demand webinar, experts from Citeline, ISRCTN Registry, and Quotient Sciences share practical guidance on compliance, implementation, and what to prepare for as the rules take effect.
👉 Watch the webinar on demand: vist.ly/4wa5n
Explore the event recap for deeper insights and extended Q&A.
What aspect of the new UK transparency requirements is your team most focused on right now? -
Citeline
@Citeline
🌏 Are you keeping pace with China’s biopharma revolution? vist.ly/4w8wd
Discover our eBook packed with expert articles, strategic insights, and guidance for financial services professionals exploring this vibrant market. From investment opportunities to global innovation trends, it’s your go-to resource.
Download now and stay ahead! vist.ly/4w8wd -
Citeline
@Citeline
Citeline is proud to receive this industry generative AI award for its integrated Citeline SmartSolutions suite that optimizes and accelerates clinical trial planning and site selection. These AI-enabled technology products help study sponsors reduce costly protocol amendments and increase predictability.
Learn more about the Citeline SmartSolutions suite — Protocol SmartDesign, Investigator SmartSelect, and Cohort SmartBuilder: vist.ly/4w78c -
Citeline
@Citeline
Is your APAC strategy built on headlines or history?
In a region as complex as Asia-Pacific, deep experience isn't a bonus—it's the baseline. Citeline has been reporting from the ground for years, delivering the context that newcomers miss.
Why expert coverage matters:
✔️ Historical Context: We see the full arc of trends, not just the daily noise.
✔️ Local Nuance: Intelligence gathered from within the region, not from afar.
✔️ Proven Reliability: Insights you can trust to drive high-stakes decisions.
Swap generalist data for specialist insight. See what you’ve been missing: vist.ly/4w5ki
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: vist.ly/4w5kq -
Citeline
@Citeline
🌍 February delivered meaningful regulatory momentum across global clinical trial landscapes—spanning data transparency, digital transformation, fee changes, and faster authorization pathways.
Three updates worth watching this month:
🇪🇺 EU: HMA–EMA RWD Catalogues introduced record completeness scores, boosting real‑world data transparency (with study‑level scores coming soon).
🇫🇷 France: ANSM confirmed a fast‑track CTA pathway launching 16 March 2026 for eligible early‑phase mono‑national trials.
🇪🇬 Egypt: The EDA rolled out a digital clinical trial application and protocol management platform, accelerating submission workflows.
❔👉 Which of these will have the biggest impact on your trial planning this year?
February updates: vist.ly/4w5hu
Last three monthly updates: vist.ly/4w5i4 -
Citeline
@Citeline
🌿🌍 Our Pharma R&D Annual Review 2026 infographic reveals the global pipeline's secrets—from budding ideas to flourishing successes.
While overall drug numbers took a slight dip, several therapeutic areas are still blossoming, proving that innovation is far from over.
Don’t miss out on the insights—dive into the data and see where the future of pharma is taking root 👉 vist.ly/4v2xp -
Citeline
@Citeline
When the industry talks global R&D shifts, it turns to Citeline data: vist.ly/4vzhc
@PharmaVoice recently referenced insights from Citeline’s 2025 Annual Clinical Trials Roundup, noting that Jiangsu Hengrui Pharmaceuticals rose to become the world’s top clinical trial sponsor — underscoring China’s growing role in biopharma innovation.
Read the full article: vist.ly/4vzhc
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
Unlock the future of biopharma with The In Vivo Report! vist.ly/4vy67
Get the inside scoop on deals, data, and decision-makers shaping the industry before it hits the news. Don't miss out on crucial insights that can elevate your strategy. Click now to learn more! -
Citeline
@Citeline
Citeline's APAC team is poised to link the dots that matter to you in real-time: vist.ly/4vv44
We proactively track trial trends and analyze policy shifts using data-led journalism, providing insights that will empower you in current industry discussions and decisions. -
Citeline
@Citeline
🌱 What’s growing in pharma R&D—and what’s gone fallow?
Our Pharma R&D Annual Review 2026 infographic takes stock of the global pipeline, from early‑stage shoots to late‑phase blooms. While overall drug numbers dipped slightly, some therapeutic areas are still thriving, proving the garden isn’t done growing yet.
Dig into the data and see where innovation is taking root 👉 vist.ly/4vuka -
Citeline
@Citeline
Curious about AI’s impact on early disease detection and mergers & acquisitions in medtech?vist.ly/4vreu
Our infographic breaks down the latest stats, including $9.2B in deals for 2025, and what clinicians and patients expect from AI innovations. See it at a glance! -
Citeline
@Citeline
Discover how you can fast-track rare disease study timelines with Citeline PatientMatch.
Harnessing the power of AI and real-world data, we bring qualified patients directly to your doorstep, accelerating your recruitment process.
Are you ready to revolutionize rare disease recruitment? vist.ly/4vq2d
#precisionrecruitment #clinicaltrials #showyourstripes #rarediseaseawareness -
Citeline
@Citeline
Ready to see how AI is revolutionizing medtech? vist.ly/4vpye
Download the new Medtech Insight eBook for expert analysis on dealmaking trends, patient-focused innovations, and real-world perspectives from clinicians and patients. -
Citeline
@Citeline
🌍 Sustainability rules are shifting fast — in the EU and the US.
In the first episode in our new season of the Over the Counter Podcast, guest Steve Ramus speaks with David Ridley and breaks down how EU rollbacks on key Green Deal measures and fragmented US state mandates are creating new challenges for consumer health companies.
His message? Leadership matters most now. The companies that keep moving—despite uncertainty—will be more competitive in the long run.
🎧 Listen: vist.ly/4vkjh #overthecounter2026 -
Citeline
@Citeline
Our March edition of Citeline’s Patient Recruitment Pulse is now live! Finding patients for rare disease clinical trials can be an uphill battle. Fortunately, there are ways sponsors can ease the process.
In this month’s Pulse, we explore key findings from our latest white paper, highlighting the challenges and best practices for recruiting patients in rare disease clinical trials.
Explore the insights: vist.ly/4vha4
What have your rare disease patient recruitment experiences been like? Let us know in the comments. -
Citeline
@Citeline
🔬 We may be on the brink of one of pharma’s biggest breakthroughs — are we finally learning how to cross the blood–brain barrier?
👉 vist.ly/4vgc6
An article in @PharmaVoice referenced the finding from Citeline’s 2025 Annual Clinical Trials Roundup that the central nervous system therapeutic area saw trials increase 15% in 2024.
🌐 We’re watching a pivotal moment unfold.
💬 What do YOU think will be the biggest hurdle — or opportunity — as BBB‑crossing therapies move closer to mainstream development? Let us know in the comments! -
Citeline
@Citeline
AI is unlocking new possibilities in clinical trial planning: vist.ly/4vd7r
One biotech team used predictive modeling and SmartDesign tools to shape protocol and site strategy, improving recruitment forecasts and feasibility outcomes. -
Citeline
@Citeline
Precision matters when patients are hard to find.
Citeline PatientMatch uses AI + real‑world data to spot protocol‑matched patients earlier and speed enrollment.
🔗 vist.ly/4vc42
Follow @Citeline. -
Citeline
@Citeline
From seed to scale, the Pharma R&D Annual Review 2026 is almost ready to harvest.
In our upcoming release, we unearth the forces shaping the global pipeline, highlighting where innovation is flourishing, which therapeutic areas are blossoming, and the approvals that could yield the biggest impact in 2026.
Keep an eye out — we’ll be sharing a first look in this years infographic, to be released very soon. -
Citeline
@Citeline
Traditional approaches aren’t quite cutting it in today’s complex patient recruitment landscape. What to do instead?
In @WorldPharmaToday, @MattHolms, Citeline’s Vice President, Commercial Patient Engagement & Recruitment, breaks down the need for a third generation of patient recruitment that incorporates data-linked patient identification at population scale: vist.ly/4v35a
We’d love to hear your thoughts on third-generation patient recruitment in the comments. -
Citeline
@Citeline
Planning a Phase III trial in a new therapeutic area without prior experience is tough: vist.ly/4uwz5
One sponsor used RWD and AI to assess feasibility, validate CRO strategy, and select the right sites; resulting in a confident plan delivered in just three weeks. -
Citeline
@Citeline
Behind the scenes on Pharma R&D… We’ve been on location filming with Ian Lloyd as he does what he does best: digging deep into the drug development landscape to uncover what’s taking root, what’s gaining ground, and what’s set to bloom in 2026.
Can you guess where we are? ✨Bonus points: what do you think this year’s theme is? Drop your guesses in the comments! -
Citeline
@Citeline
Our February Patient Recruitment Pulse is now available! vist.ly/4uth6
In addition to the ever-present buzz about AI, patient engagement and recruitment was a hot topic at SCOPE Summit 2026. The recruitment-focused program had two tracks, one on enrollment planning and patient recruitment, the other on diversity and retention, including the patient experience.
Here are a few key takeaways, including excerpts from our own presentations on AI, the feasibility-informed protocol, and a case study on real-world enrollment.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
#scopesummit #clinicaltrials #protocoldesign -
Citeline
@Citeline
As we look back on Rare Disease Day, we recognize the 300 million people worldwide living with a rare condition and the everyday realities they face.
In rare disease research, awareness and engagement remain critical. They’re the drivers that help shorten diagnostic delays, strengthen trial visibility, and open the door to better patient experiences.
Our latest white paper explores what it will take to advance rare disease recruitment with more patient-centered, data-driven strategies — on Rare Disease Day and throughout the year. Download it here: vist.ly/4unza
#patientrecruitment #clinicaltrials #showyourstripes -
Citeline
@Citeline
It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4ujk6
-
Citeline
@Citeline
The market for KRAS-targeting oncology drugs could be poised to boom in the next few years. | vist.ly/4uid6
In a @PharmaVoice article on the KRAS space, Citeline analyst Neha Anand weighed in on the market performance of KRAS drugs like Amgen’s Lumakras and outlined how the next wave of KRAS therapies in the pipeline is taking shape.
What do you think will be the biggest opportunity in this emerging market? -
Citeline
@Citeline
Lean biotech teams need smart, scalable support: vist.ly/4uftv
Instead of training on complex tools, one sponsor relied on expert-led AI and real-world data solutions to guide protocol development and CRO selection–resulting in fewer delays & strategy built for growth. -
Citeline
@Citeline
🔍 What does real sustainability look like for OTC brands in 2026? It’s more complex (and more business‑critical) than most people think.
In the latest Over the Counter episode, HBW Insight's David Ridley sits down with sustainability expert Steve Ramus to unpack the hard realities shaping ESG, eco‑pricing, and the future of pharmaceutical packaging. This is Part 2 of their deep‑dive conversation, and it delivers sharp, practical insights.
🎙️ Listen to the full episode:
vist.ly/4ues4
🤔 What’s the single biggest barrier you see to accelerating sustainability in consumer health — cost, packaging innovation, regulation, or something else? Share in the comments below! #overthecounter2026 -
Citeline
@Citeline
Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4ub86
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Curious about the risks and rewards of AI in pharma?
vist.ly/4u78y
Our latest webinar covers practical limitations, data protection concerns, and what’s next for the industry.
✔️US FDA’s AI Initiatives
✔️UK MHRA’s In Silico Trials
✔️Pharmacovigilance Innovation -
Citeline
@Citeline
How is AI shaping the future of medtech? vist.ly/4u5ba
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges. Get a first look at the trends driving smarter, more personalized healthcare! -
Citeline
@Citeline
Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4t2i5
-
Citeline
@Citeline
Reaching patients with ultra-rare conditions requires a different kind of strategy.
@SolGel partnered with Citeline to launch a 60-day, seven-country HCP awareness campaign around Gorlin syndrome — an extremely rare condition affecting one in 31,000 people.
The campaign delivered exceptional engagement and multiple qualified referrals. Check out the case study: vist.ly/4tqi5 #precisionrecruitment #clinicaltrials -
Citeline
@Citeline
Discover how CROs are staying on budget and ahead of schedule: vist.ly/4tm3z
CROs are using feasibility modelling and AI-driven forecasting to avoid delays and control costs. With RWD guiding site selection and planning, teams can stay on track and protect margins. -
Citeline
@Citeline
A Phase II small cell lung cancer study team was struggling to identify highly qualified patients using traditional outreach. By leveraging Citeline PatientMatch, the sponsor surfaced protocol-matched candidates quickly and reduced site burden.
The results: high-quality alerts, faster prescreening, and meaningful impact on early randomization.
Read the case study: vist.ly/4tfdh
#precisionrecruitment #clinicaltrial -
Citeline
@Citeline
Finding patients is often the biggest barrier to meeting rare disease study timelines.
Citeline PatientMatch brings together AI and real-world data to surface highly qualified, protocol-matched patients earlier in their care journey.
See how Citeline PatientMatch supports faster, more precise rare disease recruitment: vist.ly/4t9u7
#precisionrecruitment #clinicaltrials #showyourstripes #rarediseaseawareness -
Citeline
@Citeline
Today, on Rare Disease Day, we recognize the 300 million people worldwide living with a rare condition and the everyday realities they face.
In rare disease research, awareness and engagement remain critical. They’re the drivers that help shorten diagnostic delays, strengthen trial visibility, and open the door to better patient experiences.
Our latest white paper explores what it will take to advance rare disease recruitment with more patient-centered, data-driven strategies — on Rare Disease Day and throughout the year. Download it here: vist.ly/4t9bf
#patientrecruitment #clinicaltrials #showyourstripes -
Citeline
@Citeline
Our February Patient Recruitment Pulse is now available! vist.ly/4t6p7
In addition to the ever-present buzz about AI, patient engagement and recruitment was a hot topic at SCOPE Summit 2026. The recruitment-focused program had two tracks, one on enrollment planning and patient recruitment, the other on diversity and retention, including the patient experience.
Here are a few key takeaways, including excerpts from our own presentations on AI, the feasibility-informed protocol, and a case study on real-world enrollment.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
#scopesummit #clinicaltrials #protocoldesign -
Citeline
@Citeline
🔬 We may be on the brink of one of pharma’s biggest breakthroughs — are we finally learning how to cross the blood–brain barrier?
👉 vist.ly/4t5zj
An article in @PharmaVoice referenced the finding from Citeline’s 2025 Annual Clinical Trials Roundup that the central nervous system therapeutic area saw trials increase 15% in 2024.
🌐 We’re watching a pivotal moment unfold.
💬 What do YOU think will be the biggest hurdle — or opportunity — as BBB‑crossing therapies move closer to mainstream development? Let us know in the comments! -
Citeline
@Citeline
AI is transforming patient care and product innovation in medtech - are you keeping up? vist.ly/4s2jd
Our latest eBook from Medtech Insight covers $9.2B in AI-enabled device deals, strategies for embracing AI-driven care, and insights from industry leaders. -
Citeline
@Citeline
🌍 January 2026 Clinical Trial Disclosure Roundup
Regulators came out strong to start 2026. If your teams touch clinical operations, regulatory, or transparency, here are the updates you shouldn’t miss:
1️⃣ Health Canada Opens Major Consultation
2️⃣ Fee Increases Across Multiple Markets
3️⃣ MHRA Updates UK Application & Modification Guidance
4️⃣ Japan Clarifies jRCT Requirements
5️⃣ FAST‑EU Pilot Expands
6️⃣ Pakistan Proposes Alignment with ICH‑GCP
7️⃣ ICMJE Refines Trial Registration Policy
💡 Takeaway: 2026 is shaping up to be a year of accelerated regulatory modernization. Now is the time for sponsors and CROs to reassess disclosure processes, compliance frameworks, and global planning assumptions.
All the January updates: vist.ly/4szz6jan-2026/
Last three monthly updates: vist.ly/4szz6 -
Citeline
@Citeline
Citeline and @Evinova, a global clinical trial technology company, have entered a multiyear agreement that will integrate Citeline’s leading data products, Sitetrove and Trialtrove, into Evinova’s AI-enabled Study Designer solution.
Read the full news release: vist.ly/4sygt
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
Explore how CROs are winning contracts in unfamiliar indications: vist.ly/4svri
With AI-powered analytics, proposals are built faster and backed by evidence sponsors trust. Learn how others are expanding their reach without increasing internal resources. -
Citeline
@Citeline
No internal data. No prior experience. Still ready to launch: vist.ly/4svj8
A global sponsor used data-driven feasibility and AI tools to validate their CRO’s strategy and build a strong trial plan. They saved time, reduced risk, and moved forward with confidence. -
Citeline
@Citeline
🌍 Sustainability is shifting fast — but standing still is the real risk.
We start a new season of Over The Counter with part one of a two-part episode from HBW Insight and David Ridley. We dive into one of the most pressing questions in consumer health today: how should companies navigate a sustainability landscape that’s evolving in both the EU and the US — and sometimes moving in opposite directions?
In this episode, Steve Ramus, sustainability expert, unpacks what leaders need to know right now as regulations shift and uncertainty rises.
🎧 Listen here: vist.ly/4suit #overthecounter2026 -
Citeline
@Citeline
vist.ly/4srer | In a video interview with @Clin_Trials, Heidi Chen of @Citeline provided insights on how sponsors and CROs are maintaining innovation as they adapt to evolving ICH GCP guidelines.
-
Citeline
@Citeline
Time's ticking! Don't miss your chance to connect with us tomorrow for unrivaled insights into UK's trial transparency shift: vist.ly/4sqb6
Register now to secure your place in our webinar, brought to you in partnership with HRA, ISRCTN, and Quotient Sciences.
We're not just helping you navigate registration and result obligations, and plain language summary provisions. We're setting you on track to master new clinical trial rules. Your journey towards compliance starts here: vist.ly/4sqb6
Stay proactive, stay assured with Citeline. -
Citeline
@Citeline
A @PharmaVoice article on the Biosecure Act referenced the finding from Citeline’s 2025 Annual Clinical Trials Roundup that China’s Jiangsu Hengrui Pharmaceuticals dethroned UK-based AstraZeneca as the world’s top clinical trial sponsor in 2024: vist.ly/4sjtd
-
Citeline
@Citeline
How are regulators using AI to speed up clinical trials and improve drug safety? vist.ly/4sgvp
Discover how the FDA, EMA, and MHRA are leveraging AI to accelerate trials, enhance safety, and streamline approvals. -
Citeline
@Citeline
Discover how AI is revolutionizing pharma regulation in our on-demand webinar: vist.ly/4sexz
Join the Pink Sheet editorial team as they break down the EU AI Act, UK’s innovation approach, and what it means for drug developers. -
Citeline
@Citeline
Citeline is able to capture data in a way that ensures patient confidentiality and the ability to cross-link through the patient journey.
The right data can give sponsors an edge in patient recruitment. Watch the full webinar, Built-In Data Advantage: vist.ly/4sc8y -
Citeline
@Citeline
📣 Join us as we present to master the sweeping shift in UK clinical trials and transparency requirements: vist.ly/4s6r4
We've teamed up with HRA, ISRCTN, and Quotient Sciences to simplify your journey with registration and result publication, and plain language summaries provisions.
With less than 80 days until implementation, the countdown to compliance is on. This session offers essential preparation strategies for organizations conducting clinical trials in the UK.
Book your spot! vist.ly/4s6r4
Register to join live and secure the recording. (Free RAPS account required for registration.)
Stay tuned to Citeline for an ongoing glimpse into pharma and medtech markets. Because together, we aren't just seeking trial participants, we're fostering hope. -
Citeline
@Citeline
Is your APAC strategy built on headlines or history?
In a region as complex as Asia-Pacific, deep experience isn't a bonus—it's the baseline. Citeline has been reporting from the ground for years, delivering the context that newcomers miss.
Why expert coverage matters:
✔️ Historical Context: We see the full arc of trends, not just the daily noise.
✔️ Local Nuance: Intelligence gathered from within the region, not from afar.
✔️ Proven Reliability: Insights you can trust to drive high-stakes decisions.
Swap generalist data for specialist insight. See what you’ve been missing: vist.ly/4r2dw
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: vist.ly/4r2d2 -
Citeline
@Citeline
Disclosure Monthly Roundup – January 2026
A fast look at the global regulatory shifts shaping clinical trials:
✔️ Health Canada launched its consultation on a modernized clinical trial framework (open through 20 March 2026).
✔️ Fee increases announced across Belgium, Ireland, Sierra Leone, and Austria.
✔️ The MHRA updated its clinical trial guidance, introducing risk‑based categories and confirming alignment with the Declaration of Helsinki ahead of the 28 April 2026 regulation changes.
✔️ JPMA clarified jRCT timelines and exclusive registration rules.
✔️ The FAST‑EU pilot expanded, with Denmark joining to speed up multinational assessments.
✔️ Pakistan DRAP proposed Bio‑Study Rule updates to align with ICH‑GCP.
✔️ ICMJE tightened expectations on data access and dual registration.
Clear movement. Faster processes. Higher expectations for transparency.
January updates: vist.ly/4rvxg/jan-2026
Last three monthly updates: vist.ly/4rvxg -
Citeline
@Citeline
In an article in WIRED on approval of an oral version of Novo Nordisk’s Wegovy, @Citeline analyst @TimBlackstock provided insights into how this new version will affect the obesity market: vist.ly/4rrn5
-
Citeline
@Citeline
📣 Compliance Countdown Begins: Navigate New UK Regulations with Confidence | vist.ly/4rnjr
Join us on Feb 25 to discuss the colossal shift in UK trial transparency coming into force in less than 80 days!
We are partnering with experts from HRA, ISRCTN, and Quotient Sciences to simplify these obligations, focusing on registration, results publications, plain language summaries, and more.
Grab your seat now! Secure your understanding and compliance with these regulations. Register now to join live and get the recording. (Free RAPS account needed for registration.) vist.ly/4rnjr
Follow @Citeline for continued insights into pharmaceutical and medtech markets. Together, we don't just find trial participants, we find hope. -
Citeline
@Citeline
Matt Holms, Citeline’s VP of Sales, Patient Engagement & Recruitment, emphasizes the importance of collaboration in solving patient recruitment problems.
Watch for more on the challenges and opportunities of the current generation of patient recruitment: vist.ly/4rhm9 -
Citeline
@Citeline
Curious about AI’s impact on early disease detection and mergers & acquisitions in medtech?vist.ly/4rdkn
Our infographic breaks down the latest stats, including $9.2B in deals for 2025, and what clinicians and patients expect from AI innovations. See it at a glance! -
Citeline
@Citeline
vist.ly/4r83y | In a video interview with @Clin_Trials, Heidi Chen, @Citeline, discussed growth in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup.
-
Citeline
@Citeline
📣Get Ahead of the Game with Exclusive Webinar! 📣 vist.ly/4r39i
⏰ The clock is ticking with less than 80 days left to the implementation of the new UK transparency requirements. This GAME-CHANGING regulation takes the center stage from April 28.
Industry experts from Citeline, HRA, ISRCTN, and Quotient Sciences are here to offer you strategic preparation insights. Helping you understand the new regulations’ impact on registration, results publication, and deferrals.
Register now and secure your spot in understanding and complying with these serious regulations. If you can't attend on Feb. 25, register anyway for the recorded session.
Don't let April 28 catch you off guard. All you need is a free RAPS account to take part in this crucial discussion. Register NOW at vist.ly/4r39i.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
When the industry talks global R&D shifts, it turns to Citeline data: vist.ly/4qwhn
@PharmaVoice recently referenced insights from Citeline’s 2025 Annual Clinical Trials Roundup, noting that Jiangsu Hengrui Pharmaceuticals rose to become the world’s top clinical trial sponsor — underscoring China’s growing role in biopharma innovation.
Read the full article: vist.ly/4qwhn
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
Citeline's APAC team is poised to link the dots that matter to you in real-time: vist.ly/4qmnc
We proactively track trial trends and analyze policy shifts using data-led journalism, providing insights that will empower you in current industry discussions and decisions. -
Citeline
@Citeline
That’s it! That’s the end of #scopeinfocus #natinaction!
This week has been incredible - from hearing inspirational stories of hope, to grabbing valuable customer facetime, right the way through to planning (and chickening out of) conference tattoos. SCOPE is exciting, motivational, and at times just plain bonkers - and I hope it never changes.
If you missed us in person, be sure to catch us online! See the solutions we brought to SCOPE right here, and check out our upcoming events online and in person: vist.ly/4qijt
Thanks to the social media and web team for letting me take over the channels for the week - let’s be real: you put a great amount of trust in frankly a bit of a loose canon 😜 and you can relax now!!! Kacia, Brenton, and Ty!
Until next year! -
Citeline
@Citeline
We’ve talked about AI in action during the #natinaction social media takeover at #scopesummit, and here’s an example of how we’re bringing it to patient feasibility, to cut amendments and recruitment delays.
Mike Ruth is here to demo Cohort SmartBuilder, one of our latest additions to the SmartSolutions suite.
Want to learn more? Visit: vist.ly/4qifn
#scopeinfocus -
Citeline
@Citeline
This was a bit of a treat! Loved the AI in Clinical Ops panel today — great discussion on how GenAI is already boosting productivity, why digital protocols + semantic, AI-ready data are game changers, and the need for smart regulatory guardrails.
TL;DR: get the data, standards and governance right and AI amplifies expertise — not replaces it.
We came to SCOPE with a data in focus / AI in action message, so this session was pleasing to my marketing ears. More here: vist.ly/4qhpn
Thanks for your contributions, Sina Djali (axcellion.ai), Bhargava Reddy (Janssen Research & Development), Richard Young (CluePoints) and Donald Jennings (Eli Lilly & Co)!
#scopeinfocus #natinaction #scopesummit -
Citeline
@Citeline
Great panel on evolving clinical data management into clinical data science — thanks to Valerie Balosso (GSK), Lynne Cesario (Pfizer), Miguel Lemaire (GSK) and Shawntel Swannack (Johnson & Johnson Innovative Medicine).
A key message was that there’s a drive to move to real-time, proactive analytics. And conversations like this reinforce why Citeline exists — to give teams the real‑time intelligence, predictive analytics, and operational visibility they need to move from reactive data management to proactive data science.
When organizations can see risks earlier, act faster, and make decisions with confidence, the entire trial ecosystem moves forward.
See how we make a difference: vist.ly/4qgen -
Citeline
@Citeline
Goooood morning from Day 4 of #scopesummit!
This selfie is blurry for good reason: we’re eagerly rushing to the final day of sessions!
Excited to hear from the likes of GSK, Johnson & Johnson, Pfizer and Amgen today. I’ll keep you posted!
#scopeinfocus #natinaction -
Citeline
@Citeline
And just like that, the exhibition hall at #scopesummit is closed for another year!
We’ll be back at Rosen Shingle tomorrow for the last day of sessions - but if you missed the chance to grab one of our flyers or case studies from our booth, fear not! You can see them all here: vist.ly/4qdwp
Have a great night - and see you tomorrow for the final day of #scopeinfocus, #natinaction! 💙
P.S. this is the first and last time I take a selfie with a flyer. Just go with it if that’s ok -
Citeline
@Citeline
I call this “the SCOPE that could have been”!!! By popular demand, here is an artist’s interpretation of #natinaction if there WERE puppies and I DID get a tattoo.
Next year!
#scopesummit #scopeinfocus -
Citeline
@Citeline
This is not a drill. Come to booth 1206 for the best cupcake you’ve ever had!
#scopesummit #scopeinfocus #natinaction -
Citeline
@Citeline
So apparently I “can’t play our anagram game” because I’m “not eligible to win an Apple Watch as an employee” and I “wrote the questions so it wouldn’t be fair”…
Why not try YOUR luck at Booth 1206 this #scopesummit and see if you can win our top prize? Here’s a taster!
Why anagrams, you ask? We’ve brought this challenge to SCOPE because it mirrors exactly what we do every day: we take complex, noisy information and turn it into something clear, usable, and insight-ready.
Enough of the metaphor, though. Comment your guesses below. And let me know if we should share more…
#scopeinfocus #natinaction -
Citeline
@Citeline
A fantastic session was delivered by Claire Riches from Citeline and Melissa Harris from Fortrea on taming “unicorn” protocols here at #scopesummit!
We heard how protocol complexity is hurting recruitment and retention, and how real‑world data + AI — with humans in the lead — can pressure‑test criteria, optimize sites and speed timelines.
They provided inspiring examples, strong patient focus, and a clear call: start feasibility early and design with participants in mind.
Great conversation and practical takeaways for trial teams.
Let’s continue the conversation! Find out more about Citeline and get in touch here vist.ly/4qcxc
#scopeinfocus #natinaction #clinicaltrials #feasibility #patientcentricity #realworlddata -
Citeline
@Citeline
The sheer size of this conference is almost overwhelming, and it’s so exciting to imagine what industry changes are occurring right here at this al fresco lunch!
If you’re looking for unbiased global coverage to offer context-rich insights into the industry, look no further than Citeline News and Insights.
We’re offering you a 7-Day free trial across any one of our publications covering commercial insights, regulatory and policy, and medtech news: vist.ly/4qcsg
Click the link above, send me (Nathalie Roth) a message or come find us at Booth #1206 and we’ll get you set up! -
Citeline
@Citeline
I hope you caught Suzanne Caruso’s inspiring session on how AI is reshaping the clinical trial workflow!
What really stood out was her practical framing — focusing on specific AI tools that solve real problems, from predictive modeling and NLP to quality‑signal detection and workflow agents.
I loved her emphasis on keeping humans at the center while letting AI handle the repetitive 80% so teams can focus on high‑value decisions.
A great, grounded look at where AI is truly driving impact today.
If you missed this session , and want to discuss, Suzanne is here and we’re ready to meet you! Just swing by booth 1206 or set up a meeting for during or after #scopesummit.
#scopeinfocus #natinaction -
Citeline
@Citeline
Congrats to Christina Masturzo and Anjani Varma for their excellent session at #scopesummit!
They discussed a rescue study that was a Phase III pancreatic cancer trial where they used AI + RWD, resulting in: a small protocol tweak = ~15–20% boost in projected enrollment, 199 new US site opportunities, ~50 top investigators surfaced, and 8 new countries recommended — all delivered in just 4 days.
Mind = blown.
Looking for more case studies and use cases for our proprietary data? Look no further: vist.ly/4qc5c
And comment or get in touch on that page if you’d like to discuss how we can help on your journey!
#scopeinfocus #natinaction -
Citeline
@Citeline
So far I’ve found exactly 0 puppies at SCOPE - can anyone prove me wrong? I did see a company offering tattoos - yes, real tattoos - at their booth, which I was 🤏this🤏 close to signing up for. Maybe next year!
So what’s at our booth, 1206?
• A chance to win an Apple Watch for playing our brand new game by the name of Pharma De-Scramble!
• Information on our Best of Show entry, PatientMatch - and your chance to vote for us
• A plethora of our solutions experts ready for you to ask questions, meet for the first time in person, or just say hi!
• Use cases, demo stations, and information on our proprietary data and how we’re making AI work for you.
I’ll be there too, and after our customer reception last night, if you bring me a coffee you’ll have yourself a new best friend.
Enjoy day 3!!!
#scopesummit #scopeinfocus #natinaction -
Citeline
@Citeline
It’s Wednesday at SCOPE, and there’s still a full morning and part of an afternoon to vote for PatientMatch in the Best of Show competition! vist.ly/4qb6r
Now, I’d never expect you to vote for something without having all the facts — so here’s @georgeingram and @cassandratramutola giving you a quick overview of what PatientMatch is built for.
P.S. If you want to see it in person, just come to booth 1206 - we’ll be glad to take you through it.
See you soon!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Looking for Citeline? Our booth is easy to find! Head through the main entrance, turn right, and you’ll find us at #1206.
Want to book a meeting with us? Visit vist.ly/4q8zc
#scopesummit #scopeinfocus #natinaction -
Citeline
@Citeline
Love anagrams? Fancy a new watch? Come play Pharma De-Scramble! We’ve anagrammed some big names in Pharma – solve them and you could win an Apple Watch at the end of the conference, or $50 each day!
Fellow attendees have been stumped on a couple –bragging rights are up for grabs if you think you’re smart enough!
#scopesummit #scopeinfocus#NatInAction -
Citeline
@Citeline
It’s Exhibits Day 1 at #scopesummit!!! Here’s a natter on what we’re up to!
P.S. you can see our full schedule HERE: vist.ly/4q8a6
And our use cases HERE: vist.ly/4q8a8
See you at Booth 1206!
#scopeinfocus #natinaction -
Citeline
@Citeline
I’ve been catching up with three of our excellent product specialists! They’re walking me through how Citeline helps to meet diversity goals and patient recruitment. If you’d like to hear about it, pop by 1206 and we’ll book some time to chat!
#scopesummit #natinaction -
Citeline
@Citeline
It’s a beautiful day at #scopesummit!! Local news reckons we don’t need coats today, but I beg to differ…
Once you’re in the warm, be sure to come visit us at Booth 1206! And if you’d like to book a meeting, you can do so here vist.ly/4q7g6
See you soon!
#scopeinfocus #natinaction -
Citeline
@Citeline
Day one is done at #scopesummit! Now enjoying a well-deserved Winter Games themed mocktail and two excellent colleagues from the marketing team Lauren and Carolyn.
Come back to us tomorrow for a FULL DAY of #scopeinfocus #natinaction, and don’t forget you can check out our stage schedule here: vist.ly/4q55i
Til tomorrow! -
Citeline
@Citeline
Session 1 at SCOPE reminded us why we’re all here, and particularly why patient-centered clinical research matters, with powerful stories from Jane Myles, Brad Watts, and Lindsay Guentzel which put “hope” at the center — hope that fuels participation, but also exposes hidden burdens: slow site responses, lengthy screening, confusing consent, travel and out-of-pocket costs, lack of reliable site contacts, and unequal access to advanced therapies like CAR T.
Key takeaways:
- Hope drives patients to trials, but we must reduce the logistical and emotional load that makes participation feel like a superhuman effort.
- Patients want better communication, clear points of contact, travel support/reimbursement, and more accessible trial options.
- Education and access are critical — for patients, caregivers, and clinicians — so novel therapies can reach more people and, one day, move earlier in treatment pathways.
Grateful to Brad and Lindsey for sharing their journeys - thank you!
#scopesummit #scopeinfocus #natinaction -
Citeline
@Citeline
The crowd is forming outside the SCOPE opening keynote room - we’re going to be sitting pretty front and center! Key takeaways to follow! Don’t forget you can check out our schedule here: vist.ly/4q4dt
-
Citeline
@Citeline
Tomorrow, we go live at #scopesummit!
We’re thrilled to announce that Nathalie Roth is taking over our page as she on the floor at SCOPE. #natinaction is ready to bring you exclusive insights, behind-the-scenes moments, and real-time updates from the event. #scopeinfocus -
Citeline
@Citeline
We’re heading to SCOPE.
At Citeline, we talk with teams every day about where clinical planning starts to break down, and the real cost of getting those decisions wrong.
If you’ll be in Orlando, stop by booth #1206 or set up time with our team here: vist.ly/4pxu3 -
Citeline
@Citeline
Ready to see how AI is revolutionizing medtech? vist.ly/4pw97
Download the new Medtech Insight eBook for expert analysis on dealmaking trends, patient-focused innovations, and real-world perspectives from clinicians and patients. -
Citeline
@Citeline
Updates for December 2025.
Visit vist.ly/4pvrw for the past 3 months of critical global clinical trial disclosure and regulatory insights and updates. -
Citeline
@Citeline
Planning a Phase III trial in a new therapeutic area without prior experience is tough: vist.ly/4ptfx
One sponsor used RWD and AI to assess feasibility, validate CRO strategy, and select the right sites; resulting in a confident plan delivered in just three weeks. -
Citeline
@Citeline
AI only works when the data behind it can be trusted.
That’s why Citeline pairs curated clinical intelligence with AI built for real-world decisions.
See it in action at SCOPE — visit us at booth #1206 — or explore the use cases now: vist.ly/4pscm #citelineatscopeThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Grab your tickets — it’s time to head to Orlando.
From Monday, we’ll be handing the reins over to the team on site at SCOPE, sharing updates straight from the conference floor.
We still have a few meeting slots available.
Find time with the team:
vist.ly/4pqdy -
Citeline
@Citeline
The January edition of Citeline’s Patient Recruitment Pulse is live! vist.ly/4pmq5
In our first monthly Pulse, we dive into insights from the 2025 CISCRP Perceptions & Insights Study, highlighting where expectations, trust, and engagement stand today. -
Citeline
@Citeline
In an interview with @Clin_Trials, Matt Holms, VP of Sales @Citeline, discussed trends of sponsors assuming a larger role in site selection & CRO oversight & using robust data that includes real-world data to validate feasibility before launch:
vist.ly/4phyf -
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4pgtw
Today we revisit our chat with @NereS's executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive. -
Citeline
@Citeline
Launching a trial in a new therapeutic area without internal data is a challenge: vist.ly/4pdhv
One sponsor used real-world data and AI to validate their CRO’s strategy, select the right sites, and avoid delays and costly amendments. -
Citeline
@Citeline
Let’s connect at SCOPE 2026.
We’ll be in Orlando and look forward to reconnecting with colleagues and meeting new faces.
Stop by booth #1206 to talk with our team.
Already planning your schedule?
Find time to connect with our team - vist.ly/4pcab -
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4pbii
Over the next few weeks, we will be sharing highlights from the 2025 season. Today we revisit our chat about creativity in consumer health with @ALLCreativeLDN founder and managing director Beverley Law. -
Citeline
@Citeline
It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4p966
-
Citeline
@Citeline
vist.ly/4p8vs | In a video interview with @Clin_Trials, Heidi Chen, @Citeline, discussed the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup.
-
Citeline
@Citeline
AI is only as good as the data behind it.
When data isn’t accurate, connected, and curated, AI amplifies risk rather than reducing it.
At Citeline, data quality comes first. We keep data in focus so our AI delivers insight teams can trust.
vist.ly/4p7ut -
Citeline
@Citeline
AI is unlocking new possibilities in clinical trial planning: vist.ly/4p4x3
One biotech team used predictive modeling and SmartDesign tools to shape protocol and site strategy, improving recruitment forecasts and feasibility outcomes. -
Citeline
@Citeline
Missed ESMO 2025? Get the insights and analysis in one place: vist.ly/4n2ub
The Scrip ESMO 2025 eBook is your essential roundup of the biggest breakthroughs, expert interviews, and commercial impact from this year’s congress in Berlin. -
Citeline
@Citeline
We’re heading to SCOPE.
At Citeline, we talk with teams every day about where clinical planning starts to break down, and the real cost of getting those decisions wrong.
If you’ll be in Orlando, stop by booth #1206 or set up time with our team here: vist.ly/4n2b7 -
Citeline
@Citeline
vist.ly/4nykd | Our team’s proximity to APAC markets gives us unique insights — but we always keep the bigger picture in mind. See how we blend local knowledge with global perspectives to keep you ahead.
-
Citeline
@Citeline
As the industry prepares for SCOPE, key themes are coming into focus: vist.ly/4nx3c
Ahead of the event, our experts shared their predictions on what’s next. Let’s continue the conversation. Come meet the team at booth #1206. -
Citeline
@Citeline
Updates for December 2025.
Visit vist.ly/4ntvs for remaining countries and critical
global clinical trial disclosure and regulatory insights. -
Citeline
@Citeline
Citeline senior analyst Emma Wille provided insights on the prospect of insurance coverage for psychedelic medicines in articles in @nytimes (subscription required) vist.ly/4nsqx and @BostonGlobe (subscription required) vist.ly/4nsr3
-
Citeline
@Citeline
Protocol decisions have a bigger impact on enrollment than most teams realize.
Design with Enrollment in Mind: The Feasibility-Informed Protocol
Track: C1 – Trial Design & Protocol Development
Feb 3 | 5:10pm
If you’re attending SCOPE, this is a must-see! -
Citeline
@Citeline
It’s not just about having AI—it’s about applying it to real clinical challenges.
@Citeline applies AI across its clinical solutions to bring clarity to complex trial planning and execution.
This is AI in action.
Explore our AI-driven clinical solutions: vist.ly/4nhsq -
Citeline
@Citeline
Lean biotech teams need smart, scalable support: vist.ly/4ngzh
Instead of training on complex tools, one sponsor relied on expert-led AI and real-world data solutions to guide protocol development and CRO selection–resulting in fewer delays & strategy built for growth. -
Citeline
@Citeline
Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4nejb
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
How is AI shaping the future of medtech? vist.ly/4nafr
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges. Get a first look at the trends driving smarter, more personalized healthcare! -
Citeline
@Citeline
Join Ben Evans for a session on the intricate regulatory landscape of clinical trial data disclosure in Asia. vist.ly/4n566
Navigate through diverse transparency standards, compliance demands and truly transform the way you see global regulatory data disclosure. -
Citeline
@Citeline
SCOPE is almost here — vist.ly/4n44c
From feasibility and enrollment to protocol design and practical AI, @Citeline will be on stage sharing how teams are making more confident clinical decisions earlier backed by decision-ready data. -
Citeline
@Citeline
vist.ly/4n43h #scripjpm2026 | You may be back at your desk, but you can keep up with with the final installment of Scrip’s #jpm26 notebook.
Check out Scrip for more JPM coverage in the coming weeks! -
Citeline
@Citeline
Although the updated ICH GCP E6(R3) guidance took effect in July, sponsors are still grappling with the best approach for ensuring their clinical trials are compliant.
Our Good Clinical Practice Hub is your nexus for all things ICH. Start exploring:
vist.ly/4my8v -
Citeline
@Citeline
Learn how CROs are scaling smarter without hiring: vist.ly/4mw2x
Growth doesn’t always mean more staff. Learn how others are reallocating resources, streamlining execution, and staying competitive in a fast-moving market. -
Citeline
@Citeline
#jpm2026 Day 3 Notebook: vist.ly/4mwq9 | Check back tomorrow for updates with Scrip's daily notebook from JPM! #scripjpm2026
The impact of the US policy environment continues to be a concern for the biopharmaceutical industry.
✔️ Scrip’s @MandyJackson spoke with BMS’s Adam Lenkowsky about the expected impact of the company’s most-favored nation drug pricing deal with the Trump administration
✔️ Scrip’s Jessica Merrill interviewed @sanofi about how the firm is viewing the mounting anti-vaccine rhetoric in the US as a time to double down on vaccine M&A.
✔️ AI continues to be a transformative force, GSK’s Tony Wood explained, and @AstraZeneca announced its acquisition of Modella AI.
Catch more of the latest news and insights from company presentations, panels and interviews in our daily notebook: vist.ly/4mwq9 -
Citeline
@Citeline
In our latest People Behind the Products feature, discover how Francine harnesses her passion for clinical trial disclosure to help sponsors stay compliant with regulatory disclosure requirements. vist.ly/4mtqz #peoplebehindtheproducts
-
Citeline
@Citeline
Asia’s Biopharma Revolution: vist.ly/4mtbg
China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs. -
Citeline
@Citeline
#jpm2026 Day 2 Notebook: vist.ly/4ms79 | Check Scrip's daily notebook for more updates from JPM! #scripjpm2026
-
Citeline
@Citeline
Smarter protocol design starts here. Cohort SmartBuilder, Citeline’s newest AI-powered solution, helps identify realistic patient cohorts from the start.
Success starts with feasible cohorts.
Explore Cohort SmartBuilder: vist.ly/4mnwu -
Citeline
@Citeline
#jpm2026: Investors, Execs & Reporters Flock to SF! Day 1 buzzes with concern over Trump’s impact on biomedical research and awe for China's biopharma boom. Dive deeper into these key themes in Scrip’s daily notebooks – your insider guide full of insights and developments: vist.ly/4mmjf
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/4mmji -
Citeline
@Citeline
Are you a practicing physician? Please take a short (10 min) survey on how you discover and evaluate clinical trial information for your patients: vist.ly/4mi5k
As a thank-you, with Greater Gift, we’ll donate a vaccine to someone in need for every survey completed. -
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4mgwk
Today we revisit our chat with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond. -
Citeline
@Citeline
Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4mdsc
-
Citeline
@Citeline
In an article in WIRED on approval of an oral version of Novo Nordisk’s Wegovy, @Citeline analyst @TimBlackstock provided insights into how this new version will affect the obesity market: vist.ly/4m8qb
-
Citeline
@Citeline
A @PharmaVoice article on the Biosecure Act referenced the finding from Citeline’s 2025 Annual Clinical Trials Roundup that China’s Jiangsu Hengrui Pharmaceuticals dethroned UK-based AstraZeneca as the world’s top clinical trial sponsor in 2024: vist.ly/4m7aj
-
Citeline
@Citeline
AI is transforming patient care and product innovation in medtech - are you keeping up? vist.ly/4m3p7
Our latest eBook from Medtech Insight covers $9.2B in AI-enabled device deals, strategies for embracing AI-driven care, and insights from industry leaders. -
Citeline
@Citeline
Excited for SCOPE this year?
The focus is always on what’s coming next — what are you expecting to hear?
👉 Read our 2026 pharma predictions:
vist.ly/4k2it
And if you’re heading to Orlando, make sure to stop by booth #1206 — we’d love to connect. -
Citeline
@Citeline
No internal data. No prior experience. Still ready to launch: vist.ly/4kvub
A global sponsor used data-driven feasibility and AI tools to validate their CRO’s strategy and build a strong trial plan. They saved time, reduced risk, and moved forward with confidence. -
Citeline
@Citeline
vist.ly/4kqsk | In a video interview with @Clin_Trials, Heidi Chen of @Citeline provided insights on how sponsors and CROs are maintaining innovation as they adapt to evolving ICH GCP guidelines.
-
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4kn2s
Over the next few weeks, we will be sharing highlights from the 2025 season. Today we revisit our chat with PAGB CEO Michelle Riddalls about what the association is doing to promote self-care. -
Citeline
@Citeline
Explore how CROs are winning contracts in unfamiliar indications: vist.ly/4kk2n
With AI-powered analytics, proposals are built faster and backed by evidence sponsors trust. Learn how others are expanding their reach without increasing internal resources. -
Citeline
@Citeline
Curious about the risks and rewards of AI in pharma?
vist.ly/4kj2h
Our latest webinar covers practical limitations, data protection concerns, and what’s next for the industry.
✔️US FDA’s AI Initiatives
✔️UK MHRA’s In Silico Trials
✔️Pharmacovigilance Innovation -
Citeline
@Citeline
Matt Holms, Citeline’s VP of Sales, Patient Engagement & Recruitment, emphasizes the importance of collaboration in solving patient recruitment problems.
Watch for more on the challenges and opportunities of the current generation of patient recruitment: vist.ly/4kfua -
Citeline
@Citeline
Citeline is able to capture data in a way that ensures patient confidentiality and the ability to cross-link through the patient journey.
The right data can give sponsors an edge in patient recruitment. Watch the full webinar, Built-In Data Advantage: vist.ly/4kdwd -
Citeline
@Citeline
Discover how CROs are staying on budget and ahead of schedule: vist.ly/4kdam
CROs are using feasibility modelling and AI-driven forecasting to avoid delays and control costs. With RWD guiding site selection and planning, teams can stay on track and protect margins. -
Citeline
@Citeline
Missed ESMO 2025? Get the insights and analysis in one place: vist.ly/4kb85
The Scrip ESMO 2025 eBook is your essential roundup of the biggest breakthroughs, expert interviews, and commercial impact from this year’s congress in Berlin. -
Citeline
@Citeline
Catch Our on-demand webinar on: Navigating Disclosure Complexity' with RAPS and Citeline experts Brian Kuzich and Jack Marks. | vist.ly/4k95r
Ready to revolutionize transparency in pharma and medtech? -
Citeline
@Citeline
Join Ben Evans for a session on the intricate regulatory landscape of clinical trial data disclosure in Asia. vist.ly/4k65b
Navigate through diverse transparency standards, compliance demands and truly transform the way you see global regulatory data disclosure. -
Citeline
@Citeline
Asia’s Biopharma Revolution: vist.ly/4j2r3
China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs. -
Citeline
@Citeline
vist.ly/4jzxy | In a video interview with @Clin_Trials, Heidi Chen, @Citeline, discussed growth in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup.
-
Citeline
@Citeline
vist.ly/4jyr8 | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater.
Discover six practical strategies that biotech leaders are using to prioritize pipelines, optimize clinical trials, and accelerate growth.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
The updated ICH GCP E6(R3) guidelines are reshaping the way clinical trials are run.
With clearer roles, elevated transparency, and greater expectations across the full data lifecycle, these changes mark a significant shift for clinical research.
vist.ly/4jxmn -
Citeline
@Citeline
Curious about AI’s impact on early disease detection and mergers & acquisitions in medtech?vist.ly/4jx8i
Our infographic breaks down the latest stats, including $9.2B in deals for 2025, and what clinicians and patients expect from AI innovations. See it at a glance! -
Citeline
@Citeline
Although the updated ICH GCP E6(R3) guidance took effect in July, sponsors are still grappling with the best approach for ensuring their clinical trials are compliant.
Our Good Clinical Practice Hub is your nexus for all things ICH. Start exploring:
vist.ly/4jvue -
Citeline
@Citeline
How are regulators using AI to speed up clinical trials and improve drug safety? vist.ly/4jvdk
Discover how the FDA, EMA, and MHRA are leveraging AI to accelerate trials, enhance safety, and streamline approvals. -
Citeline
@Citeline
Smarter protocol design starts here. Cohort SmartBuilder, Citeline’s newest AI-powered solution, helps identify realistic patient cohorts from the start.
Success starts with feasible cohorts.
Explore Cohort SmartBuilder: vist.ly/4jtmw -
Citeline
@Citeline
Meet Ella, the AI-powered assistant built into Citeline’s clinical solutions. Ella provides instant answers and deeper insights, streamlining research so your team can spend more time on strategy, not searching
Discover Ella in action: vist.ly/4jrur -
Citeline
@Citeline
vist.ly/4jqyp
Discover today, how we're revolutionizing transparency in pharma and medtech. With Citeline's on-demand webinar, 'Navigating Disclosure Complexity', you can explore the intricacies of clinical trial landscape and disclosure processes. -
Citeline
@Citeline
It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4jnta
-
Citeline
@Citeline
Are you a practicing physician? Please take a short (10 min) survey on how you discover and evaluate clinical trial information for your patients: vist.ly/4jjxy
As a thank-you, with Greater Gift, we’ll donate a vaccine to someone in need for every survey completed. -
Citeline
@Citeline
AI is unlocking new possibilities in clinical trial planning: vist.ly/4jiud
One biotech team used predictive modeling and SmartDesign tools to shape protocol and site strategy, improving recruitment forecasts and feasibility outcomes. -
Citeline
@Citeline
Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4jf2f
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4jezs
-
Citeline
@Citeline
Ready to see how AI is revolutionizing medtech? vist.ly/4jdhf
Download the new Medtech Insight eBook for expert analysis on dealmaking trends, patient-focused innovations, and real-world perspectives from clinicians and patients. -
Citeline
@Citeline
In an interview with @Clin_Trials, Matt Holms, VP of Sales @Citeline, discussed trends of sponsors assuming a larger role in site selection & CRO oversight & using robust data that includes real-world data to validate feasibility before launch:
vist.ly/4jcj3 -
Citeline
@Citeline
vist.ly/4jbmp | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Launching a trial in a new therapeutic area without internal data is a challenge: vist.ly/4jars
One sponsor used real-world data and AI to validate their CRO’s strategy, select the right sites, and avoid delays and costly amendments. -
Citeline
@Citeline
Strong leadership is key to securing biotech investment. Tune in to Episode 6 of #smallbiotechsbigdecisions: vist.ly/4jab8
➡️ Watch the episode: vist.ly/4jab8
➡️ Listen on the go: vist.ly/4jabb
➡️ Explore all episodes: vist.ly/4jabb -
Citeline
@Citeline
The biggest headlines from #jpm2026. vist.ly/4j75c
Our expert journalists, analysts, and sister brand @evaluatepharma will be on the ground, bringing you context and insights from the most influential healthcare investment conference. -
Citeline
@Citeline
Powered by #trialscopeintelligence | November 2025 updates:
Visit vist.ly/4j5j5 for remaining countries and critical
global clinical trial disclosure and regulatory insights. -
Citeline
@Citeline
In our latest People Behind the Products feature, discover how Francine harnesses her passion for clinical trial disclosure to help sponsors stay compliant with regulatory disclosure requirements. vist.ly/4i2qb #peoplebehindtheproducts
-
Citeline
@Citeline
Discover how AI is revolutionizing pharma regulation in our on-demand webinar: vist.ly/4iz84
Join the Pink Sheet editorial team as they break down the EU AI Act, UK’s innovation approach, and what it means for drug developers. -
Citeline
@Citeline
See the numbers behind the clinical trial surge! vist.ly/4iwp8
Our latest infographic visualizes standout trends across the 4,900+ industry-sponsored trials completed in 2024 — the highest number in nearly a decade. Download the full report for deeper insights. -
Citeline
@Citeline
vist.ly/4iw4m | @Clin_Trials’ Dec. 4 ACT Brief podcast featured insights from Heidi Chen, @Citeline, on the shift toward more targeted and strategy-driven clinical development based on the 2025 edition of Citeline’s Annual Clinical Trials Roundup.
-
Citeline
@Citeline
In an interview with @Clin_Trials, Matt Holms, VP of Sales @Citeline, discussed trends of sponsors assuming a larger role in site selection & CRO oversight & using robust data that includes real-world data to validate feasibility before launch:
vist.ly/4iuc6 -
Citeline
@Citeline
Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4isnk
-
Citeline
@Citeline
How does your pipeline measure up? vist.ly/4ipny
With Company Compare from Pharmaprojects+, benchmark by trial activity, disease focus, and development stage to uncover new opportunities.
See the full feature set: vist.ly/4ipny -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/4ipc4 to learn more.
Watch the video in English: vist.ly/4ipca -
Citeline
@Citeline
vist.ly/4ikyd | In a video interview with @Clin_Trials, Heidi Chen, @Citeline, discussed the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup.
-
Citeline
@Citeline
Your Inside Track to #jpm2026. vist.ly/4ij9b
Deals. Disruptors. Innovations. The JPM Healthcare Conference is where the future of pharma takes shape.
Register for Daily Updates from our sister brand @evaluatepharma to get the headlines and context that matter most. -
Citeline
@Citeline
Matt Holms of @Citeline and @Clin_Trials discussed converting identified patients into enrollees through organizing data assets, activating non-research HCPs, & building avenues for referral with compliant recompense.
vist.ly/4ihmk #patientrecruitment -
Citeline
@Citeline
vist.ly/4igju | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater.
Discover six practical strategies that biotech leaders are using to prioritize pipelines, optimize clinical trials, and accelerate growth.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Matt Holms, Citeline’s VP of Sales, Patient Engagement & Recruitment, emphasizes the importance of collaboration in solving patient recruitment problems.
Watch for more on the challenges and opportunities of the current generation of patient recruitment: vist.ly/4if9h -
Citeline
@Citeline
In a video interview with Applied Clinical Trials, @MattHolms, Vice President of Sales at Citeline, discusses how technology and data-driven strategies can help overcome the persistent barriers slowing patient recruitment vist.ly/4iaxs
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
How is AI shaping the future of medtech? vist.ly/4i9h9
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges. Get a first look at the trends driving smarter, more personalized healthcare! -
Citeline
@Citeline
Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4i69a
-
Citeline
@Citeline
The 44th Annual JPM Healthcare Conference is where the future of pharma is shaped: make sure you’re on the list: vist.ly/4hzgw
Sign up for Daily Updates from our sister brand @evaluatepharma, attending #jpm26, to get the key headlines, context, and insights that matter. -
Citeline
@Citeline
Past performance can shape future strategy: citeline.com/plus
With Trends Analytics from Pharmaprojects+, explore historical development patterns to make smarter, data-driven decisions for your pipeline.
Learn more: citeline.com/plus -
Citeline
@Citeline
AI and real-world data are changing the rules of engagement. Listen to full episode of #smallbiotechsbigdecisions: vist.ly/4huan
➡️ Listen on the go: vist.ly/4huar
➡️ Explore all episodes: vist.ly/4huar -
Citeline
@Citeline
Launching a trial in a new therapeutic area without internal data is a challenge: vist.ly/4hspc
One sponsor used real-world data and AI to validate their CRO’s strategy, select the right sites, and avoid delays and costly amendments. -
Citeline
@Citeline
The ICH GCP updates are here—what’s your next move?
The latest revisions to ICH GCP guidelines introduce new expectations for trial oversight, data integrity, and more.
Our on-demand webinar breaks down what’s changed and how you can adapt:
vist.ly/4hp86 -
Citeline
@Citeline
Powered by #trialscopeintelligence | November 2025 updates:
Visit vist.ly/4hmkx for remaining countries and critical
global clinical trial disclosure and regulatory insights. -
Citeline
@Citeline
Matt Holms of @Citeline and @Clin_Trials discussed converting identified patients into enrollees through organizing data assets, activating non-research HCPs, & building avenues for referral with compliant recompense.
vist.ly/4hdcw #patientrecruitment -
Citeline
@Citeline
vist.ly/4hbu9 | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Matt Holms, Citeline’s VP of Sales, Patient Engagement & Recruitment, emphasizes the importance of collaboration in solving patient recruitment problems.
Watch for more on the challenges and opportunities of the current generation of patient recruitment: vist.ly/4h8bh -
Citeline
@Citeline
Explore how CROs are winning contracts in unfamiliar indications: vist.ly/4h7hr
With AI-powered analytics, proposals are built faster and backed by evidence sponsors trust. Learn how others are expanding their reach without increasing internal resources. -
Citeline
@Citeline
🚨 Don’t miss the report everyone is talking about.
The Scrip Asia 100 ranks the top 100 pharmaceutical companies in Asia by sales and delivers exclusive insights into the region’s most powerful moves.
Download your copy! vist.ly/4h3cr -
Citeline
@Citeline
Webinar alert! Last chance: vist.ly/4gzpa
Pharma teams don’t need more data—they need a unified data picture to make faster, better decisions.
This webinar shows how connected data and trustworthy AI optimize protocols, accelerate feasibility and link metrics. -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/4gxdb
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/4gucc
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Citeline is able to capture data in a way that ensures patient confidentiality and the ability to cross-link through the patient journey.
The right data can give sponsors an edge in patient recruitment. Watch the full webinar, Built-In Data Advantage: vist.ly/4gty2 -
Citeline
@Citeline
You bring the questions. We bring 500+ expert voices. vist.ly/4grxa | Discover how Ask the Analyst adds power to your expertise.
With Ask the Analyst, Citeline subscribers get direct access to a network of over 500 industry experts in their fields. -
Citeline
@Citeline
vist.ly/4gqc4 | In an @endpointsnews article on the potential of neurology assets in biopharma M&As, Citeline analyst Emma Wille comments on how the adoption of AI might speed identification of successful candidates.
-
Citeline
@Citeline
Missed ESMO 2025? Get the insights and analysis in one place: vist.ly/4gkyx
The Scrip ESMO 2025 eBook is your essential roundup of the biggest breakthroughs, expert interviews, and commercial impact from this year’s congress in Berlin. -
Citeline
@Citeline
October 2025 updates:
✔️ Venezuela fee hikes; Belgium’s faster assessments (Jan 2026)
✔️ UK transparency rules (Apr 2026)
✔️ Indonesia registry migration
✔️ ISRCTN registrations during ClinicalTrials[.]gov delays
✔️ ANZCTR prioritization for local trials
vist.ly/4gkdc -
Citeline
@Citeline
In a @FiercePharma article on @GSK's Blenrep, senior analyst David Dahan weighs in on @JNJNews's Darzalex, the drug's main contender: vist.ly/4ghdm
-
Citeline
@Citeline
Catch Our on-demand webinar on: Navigating Disclosure Complexity' with RAPS and Citeline experts Brian Kuzich and Jack Marks. | vist.ly/4ge29
Ready to revolutionize transparency in pharma and medtech? -
Citeline
@Citeline
Are you using ‘trustworthy’ AI?
Join us to see how unified, high-quality data integrated with trusted AI can transform your protocol optimization, feasibility, forecasting and planning.
Register today: vist.ly/4gdwn -
Citeline
@Citeline
Join Ben Evans for a session on the intricate regulatory landscape of clinical trial data disclosure in Asia. vist.ly/4ga7u
Navigate through diverse transparency standards, compliance demands and truly transform the way you see global regulatory data disclosure. -
Citeline
@Citeline
ICH GCP guidelines have changed. Are you prepared?
These updates impact everyone running clinical trials—from sponsors to CROs. Our experts break down what’s new and what you need to do next in our on-demand webinar.
✅ Watch now: vist.ly/4g7wr -
Citeline
@Citeline
Asia’s Biopharma Revolution: vist.ly/4g5u2
China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs. -
Citeline
@Citeline
The final webinar in our clinical trial disclosure series spotlights plain language summaries - a growing global requirement that bridges science and patient understanding.
Gain actionable insights to strengthen your approach to transparency: vist.ly/4g3tq -
Citeline
@Citeline
vist.ly/4fyzs | Unleash the future of clinical trials today with Citeline’s new AI Importer, redefining efficiency in protocol registration.
This trailblazing tool automatically fills 90+ fields in registration forms, reducing errors and saving you time. -
Citeline
@Citeline
Pharma teams don’t need more data — they need a unified data picture to make faster, better decisions.
This webinar shows how connected data and trustworthy AI optimize protocols, accelerate feasibility and link metrics.
Save your spot today: vist.ly/4fxg8 -
Citeline
@Citeline
The clinical trial rebound continues… for now.
Discover insights from 10,000+ trial initiations in our infographic: vist.ly/4fwpi
Which therapeutic areas are driving growth, which are in decline, how AI is reshaping trial design, and which sponsors led the way. -
Citeline
@Citeline
The updated ICH GCP E6(R3) guidelines are reshaping the way clinical trials are run.
With clearer roles, elevated transparency, and greater expectations across the full data lifecycle, these changes mark a significant shift for clinical research.
vist.ly/4ftu7 -
Citeline
@Citeline
Smart patient recruitment requires a flexible, integrated platform that reaches patients others miss. Find out how we can match the right patients with your clinical trials: vist.ly/4fsk2
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
vist.ly/4fq23 | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Episode 6 of #smallbiotechsbigdecisions explores what investors look for beyond good science. Watch the full episode here: vist.ly/4fpdh
➡️ Listen on the go: vist.ly/4fpdk
➡️ Explore all episodes: vist.ly/4fpdk -
Citeline
@Citeline
Dive into the fast-paced world of global generics, biosimilars, and value-added medicines! vist.ly/4fmhw
Discover the game-changers, keep an eye on market turbulence and meet the fresh faces on the scene with this exclusive infographic, powered by Generics Bulletin. -
Citeline
@Citeline
Planning Your Clinical Strategy for 2025? Start with the data: vist.ly/4fmb4
This infographic highlights the trial trends that defined 2024 — from disease hotspots to rising sponsors.
All data sourced from Trialtrove: vist.ly/4fmb7 -
Citeline
@Citeline
Although the updated ICH GCP E6(R3) guidance took effect in July, sponsors are still grappling with the best approach for ensuring their clinical trials are compliant.
Our Good Clinical Practice Hub is your nexus for all things ICH. Start exploring:
vist.ly/4fifx -
Citeline
@Citeline
vist.ly/4fia5 | Applied Clinical Trials’ Nov. 12 ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the growing trend of sponsors assuming greater data-backed oversight of site selection and CRO management.
-
Citeline
@Citeline
Join us in exploring the data that's reshaping the clinical trial landscape: vist.ly/4fhce
Together, we'll dive into trends from over 10,000 trial initiations and uncover which therapeutic areas are fueling growth and those on a downward trend. We'll delve into how AI is revolutionizing trial design and see who's leading the pack in new beginnings.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
#clinicaltrials #pharmar&D #drugdevelopment -
Citeline
@Citeline
Discover how clear communication transforms every step of the patient journey: vist.ly/4ffqd
A patient’s clinical trial journey begins long before the first visit, it starts with understanding. -
Citeline
@Citeline
Unravel the intricacies of clinical trial registries with us in Part 2 of our on-demand webinar series.
vist.ly/4fbij
Master the distinct nuances of registry requirements across different jurisdictions and choose the optimal registries for multi-jurisdictional studies. -
Citeline
@Citeline
Episode 6 of #smallbiotechsbigdecisions dives into the investor mindset, why good science isn’t enough, and how CEOs can build board relationships that drive long-term growth.
Watch: vist.ly/4fas7
Listen: vist.ly/4fasa
Explore: vist.ly/4fasa -
Citeline
@Citeline
Smarter protocol design starts here. Cohort SmartBuilder, Citeline’s newest AI-powered solution, helps identify realistic patient cohorts from the start.
Success starts with feasible cohorts.
Explore Cohort SmartBuilder: vist.ly/4f8gb -
Citeline
@Citeline
Are you using ‘trustworthy’ AI?
Join us to see how unified, high-quality data integrated with trusted AI can transform your protocol optimization, feasibility, forecasting and planning.
Register today: vist.ly/4f87a -
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4f78q
As 2025 draws to a close, we're taking a look back at another fascinating season of HBW Insight's Over the Counter podcast, brought to you by HBW Insight's David Ridley and @Citeline. -
Citeline
@Citeline
New ICH GCP guidelines are here. Compliance isn’t optional.
The latest revisions introduce changes that affect trial design, monitoring, and data integrity. Are you ready?
Our on-demand webinar gives you the insights you need to navigate this new era: vist.ly/4f428 -
Citeline
@Citeline
Discover how Citeline can revolutionize trial visibility and engagement: vist.ly/4f372
Struggling with recruitment? Manage complex trial info and boost patient engagement with Citeline's Trial Portfolio Websites. Invite simplicity and compliance to the process!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
October 2025 updates:
✔️ Venezuela fee hikes; Belgium’s faster assessments (Jan 2026)
✔️ UK transparency rules (Apr 2026)
✔️ Indonesia registry migration
✔️ ISRCTN registrations during ClinicalTrials[.]gov delays
✔️ ANZCTR prioritization for local trials
vist.ly/4e2m2 -
Citeline
@Citeline
In a recent @PharmaVoice article, Senior Analyst Natasha Boliter discusses the trend toward at-home vaccines: vist.ly/4ey28
While she outlines several areas of opportunity, she also points out potential roadblocks.
#astrazeneca #flumist -
Citeline
@Citeline
vist.ly/4evuy
Discover today, how we're revolutionizing transparency in pharma and medtech. With Citeline's on-demand webinar, 'Navigating Disclosure Complexity', you can explore the intricacies of clinical trial landscape and disclosure processes. -
Citeline
@Citeline
vist.ly/4euhs | Citeline's Clinical Trials Roundup provided an important insight for @PharmaVoice's article on the launch of a pivotal trial for MediciNova’s ALS drug MN-166, noting there were 60 new trial starts for ALS in 2024, more than double 2023’s starts.
-
Citeline
@Citeline
Are you a practicing physician? Please take a short (10 min) survey on how you discover and evaluate clinical trial information for your patients: vist.ly/4ethk
As a thank-you, with Greater Gift, we’ll donate a vaccine to someone in need for every survey completed. -
Citeline
@Citeline
Meet Ella, the AI-powered assistant built into Citeline’s clinical solutions. Ella provides instant answers and deeper insights, streamlining research so your team can spend more time on strategy, not searching
Discover Ella in action: vist.ly/4eskf -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/4eqv2
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
Join our impactful webinar! Discover the power of mapping patient journeys, leveraging RWD to identify top site performers, and turbocharge your recruitment strategies.
In partnership with @Xtalks | Register today! vist.ly/4eqc6 -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/4en8u
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/4ekx9 | In today’s biotech landscape, making smart, timely decisions is more critical than ever.
Explore how your team can do more with less and move with confidence in a competitive market.
#smallbiotechsbigdecisionThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/4egkt | Applied Clinical Trials’ Nov. 6 ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the bottlenecks that continue to stall recruitment and initiatives that can help break through the logjam.
-
Citeline
@Citeline
Modern trials demand modern tools: vist.ly/4efp7
Citeline’s SmartSolutions suite brings everything together: smarter protocols, feasible patient cohorts, proven site selection, and faster timelines. From first design to site activation, every step is powered by real-world data and AI-driven insights — so you can move forward with confidence.
SmartSolutions: shaping the future of trial planning.
Explore them now: vist.ly/4efp7
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
How does your pipeline measure up? vist.ly/4eeq8
With Company Compare from Pharmaprojects+, benchmark by trial activity, disease focus, and development stage to uncover new opportunities.
See the full feature set: vist.ly/4eeq8 -
Citeline
@Citeline
Cohort SmartBuilder, part of Citeline's AI-powered SmartSolutions suite of products: vist.ly/4e94j
Giving clinical planning teams real-time visibility into patient populations, helping them stress-test protocol designs and build studies with diversity and feasibility. -
Citeline
@Citeline
In a video interview with Applied Clinical Trials, Matt Holms, VP of Sales at Citeline, explains the importance of tailoring patient recruitment strategies to indication and geography and incorporating data-driven matching with supported referrals: vist.ly/4e94h
-
Citeline
@Citeline
🎙️Listen now! #overthecounterpodcast vist.ly/4e7kc
As 2025 draws to a close, we're taking a look back at another fascinating season of HBW Insight's Over the Counter podcast, brought to you by HBW Insight's David Ridley and @Citeline. -
Citeline
@Citeline
Join Ben Evans for a session on the intricate regulatory landscape of clinical trial data disclosure in Asia. vist.ly/4e38e
Navigate through diverse transparency standards, compliance demands and truly transform the way you see global regulatory data disclosure. -
Citeline
@Citeline
Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4dz2u
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Gene therapy continues to build momentum in oncology.
In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year.
Featuring data from Pharmaprojects and @ASGCTherapy.
Download the full report:This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/4dvxv | Unleash the future of clinical trials today with Citeline’s new AI Importer, redefining efficiency in protocol registration.
This trailblazing tool automatically fills 90+ fields in registration forms, reducing errors and saving you time. -
Citeline
@Citeline
Asia’s Biopharma Revolution: vist.ly/4duca
China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs. -
Citeline
@Citeline
Meet Ella, the AI-powered assistant built into Citeline’s clinical solutions. Ella provides instant answers and deeper insights, streamlining research so your team can spend more time on strategy, not searching
Discover Ella in action: vist.ly/4dtd8 -
Citeline
@Citeline
vist.ly/4dskh | Citeline’s Heidi Chen, Associate Director of Research and Commercial Services and co-author of the company’s annual Clinical Trials Roundup, spoke with @PharmaVoice about the accelerating research boom in China as well as other trends.
-
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/4ds6z to learn more.
Watch the video in English: vist.ly/4ds75 -
Citeline
@Citeline
Smarter protocol design starts here. Cohort SmartBuilder, Citeline’s newest AI-powered solution, helps identify realistic patient cohorts from the start.
Success starts with feasible cohorts.
Explore Cohort SmartBuilder: vist.ly/4dnds -
Citeline
@Citeline
Missed ESMO 2025? Get the insights and analysis in one place: vist.ly/4dmdy
The Scrip ESMO 2025 eBook is your essential roundup of the biggest breakthroughs, expert interviews, and commercial impact from this year’s congress in Berlin. -
Citeline
@Citeline
The updated ICH GCP E6(R3) guidelines are reshaping the way clinical trials are run.
With clearer roles, elevated transparency, and greater expectations across the full data lifecycle, these changes mark a significant shift for clinical research.
vist.ly/4djr2 -
Citeline
@Citeline
Manage complex recruitments with ease: vist.ly/4dh9a
Discover simplicity in complexity now! Learn how Citeline Trial Portfolio Websites can streamline the process by combining centralized trial access, automated updates, and built-in engagement tools.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Catch Our on-demand webinar on: Navigating Disclosure Complexity' with RAPS and Citeline experts Brian Kuzich and Jack Marks. | vist.ly/4df2y
Ready to revolutionize transparency in pharma and medtech? -
Citeline
@Citeline
vist.ly/4dfqr | Ella, our new AI-powered chat assistant, was trained on thousands of real, analyst-validated questions and queries.
The result? It knows how to help you find the answers you need — faster than ever — backed by Citeline’s industry-leading Trialtrove and Sitetrove data.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
In a video interview with Applied Clinical Trials, @MattHolms, Vice President of Sales at Citeline, discusses how technology and data-driven strategies can help overcome the persistent barriers slowing patient recruitment vist.ly/4dd3x
-
Citeline
@Citeline
vist.ly/4dby5 | In an @endpointsnews article on the potential of neurology assets in biopharma M&As, Citeline analyst Emma Wille comments on how the adoption of AI might speed identification of successful candidates.
-
Citeline
@Citeline
Protocol feasibility puzzle? Solved. Discover Citeline SmartSolutions: vist.ly/4db8i
With Ella’s AI-powered insights across the ecosystem, every piece works smarter together.
Smarter planning. Greater efficiency. Stronger outcomes. -
Citeline
@Citeline
In a @FiercePharma article on @GSK's Blenrep, senior analyst David Dahan weighs in on @JNJNews's Darzalex, the drug's main contender: vist.ly/4d6th
-
Citeline
@Citeline
Past performance can shape future strategy: citeline.com/plus
With Trends Analytics from Pharmaprojects+, explore historical development patterns to make smarter, data-driven decisions for your pipeline.
Learn more: citeline.com/plus -
Citeline
@Citeline
Discover how Citeline can revolutionize trial visibility and engagement: vist.ly/4d36m
Struggling with recruitment? Manage complex trial info and boost patient engagement with Citeline's Trial Portfolio Websites. Invite simplicity and compliance to the process!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Navigating through global disclosure rules? vist.ly/4cyne
Join us for our on-demand Global Clinical Trial Disclosure Webinar. Ben Evans, our Disclosure Regulations Research Manager, navigates you through disclosure requirements and timelines with actionable insights. -
Citeline
@Citeline
Join our impactful webinar! Discover the power of mapping patient journeys, leveraging RWD to identify top site performers, and turbocharge your recruitment strategies.
In partnership with @Xtalks | Register today! vist.ly/4cxq5 -
Citeline
@Citeline
Day 2 in full swing at #bioeurope!
Energy is high in Vienna as our team engages with biopharma leaders at booth #c178.
Come fuel your BIOEurope experience with a barista-crafted coffee and catch live demos in action at the Citeline booth! -
Citeline
@Citeline
vist.ly/4cu5c | Citeline's Clinical Trials Roundup provided insight for @PharmaVoice's article on the launch of a pivotal trial for MediciNova’s disease-modifying ALS drug MN-166, noting there were 60 new trial starts for ALS in 2024, more than double 2023’s starts.
-
Citeline
@Citeline
Momentum is shifting across the clinical research landscape.
See how trial initiations changed across every therapeutic area — and what it means for the year ahead in our latest Clinical Trial Roundup. vist.ly/4csf6 -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/4crvb
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Day 1 is off to a strong start, and Citeline is already proving to be the cherry on top of the #bioeurope experience. Our team is on the ground at booth #c178, engaging with biopharma leaders and diving into trial strategy, feasibility, and innovation.
-
Citeline
@Citeline
Although the updated ICH GCP E6(R3) guidance took effect in July, sponsors are still grappling with the best approach for ensuring their clinical trials are compliant.
Our Good Clinical Practice Hub is your nexus for all things ICH. Start exploring:
vist.ly/4cjpa -
Citeline
@Citeline
vist.ly/4cing | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater. Success now depends on making smarter choices with limited resources.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Explore key insights and analysis on the regulatory, political and commercial fallout: vist.ly/4ch9i
Download the article pack and uncover expert reporting and insights about what comes next. -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/4cfru
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Oncology continues to dominate global research — but it’s not the whole story. vist.ly/4ce5q
Our latest data from Trialtrove reveals how cancer trials compare with other fast-growing disease areas, including diabetes, respiratory infections, and hypertension. -
Citeline
@Citeline
Dive into the fast-paced world of global generics, biosimilars, and value-added medicines! vist.ly/4cd6x
Discover the game-changers, keep an eye on market turbulence and meet the fresh faces on the scene with this exclusive infographic, powered by Generics Bulletin. -
Citeline
@Citeline
Discover how Citeline can revolutionize trial visibility and engagement: vist.ly/4cbf5
Struggling with recruitment? Manage complex trial info and boost patient engagement with Citeline's Trial Portfolio Websites. Invite simplicity and compliance to the process!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Smarter protocol design starts here. Cohort SmartBuilder, Citeline’s newest AI-powered solution, helps identify realistic patient cohorts from the start.
Success starts with feasible cohorts.
Explore Cohort SmartBuilder: vist.ly/4c9rv -
Citeline
@Citeline
vist.ly/4c794 | Unleash the future of clinical trials today with Citeline’s new AI Importer, redefining efficiency in protocol registration.
This trailblazing tool automatically fills 90+ fields in registration forms, reducing errors and saving you time. -
Citeline
@Citeline
Looking for the cherry on top of your BIO-Europe experience?
Meet the Citeline team to discover how our trusted data and expert consulting help biopharma leaders move forward with confidence.
Visit us at booth #c178 vist.ly/4c5hp -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/4c3b8
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
How does your trial compare to the competition? Stop guessing — see for yourself with Citeline’s Trial Health Calculator. vist.ly/4bz7h
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
Gene therapy continues to build momentum in oncology.
In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year.
Featuring data from Pharmaprojects and @ASGCTherapy.
Download the full report:This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Manage complex recruitments with ease: vist.ly/4bxug
Discover simplicity in complexity now! Learn how Citeline Trial Portfolio Websites can streamline the process by combining centralized trial access, automated updates, and built-in engagement tools.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Download the infographic to preview the full editorial series: vist.ly/4bwsx
Get a visual snapshot of the companies shaping the global generics, biosimilars, and value-added medicines market.
✔️ Standout performers
✔️ Market shifts
✔️ Emerging players -
Citeline
@Citeline
vist.ly/4bt2x | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater.
Discover six practical strategies that biotech leaders are using to prioritize pipelines, optimize clinical trials, and accelerate growth.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/4bs4r
Discover today, how we're revolutionizing transparency in pharma and medtech. With Citeline's on-demand webinar, 'Navigating Disclosure Complexity', you can explore the intricacies of clinical trial landscape and disclosure processes. -
Citeline
@Citeline
🌍 Clinical trial disclosure is no longer one-size-fits-all.
As heard in this session: evolving global regulations demand specialized knowledge and constant tracking.
📹 Watch the clip to learn how Citeline helps you stay compliant in a complex landscape. -
Citeline
@Citeline
vist.ly/4bqym
Unprecedented changes are coming to UK's clinical trials in the biggest overhaul in 2 decades! These reforms — involving consent, contracting, trial transparency and much more — will drastically reshape the domain. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/4bq5a
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/4bp2e | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/4bnvd
✔️ Watch the full episode: vist.ly/4bnvd
✔️ Listen on the go: vist.ly/4bnve
✔️ Explore all episodes: vist.ly/4bnve -
Citeline
@Citeline
Trialtrove+ goes beyond trial design — it reveals how studies are performing in the real world: vist.ly/4bmn5
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
🌐 What does the future of patient recruitment look like?
🔗 vist.ly/4bm3u
Powered by proprietary data, real-world data (RWD), and a last-mile ecosystem, Citeline unveils its 3rd-generation model, to drive smarter, faster clinical trial enrollment.
📅 October 29 -
Citeline
@Citeline
Where do you stand in the pipeline race? vist.ly/4bk54
Pharmaprojects+ let’s you benchmark your portfolio against competitors: by disease area, development stage, and pipeline activity — all in just a few clicks. -
Citeline
@Citeline
Immerse yourself in the dynamic world of generics, biosimilars, and value-added medicines! Check out our infographic preview of Generics Bulletin’s Top 50 2025: vist.ly/4bibi
-
Citeline
@Citeline
vist.ly/4bhsp | Get the full breakdown of which trials completed, where, and with what success — across 4,903 industry-sponsored studies
-
Citeline
@Citeline
Calling all sponsors, CROs, sites, ethics committees, and patients! Be sure to join our expert speakers for the ‘ICH GCP E6(R3): Navigating the New Era’ webinar tomorrow to understand what’s changed in the new guidance and the real-world implications.
vist.ly/4bfmp -
Citeline
@Citeline
Citeline interviewed Samantha Intriligator, librarian at @Regeneron, to learn more about her role connecting scientists with the information they need.
She also volunteers as the program planner for PhMTI's fall seminar in Philadelphia Oct. 28-29.
vist.ly/4bdfs -
Citeline
@Citeline
#smallbiotechsbigdecisions dives into what investors really want from biotech CEOs. Listen to the full episode here: vist.ly/4bbu6
👀 Watch: vist.ly/4bbu6
👂 Listen: vist.ly/4bbu9
🔍 Explore: vist.ly/4bbu9 -
Citeline
@Citeline
The updated ICH GCP E6(R3) guidelines are reshaping the way clinical trials are run.
With clearer roles, elevated transparency, and greater expectations across the full data lifecycle, these changes mark a significant shift for clinical research.
vist.ly/4bax9 -
Citeline
@Citeline
📢 Join us at Clinical Data Disclosure Europe!
🗓️ Navigating Reporting Requirements in Asian Markets
🕧 Wed, 22 October 2025 | 12:30–12:00 CET
🎤 @BenEvans, Disclosure Regulations Research Manager, Citeline
🔗 vist.ly/4b7dj -
Citeline
@Citeline
AI, real-world data, and feasibility modeling are transforming how biotech, CRO, and pharma leaders approach clinical development.
Explore real-world use cases that show how sponsors are applying these capabilities to drive better outcomes.
vist.ly/4b6tw -
Citeline
@Citeline
🔍 Is your patient recruitment strategy truly data-driven vist.ly/4b6gu
In the second of our three-part webinar series, discover how feasibility data can unlock scalable, tailored recruitment strategies.
📅 October 22 | 🕒 Live + On-Demand | 🎟️ Free to attend -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/4b4ky
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
vist.ly/4a2p4 | Join Arran Cater, Jaclyn Spedaliere, and Radek Grabowski on Tuesday, Oct 21 at 11:45 CET at Clinical Data Disclosure Europe.
Our Citeline experts want to help you save time and stay ahead in the pharmaceutical and medtech markets as regulations shift. -
Citeline
@Citeline
It’s the final days of @myESMO - don’t miss the insights! vist.ly/4azt6
As ESMO 2025 wraps up, Scrip’s expert coverage continues with late-breaking data, R&D leader interviews, and commercial impact analysis.
👉 vist.ly/4azt7 -
Citeline
@Citeline
Gene therapy continues to build momentum in oncology.
In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year.
Featuring data from Pharmaprojects and @ASGCTherapy.
Download the full report:This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/4axgx
✔️ Watch the full episode: vist.ly/4axgx
✔️ Listen on the go: vist.ly/4axgy
✔️ Explore all episodes: vist.ly/4axgy -
Citeline
@Citeline
ESMO 2025 is in full swing! Stay up to date with Scrip’s real-time reporting from Berlin. vist.ly/4avq8
Our editorial team is on the ground at @myESMO delivering daily updates, exclusive interviews, and commercial impact analysis.
👉 vist.ly/4avqa -
Citeline
@Citeline
Immerse yourself in the dynamic world of generics, biosimilars, and value-added medicines! Check out our infographic preview of Generics Bulletin’s Top 50 2025: vist.ly/4avpx
-
Citeline
@Citeline
Step into the future of obesity management with @DaveWallace, Generics Bulletin Executive Editor, as he illuminates life-changing generic alternatives of weight-loss medication in a recent @DailyMail - UK News piece.
vist.ly/4ava9 (subscription required).This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
You bring the questions. We bring 500+ expert voices. vist.ly/4auiy | Discover how Ask the Analyst adds power to your expertise.
With Ask the Analyst, Citeline subscribers get direct access to a network of over 500 industry experts in their fields. -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/4at2v
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Download the infographic to preview the full editorial series: vist.ly/4as8f
Get a visual snapshot of the companies shaping the global generics, biosimilars, and value-added medicines market.
✔️ Standout performers
✔️ Market shifts
✔️ Emerging players -
Citeline
@Citeline
vist.ly/4arch | Welcome to the new era of pipeline strategy: Pharmaprojects+ enhances the platform you trust with powerful new capabilities.
Every feature is designed to help you validate your strategy with confidence. -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/4aqt2 to learn more.
Watch the video in English: vist.ly/4aqu4 -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/4apng
Dive into game-changing strategies to optimize funding, trial design, and patient recruitment. Discover how the right #cro partnership can streamline clinical trials and reduce risk.
✔️ Watch the full episode: vist.ly/4apng
✔️ Listen on the go: vist.ly/4apnh
✔️ Explore all episodes: vist.ly/4apnh -
Citeline
@Citeline
We’re excited to reveal our guest for
#smallbiotechsbigdecisions!
Alistair Macdonald, CEO of @worldwidetrials, joins Claire Riches to share insider strategies for winning investors, building strong partnerships, and turning bold science into real-world success. -
Citeline
@Citeline
What to look out for at @myESMO 2025! vist.ly/4amse
Scrip’s analysts break down the abstracts and announcements you need to watch, with critical commentary on market implications. See what’s ahead for oncology innovation . -
Citeline
@Citeline
🎯 Citeline is heading to Berlin! vist.ly/4akw3
We’re proud to sponsor and speak at Clinical Data Disclosure Europe, the leading forum for clinical transparency and regulatory strategy, happening October 21–22 at the Hotel Palace Berlin. -
Citeline
@Citeline
vist.ly/4ajcs | Unleash the future of clinical trials today with Citeline’s new AI Importer, redefining efficiency in protocol registration.
This trailblazing tool automatically fills 90+ fields in registration forms, reducing errors and saving you time. -
Citeline
@Citeline
In a recent @PharmaVoice article, Senior Analyst Natasha Boliter discusses the trend toward at-home vaccines: vist.ly/4ahj8
While she outlines several areas of opportunity, she also points out potential roadblocks.
#astrazeneca #flumist -
Citeline
@Citeline
vist.ly/4afti | 10 different doctors; 10 different lists of available trials and studies.
With additional search results of 2,500 clinical trial options, Dr. Beth Stillman shares continued concerns about the inconsistency and the overwhelming nature of the process. -
Citeline
@Citeline
Tack, Gothenburg! That’s a wrap on #nlsdays2025.
It’s been two inspiring days of conversations, connections, and insights driving the Nordic life sciences community forward.
A huge thank you to @SwedenBIO for hosting another fantastic @NordicLifeScienceDays, and to everyone who joined us for the launch of the Swedish Drug Discovery & Development Pipeline Report 2026.
The full report is available here: vist.ly/4adcf -
Citeline
@Citeline
The new ICH GCP E6(R3) guidance, effective since July 2025, streamlines principles, strengthens data governance, and puts patients at the center of trial design.
Live Webinar | Oct 24 | 11 AM EDT | 4 PM BST
vist.ly/4accz
Explore insights: vist.ly/4acd4 -
Citeline
@Citeline
The updated ICH GCP E6(R3) guidelines are reshaping the way clinical trials are run.
With clearer roles, elevated transparency, and greater expectations across the full data lifecycle, these changes mark a significant shift for clinical research.
vist.ly/4aa2j -
Citeline
@Citeline
Hej from Gothenburg! @DanielChancellor, @NorstellaCo kicked off #nlsdays2025 with an energetic Opening Supersession.
We’re proud to officially launch the Swedish Drug Discovery & Development Pipeline Report 2026 in collaboration with @SwedenBIO.
Come say hej at Booth B03:24! -
Citeline
@Citeline
vist.ly/4a9eq | Don't miss our presentation in the Patient Engagement & Recruitment track at SCOPE EU.
@LindsayStahl, VP & Global Head of PE&R, and Skye Hodson, VP of Clinical Solutions, will discuss how data, feasibility, and patient recruitment go hand in hand. -
Citeline
@Citeline
🧠 Why do patients hesitate to join clinical trials—and how can we change that?
🔗 Register now: vist.ly/4a8hf
Join Citeline’s Webinar: From Cautious to Committed, to explore how education and engagement can turn uncertainty into enrollment. -
Citeline
@Citeline
基調講演には、未来を読み解く“知のカタリスト”、
#尾原和啓 氏の登壇が決定!
✅イベント詳細はこちら
vist.ly/4a727
💡尾原和啓氏プロファイル
京都大学院で人工知能を研究。マッキンゼー、Google、iモード、楽天執行役員、2回のリクルートなど事業立上げ・投資を専門とし、【内閣府新AI戦略策定構成員】、【経産省対外通商政策委員】等を歴任。
著書『アフターデジタル』『プロセスエコノミー』は10万部超のベストセラーとなっている他、AI変革を描いた「努力革命」(伊藤羊一共著)はAmazonビジネス書にて新着3日連続1位を獲得。その他、Forbes Japan, Wired, Business Insider, 東洋経済などでの記事執筆、コメンテーターとしてのTV出演も多数。
「データと人間の未来」についての第一人者として、医薬品開発におけるインテリジェンスの可能性を、社会全体の変革と重ね合わせながら紐解く、特別なセッションをお見逃しなく!
ぜひご参加ください。
#医薬品開発 #医薬品 #製薬 #healthcareintelligenceday2025 -
Citeline
@Citeline
Attending SCOPE EU in Barcelona? Be sure to stop by Citeline booth 27 and say “Bon dia!" vist.ly/4a6mt
Our team is ready to talk AI and clinical trial recruitment with you.
And book a meeting with us now – slots fill up fast. We look forward to connecting with you. -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/4a5u4
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/4a5jk
✔️ Watch the full episode: vist.ly/4a5jk
✔️ Listen on the go: vist.ly/4a5jm
✔️ Explore all episodes: vist.ly/4a5jm -
Citeline
@Citeline
Get up to speed on pricing policy and how it could reshape global drug access: vist.ly/4a4jj
Following Trump’s latest executive order, international reference pricing is back on the table and pharma is feeling the heat. -
Citeline
@Citeline
Start the week with insights from Daniel Chancellor, @NorstellaCo, during the #nlsdays2025 Opening session on Nordic innovation and deal-making, followed by the launch of the Swedish Drug Discovery & Development Pipeline Report 2026, produced with @SwedenBIO.
Visit Booth B03:24. -
Citeline
@Citeline
Something exciting is coming for #smallbiotechsbigdecisions …
Our next podcast features a leading voice in clinical research, sharing ideas and strategies you won’t hear anywhere else. Stay tuned for the launch of our new episode! -
Citeline
@Citeline
🚀 Ready to transform your clinical trial recruitment strategy? vist.ly/49y5g
Join our 3-part webinar series, Your Roadmap to Patient Recruitment Success, and gain actionable insights from industry leaders.
📅 Starts Oct 15 | Free to attend | Recordings available -
Citeline
@Citeline
vist.ly/49whm | Sitetrove+ now includes Site Compare – a tool that brings real-world performance data into your feasibility and start-up planning.
Now you can compare sites by capacity, experience, and trial performance. -
Citeline
@Citeline
How does your pipeline measure up? vist.ly/49v2v
With Company Compare from Pharmaprojects+, benchmark by trial activity, disease focus, and development stage to uncover new opportunities.
See the full feature set: vist.ly/49v2v -
Citeline
@Citeline
BREAKING! vist.ly/49uf7
#citelinebreakingnews #novonordisk #akero | @KevinGrogan
____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/49ufa -
Citeline
@Citeline
Attending SCOPE EU in Barcelona? Be sure to stop by Citeline booth 27 and say “Bon dia!" vist.ly/49tqd
Our team is ready to talk clinical trial recruitment with you.
And book a meeting with us now – slots fill up fast. We look forward to connecting with you. -
Citeline
@Citeline
Manage complex recruitments with ease: vist.ly/49ry3
Discover simplicity in complexity now! Learn how Citeline Trial Portfolio Websites can streamline the process by combining centralized trial access, automated updates, and built-in engagement tools.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/49pth | In an interview with @PharmExec, Citeline Analyst Neha Anand discusses how AbbVie’s newly approved antibody-drug conjugate (ADC) Emrellis differentiates itself in a rapidly evolving oncology landscape.
-
Citeline
@Citeline
Discover how Citeline can revolutionize trial visibility and engagement: vist.ly/49nsn
Struggling with recruitment? Manage complex trial info and boost patient engagement with Citeline's Trial Portfolio Websites. Invite simplicity and compliance to the process!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
🌍 Clinical trial disclosure is no longer one-size-fits-all.
As heard in this session: evolving global regulations demand specialized knowledge and constant tracking.
📹 Watch the clip to learn how Citeline helps you stay compliant in a complex landscape. -
Citeline
@Citeline
Step into the future of obesity management with @DaveWallace, Generics Bulletin Executive Editor, as he illuminates life-changing generic alternatives of weight-loss medication in a recent @DailyMail - UK News piece.
vist.ly/49ktu (subscription required).This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/49imn | Small biotechs face unique challenges but also have potential to innovate and lead.
Our infographic highlights six strategies every small biotech should use to thrive, from prioritizing pipelines to optimizing trials and unlocking opportunities.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/49dyy | Right now, only 0.2% of oncologists actively refer their patients to clinical trials. The number of people that aren't getting into trials because it's just too hard to find the information is immoral.
#extra2025keynote ⬅️ for additional clips -
Citeline
@Citeline
vist.ly/49bpj | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater.
Discover six practical strategies that biotech leaders are using to prioritize pipelines, optimize clinical trials, and accelerate growth.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
📢 August 2025 Clinical Trial Regulatory Highlights: From the UK to Denmark to Ethiopia, regulatory agencies are streamlining processes and inviting stakeholder input.
📚 Learn more at TrialScope Intelligence: vist.ly/499js -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/498f8
Dive into game-changing strategies to optimize funding, trial design, and patient recruitment. Discover how the right #cro partnership can streamline clinical trials and reduce risk.
✔️ Watch the full episode: vist.ly/498f8
✔️ Listen on the go: vist.ly/498f9
✔️ Explore all episodes: vist.ly/498f9 -
Citeline
@Citeline
Past performance can shape future strategy: citeline.com/plus
With Trends Analytics from Pharmaprojects+, explore historical development patterns to make smarter, data-driven decisions for your pipeline.
Learn more: citeline.com/plus -
Citeline
@Citeline
🌍 Clinical trial disclosure is no longer one-size-fits-all.
As heard in this session: evolving global regulations demand specialized knowledge and constant tracking.
📹 Watch the clip to learn how Citeline helps you stay compliant in a complex landscape. -
Citeline
@Citeline
vist.ly/4824h | Need an experienced investigator or a trusted opinion leader? Sitetrove+ now includes Expert Finder, your new go-to tool to identify the right expert, faster.
-
Citeline
@Citeline
Explore key insights and analysis on the regulatory, political and commercial fallout: vist.ly/48z6a
Download the article pack and uncover expert reporting and insights about what comes next. -
Citeline
@Citeline
【講演全貌公開!】
Healthcare Intelligence Day2025✨
― 業界最高水準のデータとコンサルティングを通じて医薬品業界の未来を変える
vist.ly/48yew
日時:10月21日(火)13時より
開催方式:オンライン
本イベントでは、私たちが提供する「インテリジェンス」が、未来の医薬品開発と商業化をどう変革しうるのか、その可能性を探ります。
有識者による講演を通じて、業界の最新動向や未来の展望を共有するだけでなく、製薬企業が直面する複雑な課題に対し、データとインサイトがどのように意思決定を支え、成功へ導くのかを、具体的な事例とともにご紹介します。
医薬品開発の未来を、共に描く一日。
ぜひご参加ください。
#医薬品開発 #医薬品 #製薬 #healthcareintelligenceday2025 -
Citeline
@Citeline
vist.ly/48xc9 | Unleash the future of clinical trials today with Citeline’s new AI Importer, redefining efficiency in protocol registration.
This trailblazing tool automatically fills 90+ fields in registration forms, reducing errors and saving you time. -
Citeline
@Citeline
Meet Ella, the AI-powered assistant built into Citeline’s clinical solutions. Ella provides instant answers and deeper insights, streamlining research so your team can spend more time on strategy, not searching
Discover Ella in action: vist.ly/48wtj -
Citeline
@Citeline
What’s Next at Citeline? Smarter tools. Bigger data. Real AI impact. | vist.ly/48v5y
We’re making it easier to plan smarter, act faster, and reduce risk across clinical development.
Read the full update 👉 vist.ly/48v5y -
Citeline
@Citeline
🚀 Ready to transform your clinical trial recruitment strategy? vist.ly/48u66
Join our 3-part webinar series, Your Roadmap to Patient Recruitment Success, and gain actionable insights from industry leaders.
📅 Starts Oct 15 | Free to attend | Recordings available -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/48smr
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/48qfq | Starts in 1 hour!
Join us live: How is China Shaping the Face of The Pharma Industry? Get the insights you need to stay ahead.
Still time to register → vist.ly/48qfq
Learn more about the event: vist.ly/48qfk
@JosephHaas | @JieDexterYan | Xu Hu, PhD | @AndrewMcConaghie -
Citeline
@Citeline
vist.ly/48pcz | "The standard of care, which was really just suffering for a few extra months... was not appealing to either of us — for obvious and multiple reasons."
The Keynote from Bess Stillman at #extra2025 looked the issues with access to clinical trials. -
Citeline
@Citeline
vist.ly/48kt4 | Ella, our new AI-powered chat assistant, was trained on thousands of real, analyst-validated questions and queries.
The result? It knows how to help you find the answers you need — faster than ever — backed by Citeline’s industry-leading Trialtrove and Sitetrove data.
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
⌛Time is ticking! Dive into the dynamic landscape of China's evolving pharma industry. Register here: vist.ly/48jq7
Interested in learning more about this exciting event? Head here: vist.ly/48jpy
Emerging speakers like @JosephHaas, @JieDexterYan, Xu Hu, PhD, and @AndrewMcConaghie are gearing up to share their insights. It's not just about staying on top of the latest trends in the pharma industry, it’s about embracing what’s possible. Let’s define the future together – the future starts now! Register here: vist.ly/48jq7 -
Citeline
@Citeline
vist.ly/48i6w
Scrip’s pipeline-in-a-product series kicked off with a Dupixent case study, based on interviews with execs at both Sanofi and Regeneron.
Learn about the strategy that led to more than $15bn in annual sales and approval for eight inflammatory conditions.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Immerse yourself in the dynamic world of generics, biosimilars, and value-added medicines! Check out our infographic preview of Generics Bulletin’s Top 50 2025: vist.ly/48gz3
-
Citeline
@Citeline
Get up to speed on pricing policy and how it could reshape global drug access: vist.ly/48gr4
Following Trump’s latest executive order, international reference pricing is back on the table and pharma is feeling the heat. -
Citeline
@Citeline
🚨 The MASH treatment landscape is evolving fast.
With FDA approvals of Rezdiffra (resmetirom) and now Wegovy (semaglutide), we’re entering a new era of multi-drug regimens. It's reshaping how we approach metabolic liver disease.
vist.ly/48fyyThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Dive into the fast-paced world of global generics, biosimilars, and value-added medicines! vist.ly/48en8
Discover the game-changers, keep an eye on market turbulence and meet the fresh faces on the scene with this exclusive infographic, powered by Generics Bulletin. -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/48dj8
Dive into game-changing strategies to optimize funding, trial design, and patient recruitment. Discover how the right #cro partnership can streamline clinical trials and reduce risk.
✔️ Watch the full episode: vist.ly/48dj8
✔️ Listen on the go: vist.ly/48dja
✔️ Explore all episodes: vist.ly/48dja -
Citeline
@Citeline
See the numbers behind the clinical trial surge! vist.ly/48d3k
Our latest infographic visualizes standout trends across the 4,900+ industry-sponsored trials completed in 2024 — the highest number in nearly a decade. Download the full report for deeper insights. -
Citeline
@Citeline
📢 August 2025 Clinical Trial Regulatory Highlights: From the UK to Denmark to Ethiopia, regulatory agencies are streamlining processes and inviting stakeholder input.
📚 Learn more at TrialScope Intelligence: vist.ly/48cbz -
Citeline
@Citeline
Download the infographic to preview the full editorial series: vist.ly/48bj8
Get a visual snapshot of the companies shaping the global generics, biosimilars, and value-added medicines market.
✔️ Standout performers
✔️ Market shifts
✔️ Emerging players -
Citeline
@Citeline
vist.ly/488hm | Clinical trial disclosure is a pivotal step. It's not only about regulatory compliance but also about ingraining transparency and trust in the system.
Watch Dr. Bess Stillman's eye-opening keynote! 👇 vist.ly/488hm -
Citeline
@Citeline
基調講演には、未来を読み解く“知のカタリスト”、
#尾原和啓 氏の登壇が決定!
✅イベント詳細はこちら
vist.ly/487xz
💡尾原和啓氏プロファイル
京都大学院で人工知能を研究。マッキンゼー、Google、iモード、楽天執行役員、2回のリクルートなど事業立上げ・投資を専門とし、【内閣府新AI戦略策定構成員】、【経産省対外通商政策委員】等を歴任。
著書『アフターデジタル』『プロセスエコノミー』は10万部超のベストセラーとなっている他、AI変革を描いた「努力革命」(伊藤羊一共著)はAmazonビジネス書にて新着3日連続1位を獲得。その他、Forbes Japan, Wired, Business Insider, 東洋経済などでの記事執筆、コメンテーターとしてのTV出演も多数。
「データと人間の未来」についての第一人者として、医薬品開発におけるインテリジェンスの可能性を、社会全体の変革と重ね合わせながら紐解く、特別なセッションをお見逃しなく!
ぜひご参加ください。
#医薬品開発 #医薬品 #製薬 #healthcareintelligenceday2025 -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/486s6
✔️ Watch the full episode: vist.ly/486s6
✔️ Listen on the go: vist.ly/486s7
✔️ Explore all episodes: vist.ly/486s7 -
Citeline
@Citeline
Take a look at Scrip's deep-dive into the escalating role of China in global biopharma: vist.ly/483m8
Attend Citeline's webinar on Sept. 30 to understand the driving factors behind the industry's rapid growth.
Register: vist.ly/483mbThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Discover how Citeline can revolutionize trial visibility and engagement: vist.ly/47234
Struggling with recruitment? Manage complex trial info and boost patient engagement with Citeline's Trial Portfolio Websites. Invite simplicity and compliance to the process!This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/47zkx
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Our industry-leading Trialtrove+ solution just got better. vist.ly/47xzk
With newly infused proprietary performance data, enhanced tech, and advanced data science capabilities, your ability to optimize trial planning, site, and investigator selection just leveled up. -
Citeline
@Citeline
Get up to speed on pricing policy and how it could reshape global drug access: vist.ly/47x9b
Following Trump’s latest executive order, international reference pricing is back on the table and pharma is feeling the heat. -
Citeline
@Citeline
If you’re not using AI in trials yet, you’re already behind. Save your spot: vist.ly/47tia
Join our webinar to see how AI and high-quality data is driving smarter trial design, better site selection, and faster decisions.
September 24 | 10:00AM EST | 3:00PM BST -
Citeline
@Citeline
vist.ly/47sqy | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Manage complex recruitments with ease: vist.ly/47rnf
Discover simplicity in complexity now! Learn how Citeline Trial Portfolio Websites can streamline the process by combining centralized trial access, automated updates, and built-in engagement tools.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Your source of truth for clinical trial disclosure: vist.ly/47qvj
Our content ensures full audit readiness with direct links to source materials for added context.
Watch #extra2025 sessions featuring forward-looking analysis from clinical trial transparency leaders. -
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: vist.ly/47nt9
-
Citeline
@Citeline
Trialtrove+ goes beyond trial design — it reveals how studies are performing in the real world: vist.ly/47mtu
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
🌍 Clinical trial disclosure is no longer one-size-fits-all.
As heard in this session: evolving global regulations demand specialized knowledge and constant tracking.
📹 Watch the clip to learn how Citeline helps you stay compliant in a complex landscape. -
Citeline
@Citeline
HBW Insight's Over the Counter podcast takes you inside the conversations shaping consumer health: vist.ly/47iyq
From regulatory changes to the strategies of industry leaders, each episode brings you insights and exclusive perspectives you won’t hear anywhere else.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
AI won’t replace you — but clinical teams using it might.
Learn how leading clinical teams are using AI to work smarter, move faster, and make better decisions.
Join us online on September 24 at 10:00AM EST | 3:00PM BST: vist.ly/47isp -
Citeline
@Citeline
A @PharmaVoice article about recent large pharma breakups with biotechs cites data and analysis from Citeline's Pharma R&D Review: vist.ly/47i43
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Explore key insights and analysis on the regulatory, political and commercial fallout: vist.ly/47gvj
Download the article pack and uncover expert reporting and insights about what comes next. -
Citeline
@Citeline
#smallbiotechsbigdecisions launches a new episode on early CRO engagement. Listen here: vist.ly/47g95
Dive into game-changing strategies to optimize funding, trial design, and patient recruitment. Discover how the right #cro partnership can streamline clinical trials and reduce risk.
✔️ Watch the full episode: vist.ly/47g95
✔️ Listen on the go: vist.ly/47g96
✔️ Explore all episodes: vist.ly/47g96 -
Citeline
@Citeline
How does your pipeline measure up? vist.ly/47fst
With Company Compare from Pharmaprojects+, benchmark by trial activity, disease focus, and development stage to uncover new opportunities.
See the full feature set: vist.ly/47fst -
Citeline
@Citeline
Take a look at Scrip's deep-dive into the escalating role of China in global biopharma: vist.ly/47e5f
Attend Citeline's webinar on Sept. 30 to understand the driving factors behind the industry's rapid growth.
Register: vist.ly/47e5iThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Gene therapy continues to build momentum in oncology.
In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year.
Featuring data from Pharmaprojects and @ASGCTherapy.
Download the full report:This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/4798f
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
2025’s Generics Leaders - Full Rankings Now Live! vist.ly/4755d
Available to subscribers and trial users - start your trial today and get instant access. Start your 7-day free trial today: vist.ly/4755hThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/473wm | China’s biopharma evolution is accelerating. Our upcoming Scrip webinar breaks down what it means for global strategy:
• What's driving the rapid growth of China’s biopharmaceutical R&D
• How new doors are opening for global collaboration
• Opportunities and challenges for international companies
Strategic insights ✔️
Expert analysis ✔️
Live Q&A ✔️
Save your seat: vist.ly/473wm
Learn more about the event: vist.ly/473wh
#biopharma #chinapharma #pharmastrategy #scripwebinar
@JosephHaas | @JieDexterYan | Xu Hu, PhD | @AndrewMcConaghie -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/473hu to learn more.
Watch the video in English: vist.ly/473hy -
Citeline
@Citeline
vist.ly/46zxd | In Part 4 of an interview with @PharmExec magazine, Citeline analyst @NehaAnand discusses what approval of @abbvie's Emrelis means for pharma and biotech ADC strategies.
#oncology #nsclc #biomarkers #precisionmedicine -
Citeline
@Citeline
Feasibility planning just got smarter with Trialtrove+. vist.ly/46ykj
Trialtrove+ lets you explore clinical trial trends through visualizations and advanced analytics, so you can identify where the activity is, what’s gaining momentum, and how to plan confidently. -
Citeline
@Citeline
What’s a hippo got to do with clinical trials?
Stop by Citeline booth 201 at @DPHARM to find out!
And find out how we leverage our gold-standard data to accelerate bringing treatments to patients, and patients to clinical trials.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Webinar alert! Last chance to register. AI is transforming regulatory workflows but not without new risks: vist.ly/46u4i
Join us for a deep-dive into AI, and its implications on regulatory workflows. -
Citeline
@Citeline
vist.ly/46t46 | In Part 3 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how @abbvie’s antibody-drug conjugate (ADC) Emrelis is expanding treatment options for solid tumors with C-MET overexpression.
-
Citeline
@Citeline
Explore how top sponsors are balancing automation with ethical, participant-centered transparency: vist.ly/46r7b
AI is transforming workflows but not without new risks. Join us on September 17 as our experts reveal how a human-centered AI approach is helping sponsors. -
Citeline
@Citeline
vist.ly/46qth | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater. Success now depends on making smarter choices with limited resources.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
A @PharmaVoice article about recent large pharma breakups with biotechs cites data and analysis from Citeline's Pharma R&D Review.
————
Follow @Citeline, the leader of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/46nvn
Unprecedented changes are coming to UK's clinical trials in the biggest overhaul in 2 decades! These reforms — involving consent, contracting, trial transparency and much more — will drastically reshape the domain. -
Citeline
@Citeline
Which companies broke into the Top 50 - and what does it mean for the market? vist.ly/46jki
In part three of Generics Bulletin’s 2025 Top 50 series, we focus on the new names joining the global rankings, and the competitive moves that got them there. -
Citeline
@Citeline
#smallbiotechsbigdecisions is back with game-changing insights! Live now: vist.ly/46ikg
✔️ Watch the full conversation: vist.ly/46ikg
✔️ Listen on the go: vist.ly/46ikj
✔️ Explore all episodes: vist.ly/46ikj -
Citeline
@Citeline
China’s pharma market is undergoing rapid transformation—are you ready to navigate the change? vist.ly/46gti
Join our Scrip expert-led webinar to explore:
• How made-in-China assets are reaching global markets
• Trends in cross-border dealmaking
• Case studies of successful China-based R&D companies
30 Sept 3.30pm BST | 10.30am EST
Learn more about the event: vist.ly/46gtf
#biopharma #chinapharma #pharmastrategy #scripwebinar
@JosephHaas | @JieDexterYan | Xu Hu, PhD | @AndrewMcConaghieThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
If you’re not using AI in trials yet, you’re already behind. Save your spot: vist.ly/46fg6
Join our webinar to see how AI and high-quality data is driving smarter trial design, better site selection, and faster decisions.
September 24 | 10:00AM EST | 3:00PM BST -
Citeline
@Citeline
Past performance can shape future strategy: citeline.com/plus
With Trends Analytics from Pharmaprojects+, explore historical development patterns to make smarter, data-driven decisions for your pipeline.
Learn more: citeline.com/plus -
Citeline
@Citeline
🚨 The MASH treatment landscape is evolving fast.
With FDA approvals of Rezdiffra (resmetirom) and now Wegovy (semaglutide), we’re entering a new era of multi-drug regimens. It's reshaping how we approach metabolic liver disease.
vist.ly/46cgaThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/46ava | In Part 2 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how approval of @abbvie’s antibody-drug conjugate (ADC) Emrelis signals FDA support of ADCs in oncology.
#oncology #nsclc #biomarkers #precisionmedicine -
Citeline
@Citeline
vist.ly/469rm
As part of an ongoing series, Scrip is looking into how some of these success stories got their start, what it takes to run a development program across diseases, and what promising possibilities exist in pipelines today.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Join us at @DPHARM on Track A, 11am, Sep 16 where our very own Matt Holms will be giving insights on modernized patient recruitment.
Discover what other exciting things we're up to at Booth 201. vist.ly/467ky -
Citeline
@Citeline
Clinical trials are on the rise…again! vist.ly/46689
Access detailed metrics and insights from 4,900+ completed trials to inform your planning, benchmarking, and investment strategies. -
Citeline
@Citeline
When time matters, slow searches can derail critical decisions. vist.ly/4656t
Ella, your Citeline AI chat assistant, is now embedded across all Citeline clinical solutions .
Smarter, faster, easier. -
Citeline
@Citeline
Breaking News: Saol CRL Suggests Gap Between US FDA Rare Disease Flexibility Promises And Outcomes: vist.ly/452cq
#citelinebreakingnews #pinksheetThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
How does your trial compare to the competition? Stop guessing — see for yourself with Citeline’s Trial Health Calculator. vist.ly/45zya
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
What’s Next at Citeline? Smarter tools. Bigger data. Real AI impact. | vist.ly/45yzs
We’re making it easier to plan smarter, act faster, and reduce risk across clinical development.
Read the full update 👉 vist.ly/45yzs -
Citeline
@Citeline
Webinar alert! Explore the cutting-edge transformation of regulatory workflows through AI: vist.ly/45wni
Join Brian Kuzich and Jack Marks as they provide insights into the power of human-centered AI role in regulatory workflows. -
Citeline
@Citeline
vist.ly/45up7 | Small biotechs are uniquely positioned to harness AI, real-world data, and strategic partnerships to drive innovation and growth.
Our latest infographic highlights six key strategies that can help small biotechs navigate today’s challenges and seize new opportunities in a rapidly changing industry.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/45rm3 | In an article in Precision Medicine Online about AstraZeneca’s Tagrisso’s Q2 success, Citeline analyst Neha Anand shares insights into growing competition in the ADC therapy market. She also notes the competitive market in HR-positive breast cancer.
-
Citeline
@Citeline
After just one week using Citeline PatientMatch, study sites began receiving high-quality patient referrals: vist.ly/45qje
Want to learn more? Meet us at @DPHARM!
Come by Citeline booth 201 (just look for the hippo!), and see Citeline PatientMatch in action.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
医薬品開発の未来を、共に描く。
10月21日13時より、Healthcare Intelligence Day2025開幕
vist.ly/45pty
Citeline/Evaluateは、パイプライン戦略、競合分析、臨床試験設計から商業的成功に至るまで、
医薬品開発の全ステージをデータ・コンサルティングで支援する、業界屈指のリーディングカンパニーです。
本イベントでは、私たちが提供する「インテリジェンス」が、
未来の医薬品開発と商業化をどう変革しうるのか、その可能性を探ります。
有識者による講演を通じて、業界の最新動向や未来の展望を共有するだけでなく、
製薬企業が直面する複雑な課題に対し、データとインサイトがどのように意思決定を支え、
成功へ導くのかを、具体的な事例とともにご紹介します。
医薬品開発の未来を、共に描く一日。ぜひご参加ください。
#医薬品開発 #医薬品 #製薬 #healthcareintelligenceday2025 -
Citeline
@Citeline
AI won’t replace you — but clinical teams using it might.
Learn how leading clinical teams are using AI to work smarter, move faster, and make better decisions.
Join us online on September 24 | 10am EST | 3pm BST: vist.ly/45k24 -
Citeline
@Citeline
Have you been tuning in to the #smallbiotechsbigdecisions series? vist.ly/45jzi
Whether it’s your first episode or you’ve been following from the start, the next episode is extra special as we share key strategies for winning biotech-CRO partnerships. -
Citeline
@Citeline
The future of clinical intelligence is here. vist.ly/45gh4
Pharmaprojects+ has officially launched.
Whether you're assessing feasibility, analyzing the pipeline, or shaping trial strategy, you now have everything you need to make faster, smarter decisions. -
Citeline
@Citeline
vist.ly/45fre | In an interview with @PharmExec, Citeline Analyst Neha Anand discusses how AbbVie’s newly approved antibody-drug conjugate (ADC) Emrelis differentiates itself in a rapidly evolving oncology landscape.
-
Citeline
@Citeline
Which mid-table players are surging — and who’s quietly slipping? vist.ly/45cce
Part two of the Top 50 Generics & Biosimilars series unpacks the strategic shifts in positions 11–30. Sales spikes, aggressive expansion, and new market entrants are reshaping the leaderboard.
One Korean heavyweight who saw sales rise nearly 65% last year is now climbing into the spotlight.
Want the full breakdown? Access it via free trial 👇
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: vist.ly/45cch -
Citeline
@Citeline
AI is transforming regulatory workflows but not without new risks: vist.ly/45bjm
Join us for a deep-dive into AI, and its implications on regulatory workflows.
Discover the power of a human-centered AI approach in ensuring compliance and building trust in trials. -
Citeline
@Citeline
Don't miss out! This is your last chance to join us in our 3-part webinar series: Beyond Clinical Trial Registration: vist.ly/4596f
Let's uncover the intricacies of disclosure laws and requirements guided by the eminent disclosure expert @BenEvans. -
Citeline
@Citeline
vist.ly/457vm | Smarter clinical trials for more reliable outcomes. Gain a competitive edge with proprietary data.
Download the white paper and conduct clinical trials with a competitive edge! -
Citeline
@Citeline
A @PharmaVoice article about recent large pharma breakups with biotechs cites data and analysis from Citeline's Pharma R&D Review. vist.ly/442fr
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Explore how top sponsors are balancing automation with ethical, participant-centered transparency: vist.ly/44ytw
AI is transforming workflows but not without new risks. Join us on September 17 as our experts reveal how a human-centered AI approach is helping sponsors. -
Citeline
@Citeline
vist.ly/44y9j | Clinical trial disclosure is a pivotal step. It's not only about regulatory compliance but also about ingraining transparency and trust in the system.
Watch Dr. Bess Stillman's eye-opening keynote! 👇 vist.ly/44y9j -
Citeline
@Citeline
Don't miss out! This is your last chance to join us in our 3-part webinar series: Beyond Clinical Trial Registration: vist.ly/44u83
Let's uncover the intricacies of disclosure laws and requirements guided by the eminent disclosure expert @BenEvans. -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/44tni to learn more.
Watch the video in English: vist.ly/44tnm -
Citeline
@Citeline
Gene therapy continues to build momentum in oncology.
In Q2 2025, 80 new gene therapy trials were initiated — with 64% targeting oncology, the highest proportion in the past year.
Featuring data from Pharmaprojects and @ASGCTherapy.
Download the full report:This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/44kje | The biotech landscape is evolving rapidly and the pressure to deliver results has never been greater. Success now depends on making smarter choices with limited resources.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
You bring the questions. We bring 500+ expert voices. vist.ly/44hts | Discover how Ask the Analyst adds power to your expertise.
With Ask the Analyst, Citeline subscribers get direct access to a network of over 500 industry experts in their fields. -
Citeline
@Citeline
Who’s shaping the future in generics and biosimilars? vist.ly/44fsz
The 2025 Top 50 Report from Generics Bulletin is live, spotlighting the companies driving momentum across off-patent pharmaceuticals.
Start with the Top 10 (free to access). Unlock a 7-day trial now. -
Citeline
@Citeline
Explore key insights and analysis on the regulatory, political and commercial fallout: vist.ly/44bya
Download the article pack and uncover expert reporting and insights about what comes next. -
Citeline
@Citeline
vist.ly/44bhb | Small biotechs have the creativity to innovate but need clear strategies to succeed.
Our latest infographic outlines six key strategies that help small biotechs accelerate innovation, improve clinical development, and navigate a competitive market.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Navigating clinical trial disclosure? Join us on August 27: vist.ly/448pk
Dive into our exclusive webinar series: Global Clinical Trial Transparency.
These sessions will provide you with a fundamental understanding of the complex disclosure laws and requirements. -
Citeline
@Citeline
What’s Next at Citeline? Smarter tools. Bigger data. Real AI impact. | vist.ly/447tq
We’re making it easier to plan smarter, act faster, and reduce risk across clinical development.
Read the full update 👉 vist.ly/447tq -
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: vist.ly/444nt
-
Citeline
@Citeline
vist.ly/443yi | 10 different doctors; 10 different lists of available trials and studies.
With additional search results of 2,500 clinical trial options, Dr. Beth Stillman shares continued concerns about the inconsistency and the overwhelming nature of the process. -
Citeline
@Citeline
"When patients are hard to find, data helps you find them first."
Did you know that despite the growing adoption of decentralized and digital clinical trials, **85% of studies still fail to meet their recruitment targets**?
vist.ly/4439m -
Citeline
@Citeline
vist.ly/43yi9 | Right now, only 0.2% of oncologists actively refer their patients to clinical trials. The number of people that aren't getting into trials because it's just too hard to find the information is immoral.
#extra2025keynote ⬅️ for additional clips -
Citeline
@Citeline
Working with clinical trial disclosure? It's vital you stay ahead of the game! vist.ly/43ucg
Explore the evolving world of global regulatory requirements in our three-part webinar series: Global Clinical Trial Transparency — from Compliance to Emerging Requirements. -
Citeline
@Citeline
vist.ly/43tgs | Get the full breakdown of which trials completed, where, and with what success — across 4,903 industry-sponsored studies
-
Citeline
@Citeline
vist.ly/43pe7 | In Part 5 of an interview with @PharmExec magazine, Citeline analyst @NehaAnand discusses what approval of Emrelis could mean for @abbvie's long-term positioning in solid tumor treatment markets, especially in the face of increasing competition.
-
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: citeline.com/en/products-services/clinical/protocol-smart….
-
Citeline
@Citeline
vist.ly/43mkf
Unprecedented changes are coming to UK's clinical trials in the biggest overhaul in 2 decades! These reforms — involving consent, contracting, trial transparency and much more — will drastically reshape the domain. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/43jkw
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Working with clinical trial disclosure? It's vital you stay ahead of the game! vist.ly/43i8u
Explore the evolving world of global regulatory requirements in our three-part webinar series: Global Clinical Trial Transparency — from Compliance to Emerging Requirements. -
Citeline
@Citeline
vist.ly/43ehc | In his information-packed presentation at TrialScope EXTRA 2025, Thomas Wicks, Head of Transparency Operations, said more and more countries are coming out with clinical trial disclosure requirements, which can be a nightmare to track.
-
Citeline
@Citeline
AI is transforming regulatory workflows but not without new risks: vist.ly/43cm6
Join us for a deep-dive into AI, and its implications on regulatory workflows.
Discover the power of a human-centered AI approach in ensuring compliance and building trust in trials. -
Citeline
@Citeline
vist.ly/43bte | In Part 4 of an interview with @PharmExec magazine, Citeline analyst @NehaAnand discusses what approval of @abbvie's Emrelis means for pharma and biotech ADC strategies.
#oncology #nsclc #biomarkers #precisionmedicine -
Citeline
@Citeline
Biotech firms are recalibrating under financial stress. vist.ly/438q6
From pipeline prioritization to investor relations, Scrip goes beneath the surface to uncover what’s working—and what’s not. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: citeline.com/en/app-insights-trial/.
Unlock expert analysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/434jq | "The standard of care, which was really just suffering for a few extra months... was not appealing to either of us — for obvious and multiple reasons."
The Keynote from Bess Stillman at #extra2025 looked the issues with access to clinical trials. -
Citeline
@Citeline
vist.ly/433rx | In today’s biotech landscape, making smart, timely decisions is more critical than ever.
Explore how your team can do more with less and move with confidence in a competitive market.
#smallbiotechsbigdecisionThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Get up to speed on pricing policy and how it could reshape global drug access: vist.ly/32ya3
Following Trump’s latest executive order, international reference pricing is back on the table and pharma is feeling the heat. -
Citeline
@Citeline
vist.ly/32xdt | In Part 3 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how @abbvie’s antibody-drug conjugate (ADC) Emrelis is expanding treatment options for solid tumors with C-MET overexpression.
-
Citeline
@Citeline
Data never looked so good! citeline.com/RD25/
Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. #rd25 -
Citeline
@Citeline
vist.ly/32paz | In Part 2 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how approval of @abbvie’s antibody-drug conjugate (ADC) Emrelis signals FDA support of ADCs in oncology.
#oncology #nsclc #biomarkers #precisionmedicine -
Citeline
@Citeline
"When patients are hard to find, data helps you find them first."
Did you know that despite the growing adoption of decentralized and digital clinical trials, **85% of studies still fail to meet their recruitment targets**?
vist.ly/32npt -
Citeline
@Citeline
🔥 Latest Citeline Report! Unpack 2024's unprecedented clinical trials trends from over 4,900 industry-sponsored trials! vist.ly/32jwq
All intel powered by Trialtrove, Citeline’s top-tier research platform. Boost your strategy now at: vist.ly/32jwy -
Citeline
@Citeline
vist.ly/32iim | Smarter clinical trials for more reliable outcomes. Gain a competitive edge with proprietary data.
Download the white paper and conduct clinical trials with a competitive edge! -
Citeline
@Citeline
“Deal volume may be down—but deal value is up." vist.ly/32ewr
Biopharma dealmakers are adapting to financial stress with smarter, more strategic transactions. -
Citeline
@Citeline
vist.ly/32be8 | “Organizational Challenges in Making PLS Available,” moderated by Citeline VP of Transparency Francine Lane, was a popular session at TrialScope EXTRA 2025, addressing the pain points sponsors face in creating and disseminating PLS.
-
Citeline
@Citeline
vist.ly/326fn | In an article in Precision Medicine Online about AstraZeneca’s Tagrisso’s Q2 success, Citeline analyst Neha Anand shares insights into growing competition in the ADC therapy market. She also notes the competitive market in HR-positive breast cancer.
-
Citeline
@Citeline
vist.ly/3zywh | From major regulatory shifts in the EU and Japan to breakthrough drug approvals in oncology, neuroscience and cardiovascular care, 2025 is set to reshape the pharmaceutical landscape.
Stay ahead with exclusive insights from our 2025 article pack. -
Citeline
@Citeline
Sign up for any Citeline product and start asking your questions today: vist.ly/3zvzm
Over 1,100 pharma professionals from around the world already trust us with some of their toughest questions. -
Citeline
@Citeline
vist.ly/3zsn6 | Country-specific sanctions and penalties are being issued for clinical trial disclosure noncompliance, warned Citeline's Thomas Wicks at TrialScope EXTRA 2025.
The risk of non-compliance can be highly and extremely detrimental to a business. -
Citeline
@Citeline
What happens to drug innovation when research funding is cut? The @nytimes referenced Citeline data in its recent article on the potential impact of proposed NIH and FDA budget cuts on drug development timelines.
Read the article (subscription required): vist.ly/3zpvh
#hhs #nhs #fda -
Citeline
@Citeline
vist.ly/3zmq2 | In an interview with @PharmExec, Citeline Analyst Neha Anand discusses how AbbVie’s newly approved antibody-drug conjugate (ADC) Emrellis differentiates itself in a rapidly evolving oncology landscape.
-
Citeline
@Citeline
Planning Your Clinical Strategy for 2025? Start with the data: vist.ly/3zjns
This infographic highlights the trial trends that defined 2024 — from disease hotspots to rising sponsors.
All data sourced from Trialtrove: vist.ly/3zjnw -
Citeline
@Citeline
Finding it challenging to keep up with the intricate details of international regulatory compliance? We can help: vist.ly/3zie5
Dive into how Citeline Regulatory Solutions can help you save not just time but also keep you compliant around-the-clock. -
Citeline
@Citeline
vist.ly/3zdvi | An excerpt from our recent webinar ‘The Future of Patient Recruitment: How RWD Transforms Identifying Hard-to-Find Patients’.
-
Citeline
@Citeline
vist.ly/3zbha | Citeline’s @FenwickEckhardt, Senior Manager and Diversity Lead, participated in a panel discussion at ACRP 2025 titled “Clinical Trial Diversity & Intersectionality: Looking at the Whole Patient.”
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Where does Citeline's Mark Lansdell think Western biotech still has an edge? vist.ly/3z9cv
China’s population and resources are its strengths, says Lansdell in a @Marketplace article on innovative drug development in China.
He notes that, in some ways, China’s development in drug discovery began at the same time its dominance in manufacturing was ascendant, and for similar reasons.
Read the full article: vist.ly/3z9cv
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
#pharmaceuticals #genetherapy -
Citeline
@Citeline
vist.ly/3z7sa | What is an exosome and how does it help improve treatment delivery? Check out our infographic to find out, along with the drug disease landscape, related studies by therapeutic area, and competitive forecast.
#dna #rna #precisionmedicine -
Citeline
@Citeline
Data never looked so good! citeline.com/RD25/
Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. #rd25 -
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: vist.ly/3yykq
-
Citeline
@Citeline
When patients are hard to find, Real-World-Data makes the difference: vist.ly/3yy58
Did you know that 85% of clinical trials fail to meet their recruitment targets?
That’s where Real-World Data (RWD) is changing the game. -
Citeline
@Citeline
vist.ly/3yv9h | If you’re already posting clinical trial results, then why not just make them also easy to understand?
Tools like TrialSummaries .com can streamline the public dissemination of trial results. -
Citeline
@Citeline
BREAKING! vist.ly/3yr69
#citelinebreakingnews #scrip #sanofi | @KevinGrogan
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/3yr6bThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Did you know that engaging healthcare providers can significantly enhance your clinical trial recruitment efforts? vist.ly/3yr44
-
Citeline
@Citeline
You have questions and Citeline Regulatory Solutions has the answers.
vist.ly/3yjqm
Do you often find yourself asking how can I keep up with frequent global regulatory policy changes?
This guide is for you. -
Citeline
@Citeline
vist.ly/3yj7g | "When patients are hard to find, data helps you find them first."
— Transforming patient recruitment with RWD.
👉 Download the white paper now and gain the insights you need to hit your recruitment goals: vist.ly/3yj7g -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/3yj6h to learn more.
Watch the video in English: vist.ly/3yj6m -
Citeline
@Citeline
Citeline's comprehensive Annual Completed Clinical Trials Report: vist.ly/3yfju
Journey through a groundbreaking analysis of over 4,900 industry-sponsored trials wrapped up in 2024 – marking a phenomenal year-on-year surge in almost a decade. 📈 -
Citeline
@Citeline
Series 1 of #smallbiotechbigdecisions has wrapped, but the conversation is just getting started. Tune in now: vist.ly/3ydy7
What would you like us to cover next? Share your ideas in the comments! -
Citeline
@Citeline
74 billion data points brought together into our ecosystem. This level of depth of data we now have on these patients to be able to assist you in finding protocol-matched patients has really changed the way we're able to do patient recruitment on our end.
vist.ly/3yck7 -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/3y9sx
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
📣 📆 June Monthly Roundup 2025 📣 vist.ly/3y5ks
June 2025 updates include fee increases in Venezuela and Australia; registry system transitions with the ISRCTN and the discontinuation of the Netherlands' ToetsingOnline, migrating to the Research Portal; and more! -
Citeline
@Citeline
When patients are hard to find, Real-World-Data makes the difference: vist.ly/3x2i5
Did you know that 85% of clinical trials fail to meet their recruitment targets?
That’s where Real-World Data (RWD) is changing the game. -
Citeline
@Citeline
You bring the questions. We bring 500+ expert voices. vist.ly/3xxjt | Discover how Ask the Analyst adds power to your expertise.
With Ask the Analyst, Citeline subscribers get direct access to a network of over 500 industry experts in their fields. -
Citeline
@Citeline
That’s a wrap on Series 1 of #smallbiotechbigdecisions! Watch or listen anytime, anywhere at vist.ly/3xum5
Over four episodes, we explored the strategic choices shaping the future of biotech, from capital efficiency and clinical planning to partnerships, leadership, and the role of data in decision-making.
Series 2 is already in the works, so stay tuned! As we plan what’s next, what topics or challenges would you like us to explore? Comment below!
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: citeline.com/en/app-insights-trial/.
Unlock expert analysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Explore the new framework set to turbocharge clinical trials in the UK: vist.ly/3xtcv
Unprecedented changes are coming to UK's clinical trials in the biggest overhaul in 2 decades! These reforms will drastically reshape the domain. -
Citeline
@Citeline
Other tools give you data. We give you answers, just for you. vist.ly/3n98u74 | Become a Citeline subscriber today and start asking questions to our analysts.
In pharma and medtech, the data never stops, but what matters is knowing what’s relevant to you. -
Citeline
@Citeline
Series 1 of #smallbiotechbigdecisions is now available to watch or listen anytime, anywhere: vist.ly/3n96sh7
Topics include capital allocation, clinical strategy, partnerships, and leadership under pressure. -
Citeline
@Citeline
vist.ly/3n94jd3 | Citeline’s FenwickEckhardt, Senior Manager and Diversity Lead, participated in a panel discussion at ACRP 2025 titled “Clinical Trial Diversity & Intersectionality: Looking at the Whole Patient.”
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Clinical trials are on the rise…again! vist.ly/3n8zw2u
Access detailed metrics and insights from 4,900+ completed trials to inform your planning, benchmarking, and investment strategies. -
Citeline
@Citeline
📣 📆 June Monthly Roundup 2025 📣 vist.ly/3n8zhpb
June 2025 updates include fee increases in Venezuela and Australia; registry system transitions with the ISRCTN and the discontinuation of the Netherlands' ToetsingOnline, migrating to the Research Portal; and more! -
Citeline
@Citeline
Empowering the Next Generation of Clinical Trials with Citeline’s Industry-Leading Data and AI. vist.ly/3n8yecr to learn more.
Watch the video in English: vist.ly/3n8yecu -
Citeline
@Citeline
vist.ly/3n8xam2 | Kris Joshi joins @NorstellaCo, the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
_____
Start your 7-day free trial today: vist.ly/3n8xam5 -
Citeline
@Citeline
BREAKING! vist.ly/3n8ww4t
#citelinebreakingnews #scrip #merck | @KevinGrogan
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/3n8ww4wThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Where does Citeline's Mark Lansdell think Western biotech still has an edge? vist.ly/3n8un92
China’s population and resources are its strengths, says Lansdell in a @Marketplace article on innovative drug development in China.
He notes that, in some ways, China’s development in drug discovery began at the same time its dominance in manufacturing was ascendant, and for similar reasons.
Read the full article: vist.ly/3n8un92
————
Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
#pharmaceuticals #genetherapy -
Citeline
@Citeline
vist.ly/3n8u8k2 | In his information-packed presentation at TrialScope EXTRA 2025, Citeline Head of Transparency Operations Thomas Wicks noted that roughly two new registries open each year, with mandatory and optional requirements constantly changing.
-
Citeline
@Citeline
In a multiple myeloma space, we identified an investigator who had 127+ confirmed clinical algorithm patients, 8 trials, and we can see their trial history for a certain clinical trial of interest. vist.ly/3n8rk6c
-
Citeline
@Citeline
See what deals analyst Jenny Tan has to say about the BioNTech acquisition of CureVac. Catch her commentary in this @BioXconomy article: vist.ly/3n8rk6b
#vaccine #mrna #oncology #immunotherapy -
Citeline
@Citeline
vist.ly/3n8qkrd | Smarter clinical trials for more reliable outcomes. Gain a competitive edge with proprietary data.
Download the white paper and conduct clinical trials with a competitive edge! -
Citeline
@Citeline
In a volatile policy climate, adaptability is everything. Watch the final episode of #smallbiotechsbigdecisions here: vist.ly/3n8pdgx
In times of change, those who invest in data, innovation, and strategic flexibility will be best positioned to lead. -
Citeline
@Citeline
vist.ly/3n8kr4x | In an article recapping ASCO 2025, @medcitynews features commentary from Anna Simmons, analyst at @Citeline, and Ethan Smith, Oncology Therapy Area Director at @NorstellaCo, Citeline's parent company.
-
Citeline
@Citeline
vist.ly/3n8i4qu | From major regulatory shifts in the EU and Japan to breakthrough drug approvals in oncology, neuroscience and cardiovascular care, 2025 is set to reshape the pharmaceutical landscape.
Stay ahead with exclusive insights from our 2025 article pack. -
Citeline
@Citeline
Clinical development is no longer confined by borders. Tune in to #smallbiotechsbigdecisions for deeper insights: vist.ly/3n8hp42
As regulatory uncertainty grows in the U.S., more biotechs are looking globally to accelerate early-phase trials and reduce development risk. -
Citeline
@Citeline
Other tools give you data. We give you answers, just for you. vist.ly/3n8fgcx | Become a Citeline subscriber today and start asking questions to our analysts.
In pharma and medtech, the data never stops, but what matters is knowing what’s relevant to you. -
Citeline
@Citeline
vist.ly/3n8e2n8 | Clinical trial disclosure regulatory updates are ongoing and continue to bring trial transparency to the forefront.
-
Citeline
@Citeline
www.citeline.com/en/resources/exosomes-innovative-vesicle… | What is an exosome and how does it help improve treatment delivery? View our infographic to find out, along with the drug disease landscape, related studies by therapeutic area, and competitive forecast.
#dna #rna #precisionmedicine -
Citeline
@Citeline
The FDA is rewriting the rules. Are you ready? Watch the final episode of #smallbiotechsbigdecisions here: vist.ly/3n8ctz4
Legislative and regulatory change is rapidly reshaping the biotech landscape, with far-reaching implications for everything from clinical trial strategy to commercialization. -
Citeline
@Citeline
Breaking news! vist.ly/3n8amhc
We’re excited to announce the launch of Pharmaprojects+, the next-generation upgrade of our flagship drug development database. -
Citeline
@Citeline
vist.ly/3n8a7ky | Clinical trials are on the rise…again! Access detailed metrics and insights from 4,900+ completed trials to inform your planning, benchmarking, and investment strategies.
🔍 All data sourced from Trialtrove: vist.ly/3n8a7m3 -
Citeline
@Citeline
vist.ly/3n89ry5 | Fresh from Boston, Scrip and Pink Sheet journalists @MandyJackson and @SarahKarlinSmith bring the lowdown on the hot topics and sentiment at the BIO International Convention. insights.citeline.com/scrip/conferences/bio/post-bio-podc…
-
Citeline
@Citeline
vist.ly/3n87j8x | Alex Shimmings is an integral part of the Scrip staff. She loves writing about the science of drug development, so her role as editor is a perfect fit. Read to learn the highlight of Alex's career to date. .
-
Citeline
@Citeline
Inside the FDA’s new era is everything biotechs need to know now. #smallbiotechsbigdecisions | vist.ly/3n875k4
In our final episode, we explore the evolving regulatory landscape, from FDA policy shifts to global trial strategies and the growing role of real-world data. -
Citeline
@Citeline
vist.ly/3n84h6a
Being able to link all the HCPs appropriately — and in a very targeted manner — by being able to track their encounters throughout the system to then get the right patient, at the right time, for the right provider — to our clients. -
Citeline
@Citeline
AI, RWD, and competitive intelligence are redefining how biotech stays ahead. Watch the latest episode of #smallbiotechsbigdecisions here: vist.ly/3n7zuu4
-
Citeline
@Citeline
vist.ly/3n7xn4w | The Market Trends & Insights session led by Thomas Wicks, Citeline Head of Transparency Operations, at TrialScope EXTRA 2025 focused on key regulation updates that impact clinical trial conduct and disclosure practices, including the Helsinki Accord.
-
Citeline
@Citeline
With patient recruitment on the decline, how is your biotech staying competitive? Tune in to #smallbiotechsbigdecisions for deeper insights: vist.ly/3n7xg5r
Differentiation is now essential—not only to engage patients but also to attract strategic investment. -
Citeline
@Citeline
vist.ly/3n7v3hh | Brian Mundy, Director of Product Management, has been busy working on our new Sitetrove+ and Trialtrove+ offerings. See what sets these solutions apart from the rest, and what Brian found most challenging about his latest project.
-
Citeline
@Citeline
vist.ly/3n7tzux
In a @PharmaVoice article on the FDA’s accelerated approval of @abbvie’s ADC Emrelis, Citeline analyst Neha Anand offers commentary on the ADC market and its challenges. She says Emrelis has the potential to become a blockbuster. -
Citeline
@Citeline
Pipeline decisions. Trial planning. Site selection. | 🔗 Register now: vist.ly/3n7sdcx
Join us on July 10 to explore what’s new (and what’s next) across the Citeline platform — including enhancements to Pharmaprojects, Trialtrove, and Sitetrove. -
Citeline
@Citeline
What’s your strategy to stay ahead? New Episode 3 of #smallbiotechsbigdecisions is now live: vist.ly/3n7rxnb
Tune in and learn why competitive intelligence is no longer a luxury but a must-have for biotech leaders to stay ahead and win. -
Citeline
@Citeline
vist.ly/3n7q6te | Watch our recent webinar, The Future of Patient Recruitment: How RWD Transforms Identifying Hard-to-Find Patients, on demand now!
-
Citeline
@Citeline
vist.ly/3n7pqz3 | In an article recapping ASCO 2025, @medcitynews features commentary from Anna Simmons, analyst at @Citeline, and Ethan Smith, Oncology Therapy Area Director at @Norstellaco, Citeline's parent company.
-
Citeline
@Citeline
Let's conquer compliance together! 👉 vist.ly/3n7pb8j | Challenged by global regulatory compliance? Don't let it slow you down! Discover how Citeline can streamline the process, saving you time and reducing your non-compliance risk.
-
Citeline
@Citeline
Scrip Asks… and the biopharma industry answers: vist.ly/3n7m4j4.
We surveyed hundreds of experts to uncover the trends and challenges set to define 2025. -
Citeline
@Citeline
Outsmarting the competition starts here. The latest of #smallbiotechsbigdecisions episode 3 is now live: vist.ly/3n7ksgm
This time, we’re diving into the power of competitive intelligence — and why it’s the secret weapon biotech leaders need to navigate today’s hyper-competitive landscape.
Step inside the conversation with @DanielChancellor, VP of Thought Leadership at @NorstellaCo and @ClaireRiches, VP of Clinical Solutions at Citeline as they talk through how data, AI, and smarter planning are reshaping the future of drug development.
This episode covers:
• The surge in global drug development: 24,000+ active assets and 7,000 RNA-focused companies
• The shift in innovation hubs, with China and South Korea surpassing traditional R&D leaders
• The patient recruitment crisis: Rates have dropped from 0.775 to just 0.3 patients per site per month
• How AI, synthetic data, and real-world evidence are transforming clinical trial design
• The importance of balancing internal execution with competitive landscape monitoring to stay ahead
What's your strategy to stay ahead? Listen or watch the full episode here to learn how competitive intelligence can sharpen your strategy and accelerate smarter decisions: vist.ly/3n7ksgm
Prefer to listen on the go? The audio version is available now: vist.ly/3n7ksgi
#biotech #biotechleadership #biotechstrategy #bio2025 -
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: vist.ly/3n7ftux
Unlock world-class journalism and analysis of the pharma, biotech, medtech, and consumer health industries with a 1-week free trial.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Did you know that engaging healthcare providers can significantly enhance your clinical trial recruitment efforts? vist.ly/3n7crqi
-
Citeline
@Citeline
vist.ly/3n7cbne | A Reuters article on US drugmakers turning to Chinese companies as they face patent expirations includes data from Citeline's Pharma R&D Review.
To see the full Citeline report and supplemental materials, visit vist.ly/3n7cbnh -
Citeline
@Citeline
📣 On-Demand Webinar Now Available: vist.ly/3n7bjds
AI Drug Discovery: Overview & Outlook | A special collaboration between SMBC Nikko Securities and Citeline/Evaluate is now streaming!
💡 Get expert insights from SMBC’s pharma/healthcare lead and discover how proprietary data powers innovation in drug discovery.
🎥 Watch anytime, anywhere. -
Citeline
@Citeline
The FDA’s support for AI and RWD is opening new doors for biotech innovation. Tune into #smallbiotechsbigdecisions for expert insights: vist.ly/3n7a5ea
Stay tuned for a new episode releasing next week! -
Citeline
@Citeline
Day 2 of Scrip's daily BIO Notebook is now available! insights.citeline.com/scrip/conferences/bio/bio-notebook-…
Visit us at booth #1379 at #bio2025 to continue the conversation in person.
Don't miss our latest episode of #smallbiotechsbigdecisions www.citeline.com/en/biotech -
Citeline
@Citeline
vist.ly/3n77qxe | With Juneteenth celebrations in the US, we remember that Black individuals are not free of maladies such as sickle cell disease that impact them disproportionately. It affects 8 million people, most of whom are of African descent.
-
Citeline
@Citeline
AI, RWD, and strategic partnerships are reshaping biotech. Tune into the latest episode of #smallbiotechsbigdecisions for expert insights: vist.ly/3n77g2e
Come connect with us at booth #1379 before #bio2025 wraps up.
Stay tuned for a new episode releasing next week! -
Citeline
@Citeline
Cut through the noise. Get expert answers, fast. Discover why pharma leaders rely on Ask the Analyst: vist.ly/3n75q7f
In a world of endless data, Ask the Analyst helps Citeline subscribers make smarter decisions, faster. -
Citeline
@Citeline
Our Citeline News & Insights reporters are in Boston to cover the BIO Convention. Catch up with the highlights in Scrip's daily BIO Notebook: vist.ly/3n754jb
Visit us at booth #1379 at #bio2025 to continue the conversation in person.
Don't miss our latest episode of #smallbiotechsbigdecisions vist.ly/3n754je insights.citeline.com/scrip/conferences/bio/bio-notebook-… -
Citeline
@Citeline
What’s next for emerging biotechs? Catch the latest episode of #smallbiotechsbigdecisions vist.ly/3n74un6
Visit us at booth #1379 at #bio2025 to continue the conversation in person. -
Citeline
@Citeline
Doing more with less. Episode 2 of #smallbiotechsbigdecisions is now live on: vist.ly/3n62g5h
With tighter budgets and pressure to accelerate time-to-market, biotechs need smarter strategies to accelerate clinical development and deliver value efficiently.
#bio2025 -
Citeline
@Citeline
First episode of #smallbiotechsbigdecisions is out now! Watch here: vist.ly/3n6uxi5
We’ll be at #bio2025 at booth #1379. Let’s connect and discuss these insights in person.
Stay tuned for a new episode releasing next week! -
Citeline
@Citeline
vist.ly/3n6udb3 | The Market Trends & Insights session at TrialScope #extra2025 led by @ThomasWicks, Citeline Head of Transparency Operations, focused on key regulation updates that impact clinical trial conduct and disclosure practices.
-
Citeline
@Citeline
Launching the first episode of #smallbiotechsbigdecisions! Tune in now:
vist.ly/3n6squw
Catch us at BIOInternational booth #1379 to discuss the latest in biotech innovation.
————
Follow @Citeline for daily #biointernational updates, insights, and more! -
Citeline
@Citeline
The worldwide consequence of clinical trial non-compliance—we outline the true cost of falling short: citeline.com/en/trial-and-consequence/.
Download the latest white paper from Citeline Regulatory, Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure. -
Citeline
@Citeline
Learn what happens when clinical trials don't follow the rules—the true cost of falling short. Trust the experts: vist.ly/3n6q9ve.
Get the latest white paper from Citeline Regulatory, "Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure."
Click to follow @Citeline - your guide through the twists and turns of the drug, device, clinical trial, and market intelligence in the pharma and medtech world. -
Citeline
@Citeline
In this first episode of our special limited podcast series, #smallbiotechsbigdecisions, we explore how small biotechs are adapting to FDA uncertainty, economic headwinds, and intense competition — while staying innovative and investable. Full episode: vist.ly/3n6pwmm
-
Citeline
@Citeline
Scrip Asks… and the biopharma industry answers: vist.ly/3n6mvxe.
We surveyed hundreds of experts to uncover the trends and challenges set to define 2025.
This report covers everything from M&A momentum to political impacts and the future of AI in drug development. -
Citeline
@Citeline
Read on for Scrip's Titans Of Pharma: insights.citeline.com/scrip/leadership/titans-of-pharma-l….
______
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: www.citeline.com/en/app-insights-trial -
Citeline
@Citeline
In our first episode of Small Biotechs, Big Decisions we look at how small biotechs are adapting to stay innovative and investable in today’s climate.
The full episode launches tomorrow. Let’s connect at booth #1379. Are you ready to rethink your strategy? #biointernational -
Citeline
@Citeline
The countdown is officially on! 1 month left to enter the Scrip Awards 2025! ⏰🏆
If you haven't yet submitted your entries, now is the time to do so! Entries will close on Friday, 11 July, 2025. Enter today!
citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
Something exciting is coming for biotech leaders!
We’re kicking off a special, limited podcast series: Small Biotechs, Big Decisions featuring @DanielChancellor, VP of Thought Leadership at @Norstella and @ClaireRiches, VP of Clinical Solutions at Citeline.
Get ready to explore the biggest challenges and boldest strategies reshaping biotech today. This series uncovers what you need to know to thrive amid rising competition and rapid change.
Follow us for the launch and rethink what it takes to succeed in biotech.
Stay tuned — the journey begins soon!
#smallbiotechsbigdecisions #biotech #biotechleadership
#biotechstrategy
————
Follow @Citeline for daily #biointernational updates, insights, and more! -
Citeline
@Citeline
BREAKING! vist.ly/3n6imux | HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Just released — Citeline’s Full Annual Completed Clinical Trials Report: www.citeline.com/en/resources/2024-completed-clinical-tri…
🔍 All data sourced from Trialtrove, Citeline’s advanced clinical trial intelligence platform, find out how it can help in form your strategy: www.citeline.com/plus -
Citeline
@Citeline
You bring the questions. We bring 500+ expert voices. vist.ly/3n68a8z | Discover how Ask the Analyst adds power to your expertise.
With Ask the Analyst, Citeline subscribers get direct access to a network of over 500 industry experts in their fields. -
Citeline
@Citeline
www.pharmaceuticalcommerce.com/view/fast-tracking-the-future | On the Pharmaceutical Commerce podcast, VP of Clinical Solutions, Claire Riches dives into the FDA’s plans for using RWD to streamline the drug approval process. Got 12 minutes? Listen now!
-
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. While U.S. political events are capturing headlines, pharma reform legislation is advancing in the EU—poised to impact everything from manufacturing practices to market exclusivity.
-
Citeline
@Citeline
Despite pressures from HHS and FDA leadership for increased involvement, the director of FDA's biologics center has pledged to uphold the tradition of maintaining an unbiased distance from product reviews: vist.ly/3n63jk9
#newsandinsights #pinksheet | @SarahKarlinSmith -
Citeline
@Citeline
Discover innovative strategies for ensuring diversity in your clinical trials: citeline.com/en/resources/practical-strategies-for-ensuri….
It’s time to ensure your studies reflect the real-world population. -
Citeline
@Citeline
vist.ly/3n52jqf
In a @PharmaVoice article on the FDA’s accelerated approval of @abbvie’s ADC Emrelis, Citeline analyst Neha Anand offers commentary on the ADC market and its challenges. She says Emrelis has the potential to become a blockbuster. -
Citeline
@Citeline
Struggling to keep pace with the complexities of global regulatory compliance? vist.ly/3n5xxcf
Managing regulatory disclosure across global markets is demanding and time-consuming. Explore how Citeline can help you save time, reduce costs, and ensure ongoing compliance. -
Citeline
@Citeline
#asco25 | Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera: vist.ly/3n5wasd
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
#asco25 | @AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated: vist.ly/3n5vmg2
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
BREAKING! vist.ly/3n5vc4j
#citelinebreakingnews #scrip #sanofi
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/3n5vc4nThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
🎉 The entry deadline for the OTC Marketing Awards is 3 months away!
Join us as for our 30th anniversary to celebrate innovation & creativity in the UK’s OTC industry.
Entries close on 1 September - Start your entries today 👉 citeline.com/en/awards/otcmarketingawards/
#otcmarketingawards -
Citeline
@Citeline
2 months left to enter the Global Generics & Biosimilars Awards 2025! 🏆
Join us in Frankfurt as we honor outstanding achievements in the global off-patent pharmaceutical industry.
📅 Deadline: 1 August 2025
📍Radisson Blu Hotel, Frankfurt
#ggbawards
citeline.com/en/awards/ggbawards/ -
Citeline
@Citeline
Follow @Citeline for more #asco25 coverage: vist.ly/3n5qz78
Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Don't miss #asco25 coverage from Citeline News & Insights: vist.ly/3n5qew3
The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/.
This article bundle unpacks these transformative changes, outlining what’s already decided and what’s still in motion. -
Citeline
@Citeline
Explore proven strategies to expand your reach and drive enrollment success: citeline.com/en/resources/merits-of-a-multifaceted-approa….
Looking to boost your clinical trial enrollment and diversity? Discover how a multifaceted approach to recruitment can help you reach a wider, more diverse patient population. -
Citeline
@Citeline
The worldwide consequence of clinical trial non-compliance—we outline the true cost of falling short: citeline.com/en/trial-and-consequence/.
Download the latest white paper from Citeline Regulatory, Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure. -
Citeline
@Citeline
www.pharmavoice.com/news/sarepta-elevidys-gene-therapy-du… | A PharmaVoice article on adeno-associated viruses (AAV), features commentary from Jake Mathon, Director of Cardiometabolic, Infectious, and Genitourinary Diseases at Citeline.
-
Citeline
@Citeline
BREAKING! EU Authorization Before US? Biologics Manufacturing Is Likely To Blame | vist.ly/3n5g6zr
#citelinebreakingnews #pinksheetThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
BREAKING! vist.ly/3n5epm8
Key Takeaways:
• Bills banning the tax break have been introduced in Congress, but could face legal challenges.
• FDA drug advertisement reviews continue despite layoffs and other departures of key staff.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/3n5d2zf | In a @medcitynews article on the FDA's accelerated approval of AbbVie's Emrelis for lung cancer, Analyst Neha Anand views the approval as a major step forward in precision oncology.
Read more to see why Anand says the drug's safety could be a concern. -
Citeline
@Citeline
BREAKING! vist.ly/3n5dsj5
#citelinebreakingnews #scrip #astrazeneca #gileadThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
vist.ly/3n5b92z | The 2025 SOS Save Our Sites conference gave clinical research professionals the opportunity to meet and share their experiences.
Citeline's Carolyn Gretton was there to absorb it all. Read on for her report. -
Citeline
@Citeline
Japanese Webinar in collaboration with SMBC Nikko Securities: Focus on AI Drug Discovery | vist.ly/3n59hr7
Gain a third-party perspective on market trends across various pharmaceutical sectors, explained by financial experts! -
Citeline
@Citeline
Effective treatments lack for EGFR-mutated non-small cell lung cancer patients who have progressed on osimertinib and platinum-based chemotherapy: citeline.com/en/resources/the-unmet-need-in-egfr-mutated-….
Our analysis dives into the emerging HER3-targeted drugs and studies for these patients. -
Citeline
@Citeline
Data never looked so good! citeline.com/RD25/
Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. #rd25 -
Citeline
@Citeline
The worldwide consequence of clinical trial non-compliance—we outline the true cost of falling short: citeline.com/en/trial-and-consequence/.
Download the latest white paper from Citeline Regulatory, Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure. -
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: citeline.com/en/products-services/clinical/protocol-smart….
-
Citeline
@Citeline
citeline.com/en/pink-sheet-overview/ | From major regulatory shifts in the EU and Japan to breakthrough drug approvals in oncology, neuroscience and cardiovascular care, 2025 is set to reshape the pharmaceutical landscape.
Stay ahead with exclusive insights from our 2025 article pack. -
Citeline
@Citeline
BREAKING! vist.ly/3n4u3nb | HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing
#citelinebreakingnewsThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
BREAKING! vist.ly/3n4ss94 | Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
medcitynews.com/2025/03/a-bright-future-for-ai-in-pharma/ | In an article he wrote for @MedCity News, Luca Parisi, Director of Clinical Analytics and Data Science, sees a promising future for the use of AI in drug development.
-
Citeline
@Citeline
Ben Evans eats, sleeps, and breathes clinical trial disclosure. As Disclosure Regulations Research Manager, his focus is on TrialScope Intelligence. See what Ben's up to when he's not global clinical trial disclosure policies: vist.ly/3n4qtgz
-
Citeline
@Citeline
Analyst Tim Blackstock shares his insights on the potential uses of GLP-1s beyond obesity and diabetes with UK national publication @theipaper — vist.ly/3n4qdh4.
See what he predicts will happen when the patents expire for the weight-loss drug semaglutide. inews.co.uk/news/wonder-drug-stop-inflammation-3689587. -
Citeline
@Citeline
Japanese Webinar in collaboration with SMBC Nikko Securities: Focus on AI Drug Discovery | vist.ly/3n4px44
Gain a third-party perspective on market trends across various pharmaceutical sectors, explained by financial experts! -
Citeline
@Citeline
BREAKING! vist.ly/3n4gwxb
#citelinebreakingnews #scrip #novonordisk
_____
Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Download the app today: vist.ly/3n4gwxeThis media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Patient engagement and recruitment software can help, but choosing the right solution is key. Download our Buyer’s Guide for a smarter selection process: citeline.com/en/resources/patient-engagement-and-recruitm….
-
Citeline
@Citeline
The worldwide consequence of clinical trial non-compliance—we outline the true cost of falling short: citeline.com/en/trial-and-consequence/.
Download the latest white paper from Citeline Regulatory, Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure. -
Citeline
@Citeline
BREAKING! vist.ly/3n4epqx
• The FDA will release a new vaccine framework as soon as next week, Commissioner Martin Makary said.
• New CBER Director Vinay Prasad, who often has criticized US vaccine policy, is leading the work on the framework.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. Every drug sponsor aims to leverage Artificial Intelligence, but understanding regulatory limits is crucial.
-
Citeline
@Citeline
BREAKING! insights.citeline.com/pink-sheet/market-access/pricing-de…
President Trump's executive order establishing a most favored nation policy for drug pricing in the US is "lazy and misguided," University of Washington professor Sean Sullivan said during the ISPOR 2025 conference in Montreal. -
Citeline
@Citeline
📣 Breaking News! insights.citeline.com/scrip/drug-pricing/industry-leaders…
Early reaction to President Trump’s most favored nation pricing plan from corporate leaders at the Bank of America Global Healthcare conference reflects the lack of details and need for more clarity. -
Citeline
@Citeline
📣 Breaking News! insights.citeline.com/pink-sheet/market-access/government… | New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations
#citelinebreakingnews #medicare #pinksheet -
Citeline
@Citeline
Welcome to our newest supporter!
We're excited to announce that PAGB is joining us as a supporter of the OTC Marketing Awards 2025.
They’ll be supporting the OTC Brand Revitalisation of the Year category at this year’s Awards! 🏆
citeline.com/en/awards/otcmarketingawards/
#otcmarketingawards -
Citeline
@Citeline
Patient engagement and recruitment software can help, but choosing the right solution is key. Download our Buyer’s Guide for a smarter selection process: citeline.com/en/resources/patient-engagement-and-recruitm….
-
Citeline
@Citeline
📣 Breaking News! insights.citeline.com/pink-sheet/agency-leadership/us-fda… | US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts
-
Citeline
@Citeline
Scrip Asks… and the biopharma industry answers: vist.ly/3n48z72.
We surveyed hundreds of experts to uncover the trends and challenges set to define 2025.
This report covers everything from M&A momentum to political impacts and the future of AI in drug development. -
Citeline
@Citeline
Tune out the noise and tune in to our upcoming webinar – last call to register! Discover how data informs smarter, more targeted recruitment strategies for clinical trials: citeline.com/en/events/data-driven-recruitment-strategy/.
-
Citeline
@Citeline
📢Not long to go! Two months remaining to enter the Scrip Awards 2025!
The 21st annual Awards will be closing for entries on Friday, 11 July 2025.
🏆Ready to submit an entry? Enter now!
Entries close: Friday, 11 July, 2025
citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
vist.ly/3n45wr6 | Meet Cassandra Tramutola, patient engagement and recruitment expert. In our People Behind the Products feature, discover how she supports sponsors in optimizing their efforts to pinpoint, engage, and enroll clinical trial patients.
-
Citeline
@Citeline
Regulations are constantly changing. Are you up to date? citeline.com/en/resources/beyond-compliance-webinar/.
This session introduces a comprehensive maturity model framework for clinical trial disclosure, helping organizations assess and enhance their capabilities across eight critical domains. -
Citeline
@Citeline
Pharma’s biggest trends are here: citeline.com/RD25/. The 33rd annual Pharma R&D Review covers it all—pipeline shifts by company, therapeutic area, and drug type. Whether you're monitoring competitors or planning your next move, this report has the insights you need.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Sponsor Alert! 📢
We're pleased to welcome Precision as category sponsor for Most Innovative New OTC Product at the OTC Marketing Awards 2025!
citeline.com/en/awards/otcmarketingawards/
#otcmarketingawards -
Citeline
@Citeline
🏆 The Citeline Awards 2025 winners have been announced!
We begin with Clinical Partnership of the Year – NON-CRO. Congratulations to NewAmsterdam Pharma and the Victorian Heart Institute at Monash University. #citelineawards citeline.com/en/awards/citelineawards/ -
Citeline
@Citeline
"We talk about the science, the patients, and we forget the part in the middle, which is sites, and we need to do more to support those" — Claire Riches, VP Clinical Solutions. See you in 2026! #citelineelevatespring25
-
Citeline
@Citeline
#citelineelevatespring25 has begun in style with an opening address from Claire Riches, VP Clinical Solutions at Citeline! We'll be bringing you updates throughout our invite-only thought leadership event right in the heart of Boston.
-
Citeline
@Citeline
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: citeline.com/en/app-insights-trial/.
Unlock expert analysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
The worldwide consequence of clinical trial non-compliance—we outline the true cost of falling short: citeline.com/en/trial-and-consequence/.
Download the latest white paper from Citeline Regulatory, Trial and Consequence: The Global Enforcement Landscape of Clinical Trial Disclosure. -
Citeline
@Citeline
Explore the trends shaping 2025 with expert insights on R&D, deals, policy, and beyond: content.evaluate.com/story/outlook-2025-key-trends-and-in….
This eBook dives into the key trends shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies. -
Citeline
@Citeline
Welcome to our newest supporter!
We're excited to announce that PAGB is joining us as a supporter of the OTC Marketing Awards 2025.
They’ll be supporting the OTC Brand Revitalisation of the Year category at this year’s Awards! 🏆
citeline.com/en/awards/otcmarketingawards/
#otcmarketingawards -
Citeline
@Citeline
Join us in welcoming ICON as Headline Sponsor for the 2025 Citeline Japan Awards!
Entries are open until Monday, July 14, 2025!
citeline.com/en/awards/citelinejapanawards/
#citelinejapanawards -
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline
@Citeline
Tune out the noise and tune in to our upcoming webinar. Discover how data informs smarter, more targeted recruitment strategies for clinical trials: citeline.com/en/events/data-driven-recruitment-strategy/.
-
Citeline
@Citeline
We're thrilled to announce that Citeline’s News & Insights has been recognized by the ASBPE, with Scrip taking home two Northeast regional awards:
🏆 Gold: Data-led Journalism for Pharma Decision-makers
🥉 Bronze: Pharma Industry Coverage Beyond the Headlines -
Citeline
@Citeline
Will you be attending Swiss Biotech Day 2025? citeline.forms.ac/sbd-exclusivebreakfast-2025
We’d like to invite you to our exclusive pre-conference breakfast networking and panel discussion, a morning that promises to be a full of inspiring conversations and valuable connections with industry leaders. -
Citeline
@Citeline
Join us on May 14 to gain valuable insights on how data can unlock access to previously previously hard-to-identify patient populations: citeline.com/en/events/data-driven-recruitment-strategy/.
-
Citeline
@Citeline
www.pharmaceuticalcommerce.com/view/fast-tracking-the-future | On the Pharmaceutical Commerce podcast, VP of Clinical Solutions, Claire Riches dives into the FDA’s plans for using RWD to streamline the drug approval process. Got 12 minutes? Listen now!
-
Citeline
@Citeline
We're proud to moderate the panel on "Biotech Investor Strategy in a Dynamic Market" at Swiss Biotech Day 2025 next week. Join us as we explore the evolving landscape of venture capital in biotech, the impact of market shifts, and strategies for success: swissbiotechday.ch/panel-discussions-2025/entry/7600/.
-
Citeline
@Citeline
At ACRP 2025, Citeline’s own Fenwick Eckhardt joined a distinguished panel to discuss “Clinical Trial Diversity & Intersectionality: Looking at the Whole Patient.”
Check out our Diversity Hub for additional resources on diversity in clinical research: citeline.com/en/diversity-hub/. -
Citeline
@Citeline
3 months to enter the Global Generics & Biosimilars Awards! 🏆
Enter the Awards today and join us for a night that is set to be bigger, bolder and better than ever for 2025!
Start your entries today!
#ggbawards citeline.com/en/awards/ggbawards/ -
Citeline
@Citeline
Join us on May 5 for a unique opportunity to connect, collaborate, and innovate! Register for our pre-conference breakfast now: citeline.forms.ac/sbd-exclusivebreakfast-2025.
-
Citeline
@Citeline
🎉 The OTC Marketing Awards are turning 30 & are OPEN for entries!
✨Join us as we celebrate excellence, innovation & creativity in the UK’s OTC industry on Thursday, 20 November, 2025.
📅Entries deadline: 1 September, 2025
👉 citeline.com/en/awards/otcmarketingawards/
#otcmarketingawards -
Citeline reposted
Marion Webb
@medtechMarion
Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move insights.citeline.com//medtech-insight/leadership/analyst… @Medtech_Insight @Citeline #medtech #leadership #diabetes @IrmaRaste @EvanKirstel
-
Citeline reposted
Candel Therapeutics
@CandelTx
Honored to be named a finalist for ‘Clinical Trial Result of the Year’ at the @Citeline Awards 2025 for our phase 3 trial of CAN-2409 in prostate cancer! This recognition highlights the impact of our viral immunotherapy on advancing cancer treatment.
www.citeline.com/en/awards/citelineawards -
Citeline reposted
Vibha Ravi
@scripvibha
How to apply for the Global Generics & Biosimilars Award from Generics Bulletin, Citeline - @DaveGenerics shares all the details to nominate, sponsor and attend #awards #citeline #pharmaceutical @Citeline insights.citeline.com//generics-bulletin/products/generic…
-
Citeline
@Citeline
Discover innovative strategies for ensuring diversity in your clinical trials: citeline.com/en/resources/practical-strategies-for-ensuri….
It’s time to ensure your studies reflect the real-world population. -
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline reposted
派仔
@paizai_qwq
Excited to connect with industry leaders and explore the pharma industry's future at the 100 largest pharmaceutical companies event. #pharmainnovation #globalleaders
Citeline
@Citeline
Explore the 100 largest pharmaceutical companies of 2024, featuring global leaders like Pfizer, AbbVie, Merck & Co., and more: insights.citeline.com/pharma-insights/the-worlds-top-100-…. Discover the key players shaping the pharma industry.
-
Citeline reposted
Marion Webb
@medtechMarion
Had a great time #swaay joining a panel discussing do’s and don’ts when talking to members of the media. @Citeline @Medtech_Insight @IrmaRaste @EvanKirstel #medtech #healthcare #media
-
Citeline reposted
Derrick
@dgingery
Congrats to my @PharmaScrip colleagues!
Citeline
@Citeline
We're thrilled to announce that Citeline’s News & Insights has been recognized by the ASBPE, with Scrip taking home two Northeast regional awards:
🏆 Gold: Data-led Journalism for Pharma Decision-makers
🥉 Bronze: Pharma Industry Coverage Beyond the Headlines -
Citeline reposted
Alto Neuroscience
@AltoNeuro
In a recent @Citeline article, our CEO @AmitEtkin discusses Alto's #precisionpsychiatry approach for the treatment of #neuropsychaitric conditions, guided by insights from #eeg, cognitive tests & wearable data. Read more: insights.citeline.com/in-vivo/leadership/c-suite-speaks/f…
-
Citeline reposted
Norstella
@NorstellaCo
Recruiting eligible patients is tougher for clinical trial sponsors due to rising competition. @Citeline's data shows enrollment rates have dropped by half since 2010. Check out our latest article for practical advice: www.norstella.com/patient-availability-conundrum/
-
Citeline reposted
Pharmaceutical Commerce
@PharmaCommerce
🎙️ Just dropped: Claire Riches of @Citeline breaks down drug approval bottlenecks, RWD integration, payer roles & the future of FDA reform under HHS Sec. RFK Jr.
www.pharmaceuticalcommerce.com/view/fast-tracking-the-future
#pharma #rwd #drugdevelopment #fda #healthpolicy -
Citeline
@Citeline
www.clinicaltrialvanguard.com/executiveinterviews/citelin… | In an executive interview with The Clinical Trial Vanguard, Claire Riches, Vice President, Clinical Solutions, shares Citeline’s strategic vision for bridging clinical trials and real-world healthcare.
-
Citeline
@Citeline
Discover how you can drive superior clinical trial outcomes with proprietary data: citeline.com/en/resources/improving-clinical-outcomes-wit….
In a world where every clinical trial sponsor has access to the same public data, proprietary data provides the competitive edge you need. -
Citeline
@Citeline
Taking the power of AI to new levels: citeline.com/en/smartsolutions/. Citeline SmartSolutions help you reduce costly protocol amendments, increase predictability, and optimize planning in clinical trials.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
citeline.com/en/resources/head-and-neck-cancer-awareness/ | To coincide with Head and Neck Cancer Awareness Month, we take a look at the distribution of patients in the US, based on race, income, and living environment. Regional and state differences impact the distribution of patients based on these factors.
-
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. While U.S. political events are capturing headlines, pharma reform legislation is advancing in the EU—poised to impact everything from manufacturing practices to market exclusivity.
-
Citeline
@Citeline
Does your clinical trial meet the FDA’s new diversity requirements? Unlock strategies to ensure diverse patient populations and learn how to meet the FDA guidelines, improve recruitment and gather real-world data to enhance the efficacy of your studies: citeline.com/en/resources/practical-strategies-for-ensuri….
-
Citeline
@Citeline
Global Generics & Biosimilars Awards new sponsor alert! 📢
We are thrilled to welcome Pharmacloud as category sponsor for Leader of the Year at the 2025 Awards!
Interested in sponsoring the Awards? Get in touch with our team today!
discover.citeline.com/GGBAwardsSponGuide25-Form
#ggbawards -
Citeline
@Citeline
Join us on May 14 to gain valuable insights on how data can unlock access to previously previously hard-to-identify patient populations: citeline.com/en/events/data-driven-recruitment-strategy/.
-
Citeline
@Citeline
Will you be attending Swiss Biotech Day 2025? citeline.forms.ac/sbd-exclusivebreakfast-2025
We’d like to invite you to our exclusive pre-conference breakfast networking and panel discussion, a morning that promises to be a full of inspiring conversations and valuable connections with industry leaders. -
Citeline
@Citeline
Book your table to the Citeline Awards 2025! 🏆
Secure your tables to the Awards today and be in the room with the very best in R&D healthcare.
Join us in Boston on Thursday, May 8, 2025.
citeline.com/en/awards/citelineawards/
#citelineawards -
Citeline
@Citeline
Through Trialtrove+ and Sitetrove+ we’re delivering insights that allow you to optimize your clinical trial planning, site, and investigator selection: citeline.com/plus/:
Hear Suzanne Caruso, Gen Mgr at Citeline, introduce the key benefits of Trialtrove+ and Sitetrove+. -
Citeline
@Citeline
The @Citeline Consulting & Analytics team help you optimize clinical trial success with Feasibility as a Service. Our experts deliver data-driven insights across trial stages using our extensive global research data to provide actionable recommendations: citeline.com/en/optimize-with-consulting-and-analytics/
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
We're thrilled to announce that Citeline’s News & Insights has been recognized by the ASBPE, with Scrip taking home two Northeast regional awards:
🏆 Gold: Data-led Journalism for Pharma Decision-makers
🥉 Bronze: Pharma Industry Coverage Beyond the Headlines -
Citeline
@Citeline
🏆Now Open: Citeline Japan Awards 2025 – Honoring excellence in Japan's global healthcare sector.
We are proud to announce the launch of the Awards, taking place on Tuesday, October 21, 2025.
📅 Deadline: July 4, 2025
citeline.com/en/awards/citelinejapanawards/
#citelinejapanawards -
Citeline
@Citeline
Effective treatments lack for EGFR-mutated non-small cell lung cancer patients who have progressed on osimertinib and platinum-based chemotherapy: citeline.com/en/resources/the-unmet-need-in-egfr-mutated-….
Our analysis dives into the emerging HER3-targeted drugs and studies for these patients. -
Citeline
@Citeline
citeline.com/en/pink-sheet-overview/ | From major regulatory shifts in the EU and Japan to breakthrough drug approvals in oncology, neuroscience and cardiovascular care, 2025 is set to reshape the pharmaceutical landscape.
Stay ahead with exclusive insights from our 2025 article pack. -
Citeline
@Citeline
Data never looked so good!
Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. -
Citeline
@Citeline
Join us on May 5 for a unique opportunity to connect, collaborate, and innovate! Register for our pre-conference breakfast now: citeline.forms.ac/sbd-exclusivebreakfast-2025.
-
Citeline
@Citeline
Boost your clinical trial recruitment efforts with the right patient engagement and recruitment solution. Download the guide now to ensure you're set up for success: citeline.com/en/resources/patient-engagement-and-recruitm….
-
Citeline
@Citeline
Protocol amendments are a constant headache for clinical study teams. Think of Protocol SmartDesign as your preventive medicine: citeline.com/en/products-services/clinical/protocol-smart….
-
Citeline
@Citeline
Explore the 100 largest pharmaceutical companies of 2024, featuring global leaders like Pfizer, AbbVie, Merck & Co., and more: insights.citeline.com/pharma-insights/the-worlds-top-100-…. Discover the key players shaping the pharma industry.
-
Citeline
@Citeline
Want to drive better clinical trial outcomes? Gain the competitive edge needed to excel in today’s pharmaceutical landscape: citeline.com/en/resources/improving-clinical-outcomes-wit….
Discover how leveraging in-depth, proprietary data can transform your strategies and operational efficiency. -
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline
@Citeline
citeline.com/en/resources/head-and-neck-cancer-awareness/ | To coincide with Head and Neck Cancer Awareness Month, we take a look at the distribution of patients in the US, based on race, income, and living environment. Regional and state differences impact the distribution of patients based on these factors.
-
Citeline reposted
Flagship Pioneering
@FlagshipPioneer
Congratulations to Kerry Benenato, Chief Platform Officer at #flagshipfounded @SailBiomeds, on being named one of In Vivo's @Citeline 2025 Rising Leaders.
Sail Biomedicines
@SailBiomeds
We're thrilled to share that Kerry Benenato, Chief Platform Officer at Sail Biomedicines, has been named one of In Vivo’s 2025 Rising Leaders! This honor celebrates bold ideas, transformative thinking, and the people driving life sciences forward.
Kerry brings deep expertise in mRNA product development and is helping shape the future of programmable medicines at Sail. Her prior work at Moderna was instrumental in the development of Spikevax, and her leadership continues to drive innovation in circular RNA therapies.
Please join us in congratulating Kerry on this well-deserved recognition!
See the full list: insights.citeline.com/in-vivo/leadership/rising-leaders/i…
#invivorisingleaders #erna #endlessrna #rnatherapeutics #rna -
Citeline reposted
Ian Haydock
@ScripIanHaydock
Join @ScripJungWon in her latest Korean-language #podcast for @Citeline, this time looking at #tariffs and the #pharma supply chain. On your usual platforms including @Spotify below.
open.spotify.com/episode/3PLyw3WF6nLwfT3yj3MIjV -
Citeline reposted
Ian Haydock
@ScripIanHaydock
Thanks to everyone who attended my session on the @citeline Annual R&D Report at #cphijapan yesterday! @norstella (Photo: @scriplisatakagi)
-
Citeline
@Citeline
Seats are filling up! Don’t miss our live webinar on April 15: citeline.com/en/rd25-webinar/.
Join our expert trendspotters as they explore the drugs, trends, and therapeutic categories in vogue this year. Get the inside scoop on what’s shaping pharma R&D in 2025. -
Citeline
@Citeline
Will you be attending Swiss Biotech Day 2025? citeline.forms.ac/sbd-exclusivebreakfast-2025
We’d like to invite you to our exclusive pre-conference breakfast networking and panel discussion, a morning that promises to be a full of inspiring conversations and valuable connections with industry leaders. -
Citeline
@Citeline
Struggling to navigate the ever-changing world of clinical trial disclosure? citeline.com/en/resources/transforming-clinical-trial-dis…
Discover how AI can streamline your approach as we explore how intelligence compliance tools can save you time, enhance accuracy and ensure you meet global transparency demands. -
Citeline
@Citeline
Discover the Future of Brain Health & Mental Health Treatment. Download our ebook, Medtech on the Brain: citeline.com/en/resources/medtech-on-the-brain/. Learn from experts about the regulatory environment, reimbursement strategies, and key investment opportunities. Get your copy today!
-
Citeline
@Citeline
3 months to enter the Scrip Awards 2025! ⏰
Join us as we celebrate over two decades of advances in global healthcare! The Awards will take place at the London Hilton on Park Lane.
Entries close Friday, 11 July, 2025.
citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
🚨The Citeline Awards 2025 shortlist is LIVE! We’re thrilled to unveil the incredible 2025 finalists.
📅 Book your table now and take advantage of our early bird discount — available until April 21!
citeline.com/en/awards/citelineawards/
#citelineawards -
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. Every drug sponsor aims to leverage Artificial Intelligence, but understanding regulatory limits is crucial.
-
Citeline
@Citeline
We are delighted to welcome Parexel as a sponsor of the Scrip Awards 2025!
Parexel will be sponsoring the prestigious Pharma Company of the Year category, recognizing excellence in the industry.
citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
Will you be attending Swiss Biotech Day 2025? citeline.forms.ac/sbd-exclusivebreakfast-2025
We’d like to invite you to our exclusive pre-conference breakfast networking and panel discussion, a morning that promises to be a full of inspiring conversations and valuable connections with industry leaders. -
Citeline
@Citeline
We are delighted to welcome Parexel as a sponsor of the Scrip Awards 2025! Parexel will be sponsoring the prestigious Pharma Company of the Year category, recognizing excellence in the industry.
citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
Explore the trends shaping 2025 with expert insights on R&D, deals, policy, and beyond: content.evaluate.com/story/outlook-2025-key-trends-and-in….
This eBook dives into the key trends shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies. -
Citeline
@Citeline
Sponsor alert! 📢
Parsity Group are category sponsor, Biosimilar Initiative of the Year, at this year's Global Generics & Biosimilars Awards!
#ggbawards citeline.com/en/awards/ggbawards/ -
Citeline
@Citeline
Seats are filling up! Don’t miss our live webinar on April 15: citeline.com/en/rd25-webinar/.
Join our expert trendspotters as they explore the drugs, trends, and therapeutic categories in vogue this year. Get the inside scoop on what’s shaping pharma R&D in 2025. -
Citeline
@Citeline
Welcome to our latest supporter! IGBA have joined us for the Global Generics & Biosimilars Awards 2025! It’s great to have them supporting the Awards! citeline.com/en/awards/ggbawards/ #ggbawards
-
Citeline
@Citeline
We are delighted to announce ICON as headline sponsor for the Scrip Awards 2025! ICON have been a longstanding supporter of the Awards for a number of years.
Entries are now open until Friday, 11 July 2025: citeline.com/en/awards/scripawards/
#scripawards -
Citeline
@Citeline
Seats are filling up! Don’t miss our live webinar on April 15: citeline.com/en/rd25-webinar/.
Join our expert trendspotters as they explore the drugs, trends, and therapeutic categories in vogue this year. Get the inside scoop on what’s shaping pharma R&D in 2025. -
Citeline
@Citeline
See how multifaceted recruitment can reduce timelines and expand diversity: citeline.com/en/resources/merits-of-a-multifaceted-approa….
Worried traditional methods holding your clinical trial enrollment back? Unlock insights from the industry’s leading recruitment experts and explore our best practices. -
Citeline reposted
Clinical Trials For All
@TrialsForAll
Real-world data plays a crucial role in making clinical trials more patient-centric. This post explores how capturing patient experiences can lead to better trial designs and improved outcomes.
www.linkedin.com/posts/citelineclinical_igan-patientcentr…
#patientcentricity #clinicaltrials #realworlddata -
Citeline reposted
Clinical Trials For All
@TrialsForAll
Collaboration is key to clinical research! Check out this highlight from the latest DCRI Think Tank on improving trial design and accelerating innovation.
www.linkedin.com/posts/duke-clinical-research-institute_d…
#clinicaltrials #researchinnovation #collaboration -
Citeline reposted
Norstella
@NorstellaCo
Which pharma company has the largest R&D engine? Pfizer? Roche? Johnson & Johnson? Not who you might think. Read this article to learn about the latest innovation hotspots and how the biopharma industry can adapt and thrive in this new reality. www.norstella.com/biopharmas-rd-engine/
-
Citeline
@Citeline
🎉 The 21st annual Scrip Awards are now open for entries!
Join us on Thursday, 11 December 2025, at the London Hilton on Park Lane for an unforgettable night honouring excellence.
🏆 citeline.com/en/awards/scripawards/
Entries close: Friday, 11 July, 2025
#scripawards -
Citeline
@Citeline
Sustainability, self-care, and regulation are top of mind for consumer heath industry leaders as they look forward to 2025. Read more in Citeline Commercial's HBW Insight's 2025 series: insights.citeline.com/hbw-insight/perspectives/
-
Citeline
@Citeline
Data never looked so good!
Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. -
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline
@Citeline
⭐ Exciting news for the OTC Marketing Awards 2025! 🎤 Comedian Ivo Graham is confirmed as our host!
He’s booked—are you? Now’s the perfect time to secure your table & lock in the early-bird discount before it’s gone!
app.info.citeline.com/e/er?s=2492560&lid=29297&elq=~~eloq…
#otcmarketingawards -
Citeline
@Citeline
Taking the power of AI to new levels: citeline.com/en/smartsolutions/. Citeline SmartSolutions help you reduce costly protocol amendments, increase predictability, and optimize planning in clinical trials.
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
What happens to our bodies with vast quantities of unchallenging online content and a misguided dopamine reward system? primalpictures.com/blogs/brain-rot-questions/. Learn more anatomy and physiology from @PrimalPictures on the #primalblog
-
Citeline
@Citeline
Discover the Future of Brain Health & Mental Health Treatment. Download our ebook, Medtech on the Brain: citeline.com/en/resources/medtech-on-the-brain/. Learn from experts about the regulatory environment, reimbursement strategies, and key investment opportunities. Get your copy today!
-
Citeline
@Citeline
Seats are filling up! Don’t miss our live webinar on April 15: citeline.com/en/rd25-webinar/.
Join our expert trendspotters as they explore the drugs, trends, and therapeutic categories in vogue this year. Get the inside scoop on what’s shaping pharma R&D in 2025. -
Citeline
@Citeline
Explore the 100 largest pharmaceutical companies of 2024, featuring global leaders like Pfizer, AbbVie, Merck & Co., and more: insights.citeline.com/pharma-insights/the-worlds-top-100-…. Discover the key players shaping the pharma industry.
-
Citeline
@Citeline
Not all solutions are created equal—choosing the right one can help you reach enrollment goals faster and gain valuable insights into trial performance: citeline.com/en/resources/patient-engagement-and-recruitm….
-
Citeline
@Citeline
AI in pharma: Benefits, risks, and the road ahead. Download the white paper today! citeline.com/en/resources/ai-in-pharma-benefits-risks-and….
_____
Follow @Citeline — the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets. -
Citeline
@Citeline
We are thrilled to welcome our latest sponsor Adalvo who are sponsoring API Supplier of the Year category at the Global Generics & Biosimilars Awards.
Entries are open until August 1, 2025—start your submission today for a chance to win! 🚀 www.citeline.com/en/awards/ggbawards
#ggbawards -
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. While U.S. political events are capturing headlines, pharma reform legislation is advancing in the EU—poised to impact everything from manufacturing practices to market exclusivity.
-
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline
@Citeline
Pharma’s biggest trends are here: citeline.com/RD25/. The 33rd annual Pharma R&D Review covers it all—pipeline shifts by company, therapeutic area, and drug type. Whether you're monitoring competitors or planning your next move, this report has the insights you need.
This media couldn't be displayed. See it on the original post. -
Citeline reposted
Norstella
@NorstellaCo
Norstella has been named to @FastCompany's list of the World’s Most Innovative Companies for 2025, highlighting our commitment to securing patient access to life-saving treatments and revolutionizing the pharma intelligence landscape. www.norstella.com/press-releases/norstella-named-fast-com…
#fcmostinnovative -
Citeline reposted
Marion Webb
@medtechMarion
HIMSS 2025: Interview with Aneesh Chopra, Arcadia’s Chief Strategy Officer, About The Future Of Health Data, Interoperability, AI insights.citeline.com//medtech-insight/himss-2025-intervi… @Citeline @IrmaRaste @EvanKirstel #data #healthcare #interoperability #ai
-
Citeline reposted
Pharma Ignite
@PharmaIgnite
There is still an unmet need for new and different obesity therapeutic interventions: www.bioxconomy.com/partnering/abbvie-weighs-in-on-obesity…. Tim Blackstock, @Citeline 's Cardiovascular and Metabolic & Infectious Diseases Therapy Area Director, comments in a recent BioXconomy article on the AbbVie/Gubra deal.
-
Citeline reposted
Adial
@AdialPharma
@Citeline's Generics Bulletin features insights from @AdialPharma CEO Cary Claiborne on AD04, a non-abstinence-based therapy for #aud. Using genetic biomarkers, AD04 offers a personalized novel approach to reducing alcohol consumption.
Read more: insights.citeline.com/generics-bulletin/leadership/interv…
$ADIL #personalizedmedicine #addictiontreatment #pharma -
Citeline reposted
Norstella
@NorstellaCo
China is emerging as a key player in global clinical trials, with a growing number of trials initiated in the country. Janelle Hart of @Citeline discusses trends and barriers in China's drug development with Xu Hu and Dexter Yan. Click to read the article: www.norstella.com/spotlight-china/
-
Citeline reposted
Pharma Ignite
@PharmaIgnite
AI in pharma: Benefits, risks, and the road ahead. Download the white paper today! citeline.com/resources/ai-in-pharma-benefits-risks-and-th….
_____
Follow @Citeline — the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets. -
Citeline reposted
Marion Webb
@medtechMarion
ModMed Unveils AI-Powered Scribe At AOOS Following Clearlake Capital Acquisition insights.citeline.com//medtech-insight/modmed-unveils-ai-… @Citeline @Medtech_Insight @IrmaRaste @EvanKirstel #aaos25 #healthcare #ehr #medtech #data #ambientlistening
-
Citeline
@Citeline
The GGB Awards 2025 features categories celebrating diverse achievements across the global off-patent pharmaceutical industry such as:
• Biosimilar Initiative of the Year
• Leader of the Year
• Industry Partner of the Year
citeline.com/en/awards/ggbawards/
#ggbawards -
Citeline
@Citeline
🏆 The countdown to the Citeline Awards 2025 is on!
Book your table now & celebrate excellence with the best in the business. 🎉Early-bird discount ends this Friday, March 21!
citeline.com/en/awards/citelineawards/
#citelineawards -
Citeline
@Citeline
Sustainability, self-care, and regulation are top of mind for consumer heath industry leaders as they look forward to 2025. Read more in Citeline Commercial's HBW Insight's 2025 series: insights.citeline.com/hbw-insight/perspectives/
-
Citeline
@Citeline
The @Citeline Consulting & Analytics team help you optimize clinical trial success with Feasibility as a Service. Our experts deliver data-driven insights across trial stages using our extensive global research data to provide actionable recommendations: citeline.com/en/optimize-with-consulting-and-analytics/
This media couldn't be displayed. See it on the original post. -
Citeline
@Citeline
Download 5 key articles from our expert journalists at Pink Sheet: citeline.com/en/pink-sheet-overview/. Every drug sponsor aims to leverage Artificial Intelligence, but understanding regulatory limits is crucial.
-
Citeline
@Citeline
Data never looked so good! citeline.com/rd25/. Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed.
-
Citeline
@Citeline
🧠 Medtech on the Brain 🧠 Unveiling Innovations in Mental Health & Neurological Diseases: citeline.com/en/resources/medtech-on-the-brain/. Our new ebook brings you insights from industry leaders on the latest advancements in neurological care, regulatory shifts, and investment trends.
-
Citeline
@Citeline
Sneak peek time! 👀 We had a blast on set shooting the Pharma R&D Annual Review 2025 campaign video. Here’s a behind-the-scenes look at how it all came together—from lighting setups to final takes. Stay tuned for the final and that important review of the global pharma pipeline!
-
Citeline
@Citeline
We have the highlights and key takeaways from #jpm2025: insights.citeline.com/pharma-insights/jp-morgan-healthcar….
Free to read: major deals like J&J's $14.6B acquisition, GSK’s oncology expansion, and insights into biopharma challenges like patent cliffs, regulatory uncertainty, and market dynamics. -
Citeline
@Citeline
Do you love puzzles? How about health? How about winning a health-tracking device for solving a puzzle at #bioeuropespring? citeline.com/en/events/bio-europe-spring-2025/.
Play "Name That Sponsor" at Booth #78 — you'll have a chance of winning an Oura gift card (for the cost of your very own ring)! -
Citeline
@Citeline
Discover innovative strategies for ensuring diversity in your clinical trials citeline.com/en/resources/practical-strategies-for-ensuri….
It’s time to ensure your studies reflect the real-world population. Learn how you can make your trials more inclusive and impactful as we share key insights and recommendations. -
Citeline
@Citeline
Through Trialtrove+ and Sitetrove+ we’re delivering insights that allow you to optimize your clinical trial planning, site, and investigator selection: citeline.com/plus/:
Hear Suzanne Caruso, Gen Mgr at Citeline, introduce the key benefits of Trialtrove+ and Sitetrove+. -
Citeline
@Citeline
Explore the trends shaping 2025 with expert insights on R&D, deals, policy, and beyond: content.evaluate.com/story/outlook-2025-key-trends-and-in….
This eBook dives into the key trends shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies. -
Citeline
@Citeline
Do you love puzzles? How about health? How about winning a health-tracking device for solving a puzzle at #bioeuropespring? citeline.com/en/events/bio-europe-spring-2025/.
Play "Name That Sponsor" at Booth #78 — you'll have a chance of winning an Oura gift card (for the cost of your very own ring)! -
Citeline
@Citeline
In this use case, Citeline’s robust datasets — Sitetrove, Trialtrove, Pharmaprojects, Protocol SmartDesign, and Investigator SmartSelect — combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease: citeline.com/en/resources/patient-centric-approach-to-cli….
-
Citeline
@Citeline
We're delighted to welcome IHP as a supporter of the Corporate Social Responsibility (CSR) Initiative of the Year category at the Global Generics & Biosimilars Awards!
Enter the Awards today! ⏳
Entries close on Friday, 1 August 2025!
🔗 citeline.com/en/awards/ggbawards/
#ggbawards -
Citeline
@Citeline
We're thrilled to attend CDMO Live, happening May 7-8, 2025: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2….
This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! pharmasource.global/events/cdmolive/. -
Citeline
@Citeline
Every clinical trial is different, and each requires a customized approach for patient recruitment: citeline.com/en/solutions/clinical/patient-engagement-and….
Whether you’re looking to enroll a broad population or a specialized subset of rare disease patients, we’ve got you covered. -
Citeline reposted
Clinical Trials For All
@TrialsForAll
No trial, especially for #rarediseases, should fail due to recruitment issues! Global strategies, decentralized trials, and patient advocacy can transform rare disease treatment. www.linkedin.com/posts/iddi_rarediseases-clinicaltrials-p…
#clinicaltrials #dcts -
Citeline reposted
Clinical Trials For All
@TrialsForAll
Curious about the clinical trial process? Our Clinical Trial Journey Map shows what to expect, from application to participation and beyond. Watch now: www.youtube.com/watch?v=FEdSnZ-SVeQ
#clinicaltrials #patientjourney #researchmadesimple -
Citeline reposted
Marion Webb
@medtechMarion
Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau insights.citeline.com//medtech-insight/barcelona-health-h… @Medtech_Insight #medtech #healthcare #digitalhealth #barcelona @IrmaRaste @EvanKirstel @BCNHealthHub @Citeline
-
Citeline reposted
Quantum Media Group, LLC
@QuantumMediaLLC
🎉 Excited to share that our client, @YakyYanay, CEO and President of @Pluribiotech, is featured in @Citeline. The discussion on MAIT cells for solid tumor treatment is a game-changer in cancer research! 💪 Click the link to read the article: Read more here 📖👀 #biotech #pluri
-
Citeline reposted
Marion Webb
@medtechMarion
Abbott First To Offer OTC Continuous Glucose Monitor On Amazon insights.citeline.com//medtech-insight/abbott-first-to-of… @Medtech_Insight @Citeline #cgm #healthcare #diabetes #consumer
-
Citeline reposted
GENETHON France
@GenethonFr
🌍💜💛RARE DISEASE DAY
@Frederic_Revah , CEO of @GenethonFr, gave an interview to @davidwild77, @Citeline reporter, about the role of non-profit organizations in medical research for rare diseases.
@rarediseaseday
Full article 👉insights.citeline.com/in-vivo/market-intelligence/in-sear… -
Citeline
@Citeline
Our final Award of the evening has been handed to Moderna and ProofPilot, winners of the Citeline Award for Clinical Partnership of the Year! Congratulations to all of tonight’s winners! #citelineawards citeline.com/awards/citelineawards/
-
Citeline
@Citeline
Congratulations to Karuna Therapeutics – A Bristol Myers Squibb Company for winning the Clinical Trial Result of the Year award, sponsored by Bioforum! #citelineawards
citeline.com/en/awards/citelineawards/ -
Citeline
@Citeline
We're thrilled to announce that Moderna and ProofPilot are the winners of the Citeline Awards for Best Patient-facing Technology Initiative! Congratulations! #citelineawards
citeline.com/en/awards/citelineawards/















































































































































































































































































































































































































































































